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Introduction 
1 
1. INTRODUCTION 
Tuberculosis (TB) is an infection caused by Mycobacterium tuberculosis. It 
is the world’s second commonest cause of death from infectious disease after 
HIV/AIDS. WHO declares TB as a public health emergency. The prevalence of TB 
is higher in south East Asia and sub Saharan Africa as compared to western 
countries. The prevalence of all forms of TB in India is estimated 5.05/1000 and of 
smear positive cases 2.27/1000
1
. 
Treatment of TB was initially complicated and challenging as it requires 
administration of drugs over a long period. This resulted in poor patient compliance. 
To overcome this disadvantage, a multi drug regimen was recommended that 
shortened the duration of treatment of TB. The anti-tuberculous drugs include 
rifampicin (RIF), isoniazid (INH), ethambutol (ETH), pyrazinamide (PYZ), 
streptomycin as first line drugs and capreomycin, anamycin, ethionamide, para-
amino salicylic acid, cyclosporine, thiacetazone, ciprofloxacin, levofloxacin, 
ofloxacin, and sparfloxacin as second line drugs. The first line drugs are 
recommended for six months duration of treatment and the second line drugs for two 
months treatment. Initially the first line anti-TB drugs were administered separately 
and later on a fixed dose formulation of the first line drugs were recommended to 
overcome the bacterial resistant encountered with individual drugs administration. 
Rifampicin is well absorbed from the stomach, whereas isoniazid is 
comparatively well absorbed from all three segments of the small intestine
2
. 
However rifampicin degrades in the stomach and the degradation has varied from 
8.5-50%, during the gastric emptying time for most dosage forms in humans
3 
and 
decomposition of rifampicin is further influenced by the presence of isoniazid in 
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stomach after ingestion
4
. To improve this disadvantage isoniazid was administered 
in enteric coated form to prevent its release in the stomach so as to protect 
rifampicin from isoniazid induced degradation in the stomach. Despite this 
disadvantage the fixed dose combination (FDC) of rifampicin, isoniazid, 
ethambutol, pyrazinamide remains in use in the treatment of TB to attract patient 
compliance; However the bioavailability of rifampicin has become unacceptable in a 
number of FDC anti- TB formulations. 
Various pharmaceutical approaches were attempted to improve the bio 
availability of rifampicin. Controlled drug delivery system, nanoparticles, 
liposomes, and microspheres were developed for the sustained drug delivery of anti-
TB drugs that have demonstrated better chemotherapeutic efficacy when 
investigated in animal models
5
. Among these approaches nanoparticulate delivery of 
anti-TB drugs has assumed significance recently. Nanoparticles are stable solid 
colloidal particles consisting of biodegradable polymers or lipid materials and range 
in the size from 10 to 1000nm. Drugs can be absorbed onto the particle surface, 
entrapped inside the polymer/lipid or dissolved within the particle matrix
6
. 
Nanoparticular drug delivery though was focused initially on anti-cancer 
drug in the area of oncology its utility is extended to other areas of diseases 
including TB. It has been established in animal model that oral nanoparticle based 
anti-TB drug therapy can allow for reduction in dosing frequency for better 
management of TB. The past several years have seen the development of a number 
of rifampicin controlled release formulations for the improvement of clinical 
efficacy of the drug and patient compliance
2
.  
In earlier studies, Dalencon et al reported the loading of rifabutin in 
nanocapsules, and the preparation was evaluated in experimental toxoplasmosis
7
. 
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Lopes et al reported the encapsulation of ethionamide, a second- line antitubercular 
drug
8
. Evaluation of three front-line antituberculosis drugs (RIF, isoniazid, 
pyrazinamide) co-encapsulated in PLGA NPs was carried out by Pandey et al
9
. Anti 
tuberculosis drug-loaded solid lipid NPs have produced encouraging results
10
.  
Physicochemical properties play a major role to generate pharmaceutically 
acceptable nanoparticulate system. To obtain biocompatible nanoparticle system, 
molecular weight of polymers, concentration of surfactants and their influence on 
particle size and release need to be considered. In nanoparticle system particle size 
becomes increasingly importance since small particle have high absorption area, 
therefore they penetrate cell membrane more efficiently
11
. This may depend on the 
polymer molecular weight, properties of drug and device characteristics (preparation 
conditions, particle size, morphology and drug loading)
 12
.  Surfactants are used to 
stabilize nanoparticles by hindering their growth. The increase in the surfactant 
amount in colloidal dispersions may contribute to the reduction of mean particle size 
because of the surface active properties of surfactants
13
. They improve the stability 
of system through static electricity repulsive forces, steric hindrance, and Van der 
waals force by absorbing on to the surface of nanomaterials
14,15
. 
Despite several approaches attempted by researchers in the past, the 
improved bioavailability of rifampicin either from rifampicin alone or from fixed 
dose formulations has not been successfully achieved owing to degradation of 
rifampicin in the acidic environment of the stomach. 
Previous study reveals that rifampicin collected in the plasma sample can be 
stabilized by using ascorbic acid as anti-oxidant. It has been reported that rifampicin 
degrades in plasma at ambient temperature, and a 54% loss was observed within 8 
hrs. This degradation can be effectively prevented by adding ascorbic acid, thus 
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prolonging stability for up to 12 hrs
16
. Additionally administration of ascorbic acid 
(1000 mg/day) is recommended in tuberculous patient
17
. Besides, ascorbic acid is 
also added to the medium as an anti-oxidant to prevent oxidative degradation of 
rifampicin during the in-vitro diffusion
18
 and dissolution
19
 studies.  
Different polymers have been recommended for preparation of nanoparticles. 
Polymers may be bio degradable or non degradable. Biodegradable polymers are 
preferred as they are eliminated from the body and so polymer induced toxicity can 
be ruled out. Natural bio degradable polymers are more desirable as they are highly 
biocompatible. As TB requires long term treatment, naturally occurring bio 
degradable polymers are recommended for chronic infections
20
. Considering this, 
chitosan (CS) has been chosen as a polymer for the development of nanoparticles in 
the study. Chitosan is a naturally occurring bio compatible cationic polysaccharide 
obtained from the deacetylation of chitin. Compared to other natural polymers 
chitosan has a positive charge and is mucoadhesive and it is used extensively in drug 
delivery applications
21
. Besides chitosan being natural is considered ideal polymer 
for development of drug delivery systems used for chronic disease. They have the 
capacity to protect sensitive bioactive macromolecules from enzymatic and chemical 
degradation during storage
22
.
 
Chitosan has many advantages particularly for 
developing micro/nanoparticles. These include its ability to control the release of 
active agents; it avoids the use of hazardous organic solvents while fabricating 
particle since it is soluble in aqueous acidic solution
23
. There is a growing interest in 
producing nanoparticles containing antituberculous drugs using natural polymer 
such as chitosan
24
.  
Nanoparticles have been prepared most frequency by three methods (1) 
dispersion of performed polymers (2) polymerization of monomers and (3) ionic 
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gelation or coacervation of hydrophilic polymers. However, other methods such as 
supercritical fluid technology
25 
and particle replication in non wetting templates
26 
have also been described in the literature for production of nanoparticles. The latter 
was claimed to have absolute control of particle size, shape and composition, with 
could set an example for the future mass production of nanoparticles in industry. 
Thus, the literature reveals the importance of nanoparticulate approach for 
improving bio availability of rifampicin. Besides naturally occurring polymer such 
as chitosan is recommended for development of nanoparticles for chronic infections 
like TB.  The usefulness of ascorbic acid in stabilizing rifampicin against 
degradation in acidic environment of stomach has not been established, although 
ascorbic acid finds its use in dissolution medium or in plasma sample as stabilizing 
agent. More importantly, in clinical practice, daily administration of ascorbic acid 
(1000mg/day) is recommended to control tuberculous by promoting immune 
response. 
Considering the above factors, a two directional approach was attempted in 
the present study to investigate, first, whether ascorbic acid can protect rifampicin 
from degradation in the acid environment in the presence/absence of isoniazid and 
second, whether nanoparticulate delivery of rifampicin admixed with ascorbic acid 
can improve bioavailability of rifampicin. 
Aim and objective 
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2. AIM AND OBJECTIVE 
 
The present study attempted to develop ascorbic acid stabilized rifampicin 
nanoparticles for oral delivery for enhanced bioavailability of rifampicin and 
evaluate for physicochemical, in-vitro release and pharmacokinetics characteristics. 
The objectives of the study were as follows 
 
1. Preparation of standard curve of rifampicin in 0.1N HCL 
2. Preparation of rifampicin loaded chitosan nanoparticles by ionic gelation method  
    with different variables such as 
    a) Chitosan of different grades (150KDa, 300KDa, 450KDa) 
    b) Tween 80 in 0.25%, 0.5%, 1.0% concentrations 
    c) Stirring speed at 400rpm, 800rpm, 1200rpm 
3. Preparation of rifampicin-ascorbic acid loaded chitosan nanoparticles by ionic     
    gelation method from best formulation of rifampicin nanoparticles. 
4. Evaluation of rifampicin loaded chitosan nanoparticles 
    a) Drug and carrier interaction by FTIR Spectroscopy. 
    b) Thermal analysis by Differential Scanning Calorimetry (DSC).  
    c) Morphology by Scanning Electron Microscopy (SEM) 
    d) Surface characteristics by Zeta potential analyzer 
    e) Particle size determination by Zetasizer 
    f) Rifampicin encapsulation efficiency and loading capacity of the nanoparticles. 
g) In-vitro dissolution stability study of  
 Rifampicin 
 Rifampicin with isoniazid 
 Rifampicin with ascorbic acid (125mg) 
Aim and objective 
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 Rifampicin with ascorbic acid (250mg) 
 Rifampicin with ascorbic acid (500mg)  
 Rifampicin with ascorbic acid (1000mg) 
 Rifampicin with ascorbic acid (125mg) and isoniazid 
 Rifampicin with ascorbic acid (250mg) and isoniazid 
 Rifampicin with ascorbic acid (500mg) and isoniazid 
 Rifampicin with ascorbic acid (1000mg) and isoniazid 
  h)  In-vitro diffusion, in-vivo pharmacokinetic study of  
 Control (Rifampicin) 
 Rifampicin+ Isoniazid 
 Rifampicin-ascorbic acid  
 Rifampicin-ascorbic acid + Isoniazid 
 Rifampicin nanoparticles  
 Rifampicin nanoparticles + Isoniazid 
 Rifampicin-ascorbic acid nanoparticles  
 Rifampicin-ascorbic acid nanoparticles + Isoniazid 
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3. REVIEW OF LITERATURE 
3.1 Epidemiology of tuberculosis 
TB is an infection caused by M. Tuberculosis. The highest prevalence of 
tuberculosis infection and estimated annual risk of tuberculosis infection are in sub-
Saharan Africa and Southeast Asia. It is endemic in most developing countries and 
resurgent in developed and developing countries with high rates of human 
immunodeficiency virus (HIV) infection, particularly in Africa, although increases 
are also expected in Southeast Asia. In many industrialized countries, TB has 
recently failed to decline, and in Eastern Europe and the former Soviet Union, cases 
and deaths are increasing. Drug resistance is a serious problem, especially in the 
United States
27
.  
India is classified along with the sub-Saharan African countries to be among 
those with a high burden and the least prospects of a favorable time trend of the 
disease as of now (Group IV countries). The average prevalence of all forms of 
tuberculosis in India is estimated to be 5.05 per thousand, prevalence of smear-
positive cases 2.27 per thousand and average annual incidence of smear-positive 
cases at 84 per 1,00,000 annually
1
.  
TB remains a major cause of morbidity and mortality worldwide in the 21
st 
Century. The WHO and other organizations have put vast resources into studying 
the disease, as well as implementing and monitoring treatment. There are large 
disparities between the rates of TB in children in resource poor countries and those 
in industrialized countries. Factors such as poverty, overcrowding and HIV infection 
have contributed greatly to the resurgence of childhood TB, particularly in Sub-
Saharan Africa. The mortality rates from TB in children from resource-poor counties 
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are unacceptably high. While there are many challenges in the diagnosis and 
treatment of TB in children, perhaps the greatest challenge globally is to begin to 
identify the extent of disease in this forgotten group
28
. The TB incidence (number of 
new cases arising each year) and mortality in each of the WHO regions is depicted 
in Figure 1
29
. 
Effective control of tuberculosis (TB) requires an understanding of the 
changing epidemiology of the disease. The success in reducing the tuberculosis 
burden reflects several factors, including improved public health efforts, physician 
and patient education, infection control measures, and the use of directly observed 
therapy (DOT). Future efforts to curtail the incidence of TB will require vigilant 
public health efforts, improving education of patients and health care personnel, 
identifying mechanisms and routes of transmission, and assuring adequate treatment 
and prophylactic regimens among infected individuals
30
.  
 
Figure 1. Estimated TB incidence and mortality in 2003. 
Data extracted from WHO Tuberculosis data sheet (WHO-Geneva 2003). 
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3.2 Current chemotherapy for tuberculosis 
Since the control measures for TB such as Bacillus Calmette-Guérin (BCG) 
vaccination and chemoprophylaxis appear to be unsatisfactory, treatment with anti-
tubercular (anti-TB) drugs becomes the only option available. The goals of treatment 
are to ensure cure without relapse, to prevent death, to impede transmission, and to 
prevent the emergence of drug resistance. Long-term treatment with a combination 
of drugs is required
31
. Treatment of active TB with a single drug should never be 
attempted, and a single drug should never be added to a failing regimen, the result 
being development of MDR TB
32
. As suggested by WHO
33
, treatment of TB and 
drug resistant cases requires multi-drug therapy, comprising:  
1. An initial intensive phase of rifampicin (RIF), isoniazid (INH), pyrazinamide 
(PYZ), and ethambutol (ETB) daily for 2 months. 
2. A continuation phase of RIF and INH for a further 4 months, either daily or 3 
times per week, to be administered as advised in Table 1.  
   Table 1 Regimen 1 for treatment of new smear positive adult patients 
Intensive phase- 2 months Under 50 kg Over 50 kg 
RIF/INH/PYZ/ETB 
Combination tablets 120/60/300/200mg daily 5 
days per week 
 
4 tablets 
 
5 tablets 
Continuous phase Under 50 kg Over 50 kg 
RIF/INH 
Combination tablets 150/100mg 
Combination tablets 150/300 mg 
 
3 tablets 
- 
 
- 
 tablets 
 
      Data extracted from (Gibbon C)
34
. 
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INH eradicates most of the rapidly replicating bacilli in the first 2 weeks of 
treatment, together with streptomycin and ETB. Thereafter, RIF and PYZ have an 
important role in the sterilization of lesions by eradicating organisms; these two 
drugs are crucial for successful 6-months treatment regimens. RIF kills low or non-
replicating organisms and the high sterilizing effect of PYZ serves to act on semi 
dormant bacilli not affected by any other anti-TB agents in sites hostile to the 
penetration and action of the other drugs
35, 36
.  
INH and RIF, the two most potent anti-TB drugs, kill more than 99% of 
tubercular bacilli within 2 months of initiation of therapy
37,38
. Using these drugs in 
conjunction with each other reduces anti-TB therapy from 18 months to 6 months. 
The sites of action of these principal anti-TB agents are schematically illustrated in 
Figure 2
39,40,41
.  
The emergence of strains resistant to either of these drugs causes major 
concern, as treatment is then deferred to drugs that are less effective, have more 
toxic side effects, and result in higher death rates, especially among HIV-infected 
person
41
. The current armamentarium of drugs available for the treatment of TB, 
their mechanism of action, and activity have been reviewed by numerous authors
2 
and appear in Table 2. 
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Figure 2. Sites of action of the principle anti-TB drugs 
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Table 2 Classes of anti-TB drugs 
Agent Mechanism of action Activity against M. tuberculosis 
First-line agents 
Rifampicin (RIF) 
 
Inhibits bacterial RNA synthesis by binding to the β subunit 
of bacterial DNA-dependent RNA-polymerase (DDRP), 
inhibition of DDRP leads to blocking of the initiation chain 
formation in RNA synthesis. One of the most effective 
antituberculosis agents available and is bactericial for intra-
and extra-cellular bacteria.  
 
RIF inhibits susceptible organisms at 
concentrations of less than 1 µg/ml. 
Isoniazid (INH) 
 
Most active drug for the treatment of TB caused by 
susceptible strains.  Is a pro-drug activated by KatG, which 
exerts its lethal effects through inhibition of synthesis of 
mycolic acids, an essential component of mycobacterial cell 
walls, through formation of a covalent complex with an acyl 
carrier protein (AcpM) and KasA, a beta-Ktoacyl carrier 
protein synthetase.   
INH inhibits tubercle bacilli as a 
concentration of 0.2 µg/ml. 
 
Pyrazinamide (PYZ) Converted to the active pyrazanoic acid (encoded by pncA) 
by pyrazinmidase in susceptible organisms.  Pyrazanoic acid 
lowers pH in the immediate surroundings of     M.tuberculosis 
Inhibits M.tuberculosis and other 
mycobacteria at concentrations of 20µg/ml. 
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– organisms is unable to grow.  May also function as an 
antimetabolite of nicotinamide and interfere with the 
synthesis of NAD, inhibiting the synthesis of short-chain, 
fatty-acid precursors. 
Aminoglycosides 
(injectable)  
Streptomycin, kanamycin, 
amikacin, capreomycin. 
The aminoglycosides are irreversible inhibitors of protein 
synthesis through binding to specific 30s-submit ribosomal 
proteins. 
Bacterial in vitro and in vivo clinical data 
support use. 
 
 
Inhibit bacterial DNA synthesis through inhibition of bacterial 
topoisomerase II (DNA gyrase) and topoisomerase IV, which 
are responsible for the relaxation of supercoiled DNA and the 
separation of replicated chromosomal DNA, respectively 
Bactericidal broad spectrum antibacterials 
in-vitro and in-vivo clinical data support 
use.  Ciprofloxacin and levofloxacin inhibit 
strains of M. tuberculosis at concentrations 
of less than 2µg/ml.   Newer agents 
(moxifloxacin, gatifloxacin, sparfloxacin 
have lower minimum inhibitory 
concentrations. 
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Other drugs 
Clofazimine 
 
 
 
 
Amoxicillin/ 
clavulanic – acid 
 
Clarithromycin 
 
 
 
 
 
Rifabutin 
 
Potentially useful agents with conflicting animal or clinical 
evidence or agents with unclear efficacy because of possible 
cross-resistance.  
Unknown but may involve DNA binding possesses direct anti 
mycobacterial and immunosuppressive properties 
Amoxicillin (a penicillin) inhibits cell wall synthesis, 
Clavulinic acid is a beta-lactamase inhibitor  
 
Inhibition of protein synthesis via binding to 50S ribosomal 
RNA as aminocacyl translocation reaction and the formation 
of initiation complexes are blocked 
 
 
 
Activity is similar to that of rifampicin, inhibits bacterial 
RNA synthesis by binding strongly to the β submit of 
bacterial DNA dependent RNA-polymerase 
 
Bacteriostatic in-vitro MIC 90<1.0mg in-
vitro. Apt concentrations attainable in vivo 
particularly in macrophages 
β-lactams in combination with beta 
lactamase inhibitors bactericidal in vitro. 
Although in-vitro anti-myco bacterial 
properties reported data from animal in 
vivo studies conflicting.  
May be useful against some isolates of 
MDRTB (resistant to RIF in vitro but 
sensitive to rifabutin). Effective in 
prevention and treatment of disseminated 
atypical mycobacterial infection in AIDS 
patients with CD4 counts < 50. 
In vivo and in vitro evidence of 
bacteriostatic activity.  Cross – resistance 
frequently seen between thiacetazone and 
both INH and ethionamide. 
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TB is treated with a multi-drug regimen, and is thus exceptionally vulnerable 
to incidences of side effects, unsatisfactory patient compliance and slow 
improvement of patients
42
. Therefore, despite the availability of these highly 
effective treatments for TB, cure rates remain low as commercial anti-TB 
formulations are inconvenient to administer and patients do not take the prescribed 
medications with sufficient regularity and duration to achieve a cure
43
.  
Patients have to consume a large number of tablets (up to eight at one time), 
which is a common cause for non-compliance. It can be anticipated that non-optimal 
application of these short course regimens will result in the deterioration of their 
therapeutic potential, an escalation in the mortality rate and increased risk of 
developing acquired drug resistance
29,44,45
. Resistance of M.tuberculosis to anti-TB 
agents is a worldwide problem in both immune competent and HIV-infected 
population
46,47
. 
3.3 Novel drug delivery systems for the treatment of TB 
Chemotherapy of TB is complicated by the need of multidrug regimens that 
need to be administered over long periods. Poor patient compliance is the single 
most common reason for chemotherapy failure in TB
42
. To minimize toxicity and 
improve patient’s compliance, extensive progressive efforts have been made to 
develop various implant, micro particulate, and various other carrier-based drug 
delivery systems to either target the site of M. tuberculosis infection or reduce the 
dosing frequency, which forms an important therapeutic strategy to improve patient 
outcomes
5,48
. The systems under discussion employ either biodegradable polymers 
or systems requiring removal after use, and can release the drug either by membrane 
or matrix-controlled diffusion.  
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Recent trends in controlled drug delivery have seen micro encapsulation of 
pharmaceutical substances in biodegradable polymers as an emerging technology. 
Carrier or delivery systems such as liposomes and microspheres have been 
developed for the sustained delivery of anti-TB drugs and have demonstrated better 
chemotherapeutic efficacy when investigated in animal models (e.g. mice)
5
. Anti-TB 
drugs have been successfully entrapped and delivered in biodegradable polymers 
such as poly (DL-lactide-co-glycoside) (PLG), which are biocompatible and release 
drug in a controlled manner at therapeutic levels
49
. 
Dutt and Khuller (2001)
50 
have entrapped INH and RIF in PLG polymers. 
When injected subcutaneously as a single dose, the micro particles, having a 
diameter ranging from 11.75 μm to 71.95 μm, provided sustained release of drugs 
over 6–7 weeks when tested in mice. The authors previously observed that particles 
with a size range >10 μm remained at the site of injection forming a depot. The 
entrapped contents of the micro particles were gradually released by diffusion 
through the polymeric particles. Such depots can show release profiles extending 
over several months culminating in degradation of the entire polymeric device. 
However, these formulations have to be injected either subcutaneously or 
intravenously, and the pain and discomfort associated with these routes of 
administration, in general, is often not acceptable. Hence, there is a continuous need 
to develop an oral drug delivery system that is convenient for patients
18
. 
Amidst these concerns, Ain et al (2002)
51
 reported the pharmacokinetics of 
PLG encapsulated anti-TB drugs; orally administered either individually or in 
combination in mice. A study conducted by Pandey et al (2003) 
48
 reported the 
formulation of three frontline anti-TB drugs, i.e. RIF, INH and PYZ encapsulated in 
PLG nanoparticles. On oral administration of drug-loaded nanoparticles to M. 
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tuberculosis-infected mice at every 10th day, no tubercle bacilli could be detected in 
the tissues after 5 oral doses of treatment. Therefore, oral nanoparticle-based anti-
TB drug therapy can allow for a reduction in dosing frequency for better 
management of TB. 
Prabakaran
42
 developed an osmotically regulated capsular multi-drug oral 
delivery system comprising asymmetric membrane coating- and dense semi 
permeable membrane coating-capsular systems for the simultaneous controlled 
administration of RIF and INH for the treatment of TB. This was in an attempt to 
reduce the problems associated with multidrug therapy. The modified asymmetric 
system provided satisfactory sustained release of RIF and INH, with an initial burst 
release that may be sufficient to achieve minimum effective concentration in blood. 
Thereafter, the system provided the release of the drugs in a near zero order rate – an 
ideal release profile for controlled drug delivery. In turn, this would improve the 
safety profile of the drugs and enhance the activity duration of drug exhibiting short 
half-lives. The once daily system is optimal, and could potentially enhance patient 
compliance.  
Further attempts to solve the problems inherent in multidrug therapy have 
included the development of biodegradable polymeric micro- or nanoparticulate 
carrier systems to target alveolar macrophages that harbour M.tuberculosis. In the 
case of pulmonary TB, delivering the drug directly to the site of infection through 
inhalation of an aerosolised delivery system has the inherent advantages of 
bypassing first-pass metabolism and maintaining local therapeutically effective 
concentrations with decreased systemic side effects
15
. Because M. tuberculosis is   
known to infect alveolar macrophages and affect the pathogenesis of TB, there have 
been renewed interests in targeting of anti-TB drugs to these cells. Despite the 
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success of these systems in targeting and providing sustained release of anti-TB 
drugs to alveolar macrophages, the methods used to generate particles in these 
studies vary in their capability for the production of reproducible particles with the 
optimal size for inhalation therapy (i.e. <5μm).  
Barrow et al (1998)
52
 formulated RIF-loaded microspheres using the method 
of solvent evaporation, aiming to maintain a size of 1 to 10-μm. Only the size 
distributions of two formulations were reported, being 3 to 4 μm and distribution 
demonstrated a Gaussian curve.   
Dutt and Khuller ( 2001)
53 
encapsulated INH and RIF into hardened PLG 
micro particles by a double emulsification solvent evaporation procedure, and these 
had a resultant volume mean diameter of 11.75 μm for INH microparticles and 11.64 
μm for RIF microparticles. These are currently undergoing Phase I trials. Sharma et 
al (2001)
54
 incorporated both INH and RIF into PLG microspheres using a 
combination of solvent extraction and evaporation, but these particles had a mean 
diameter of 6.214 μm and only 38% of the microspheres fell in the size range of 
0.5–3 μm. Suarezet et al (2001)55 attained the airway delivery of RIF microparticle 
shaving volume median diameters of 2.76 ± 1.57μm. O'Hara and Hickey56 
succeeded in obtaining RIF loaded PLG particles with median diameters by volume 
of 2.76 μm and 3.45 μm by spray drying and solvent evaporation respectively.  
Zhou et al (2005)
15
 did achieve the formulation of spherical micro particles 
between 1 and 3 μm in diameter. The microparticles, prepared by the precipitation 
with a compressed anti solvent process, were evaluated for their potential in 
targeting an ionizable prodrug of INH, isoniazid methane sulfonate (INHMS), for 
sustained delivery of INH to alveolar macrophages. 
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Most recently Zahoor et al (2006)
57
 undertook pharmacokinetic and 
chemotherapeutic studies with aerosolized alginate nanoparticles encapsulating INH, 
RIF and PZA and RIF, INH, PYZ, ETB. The nanoparticles were prepared by cation-
induced gelification of alginate and were 235.5± 0 nm in size, with drug 
encapsulation efficiencies of 70–90% for INH and PZA and 80–90% for RIF and 
88–95% for EMB. The majority of particles (80.5%) were in the respirable range, 
with a mass median aerodynamic diameter of 1.1 ± 0.4 μm and geometric standard 
deviation of1.71 ± 0.1 μm. The chemotherapeutic efficacy of three doses of drug-
loaded alginate nanoparticles nebulised 15days apart was comparable with 45 daily 
doses of oral free drugs. Thus, inhalable alginate nanoparticles could potentially 
serve as an ideal carrier for the controlled release of anti-TB drugs. Clinical trials are 
envisaged in the future for evaluation of this system before use in humans.  
Pandey and Khuller
58
 evaluated the chemotherapeutic potential of nebulised 
solid lipid nanoparticles (SLNs) incorporating RIF, INH and PYZ against 
experimental TB. SLNs are nanocrystalline suspensions in water, prepared from 
lipids, which are solid at room temperature. The SLNs, prepared by the emulsion 
solvent diffusion technique, possessed a favourable mass median aerodynamic 
diameter suitable for broncho alveolar drug delivery. Following a single nebulisation 
to guinea pigs, therapeutic drug concentrations were maintained in the plasma for 5 
days and in the organs for 7 days whereas free drugs were cleared after 1–2 days. 
 Vyas
59
 formulated aerosolized liposomes incorporating RIF via a cast-film 
method employing egg phosphatidylcholine- and cholesterol based liposomes. 
Liposomes coated with alveolar macrophage-specific ligands demonstrated 
preferential accumulation in alveolar macrophages, maintaining high concentrations 
of RIF in the lungs even after 24 hours. 
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 In another approach to solve the predicament of poor patient compliance, 
depot-delivery of anti-TB drugs has been investigated. Studies have demonstrated 
that a single implant of INH in polylactic-co-glycolic acid (PLGA) copolymer could 
ensure sustained levels of free INH for a period of up to 8 weeks following 
implantation in rabbits
49
.  
A number of the aforementioned developments in drug delivery represent 
attractive options with significant merit, and the pertinent points regarding each 
exemplary investigation are summarized in Table 3. However, the need to develop 
an oral drug delivery system with improved patient acceptance is affirmed by the 
accelerated pace of oral drug delivery system development fostered by the need to 
deliver medications to patients more efficiently and with fewer side effects, 
especially in developing countries where controlled-delivery implants and 
injectables could be too expensive. 
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Table 3 Synopsis of novel anti-TB drug delivery systems
2
 
Drug 
Delivery System and 
Polymer employed 
ROA Preparation Method Characterization studies and system suitability 
INH 
 
 
 
 
Porous, non-porous and 
hardened microparticles 
employing PLG 
 
SC injection 
 
 
  
Double emulsification 
solvent evaporation 
Size: Mean volume diameters were 62.11 µm, 71.95 µm, 11.75 
µm, for porous, non-porous and hardened micro particles, 
respectively.  
In vitro studies:  sustained release of INH up to 6 days from non-
porous microparticles.  Porous microparticles released INH over 3 
days.Hardened PLG microparticles sustained releases of INH for 
up to 7 weeks. 
In vivo disposition studies (In mice): porous and non-porous 
microparticles released INH in plasma for up to 2 days.  Hardened 
PLG microparticles sustained release INH for up to 7 weeks.  
Concentrations of INH obtained were higher than the MIC of INH. 
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RIF, INH, 
PYZ, ETB 
Microparticles employing 
PLG 
Oral, singly or  
in combination 
Double emulsification 
solvent evaporation 
DEE: 8-10% for PZA: 10-11% for INH and 12-18% for RIF. 
Size: diameters were I. II µm for I.40 µm for RIF and 2.20 µm for 
PZA microparticles. 
In vitro studies:  entrapped drugs were released in a sustained 
manner.  In the intestinal fluid drug release was obtained for up to 
20 days. 
In vivo studies:  entrapped drugs remained in circulation up to 72 
has compared to free drugs (eliminated within 24h).  Level of PLG 
encapsulated INH was found to be higher than its MIC value (0.1 
µm/ml). 
Pharmacokinetics: (PLG encapsulated of drugs and free drugs):  
increased C, AUC and   t1/2 (e) when drug were given entrapped in 
PLG microparticles indicated the potential of PLG for effective 
treatment TB. 
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RIF, INH, 
PYZ 
Nanoparticles employing 
PLG 
Oral 
 
Multiple emulsion 
technique 
Size: majority (>80%) in the size range of 186-290nm, 
polydispersity index of 0.38=0.04 
DEE: 56.9±2.7% for RIF, 66.3=508% for INH and 68±5.6% for 
PZA 
Drug loading: 570 to 680 mg drug per gram of polymer. 
In vitro studies: drug release profile in PBS showed an initial (up 
to 48h) burst release followed by a negligible release of either 
drug up to 6 weeks. 
In vivo studies:  (experimental infection and chemotherapy):  
following oral administration of drug loaded nanoparticles to M. 
tuberculosis infected mice at every 10
th
 day-no tubercle bacilli 
could be detected in the tissues after 5 oral doses of treatment. 
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RIF, INH 
 
 
Osmotically regulated 
capsular multi-drug oral 
delivery system 
employing HPMC and 
NaCMC 
Oral  
 
Phase inversion 
process-precipitation 
of membrane structure 
on stainless steel 
mould pin  
SEM:  Porous structure of the membranes was evident. 
In vitro studies:  sustained release of RIF and INH with Intel 
burst release.  Which may be sufficient to achieve MIC in blood.  
Therefore the system sustained the release of the drugs in a near 
zero order rate. 
In vitro release kinetics:  first order kinetics.  Statistical analysis 
of release rate data-modified asymmetric system the preferred 
system. 
INH, RIF Microparticles employing 
PLG 
SC, inhaled Double emulsification 
solvent evaporation 
Size: volume mean diameters of 11.75 µm (INH – loaded) and 
11.64 µm (RIF-loaded) 
DEE: 10-11% (INH-loaded) and 12-14% (RIF-loaded) 
In vivo-combination drug disposition studies and experimental 
infection and chemotherapy studies:  
Single dose of PLG microparticles-sustained release of INH and 
RIF for up to 7 and 6 weeks, respectively.  Free drugs in 
combination injected in the same doses were detectable in vivo up 
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to 24 h only.  One dose of PLG microparticles cleared bacteria 
more effectively from lungs and liven in experimental marine 
model of TB (compared with a daily administration of the free 
drugs) phase trials. 
INH, RIF, 
PZA and 
RIF, INH, 
PYZ, ETB 
Nanoparticles employing 
alginate  
Inhaled Cation- induced 
gelification of alginate 
Size: 235.5 ±0 nm in size, with majority of particles (80.5%) were 
in the respirable range, with mass median aerodynamic diameter 
of i.± 0.4µm and geometric standard deviation of 1.71±0.1µm. 
DEE: 70-90% for-90% for INH and RIF, 80-90% for RIF and 88-
95% for ETB. 
In vivo studies (disposition studies and chemotherapeutic 
studies): The formulation was orally administered to mice at two 
does levels. A comparision was made in mice receiving free drugs 
at equivalent doses. Relative bioavaibilities of drugs encapsulated 
in alginate nanoparticles significantly higher compared with oral 
free drugs. Drug levels were maintained ar or above the MIC90 
post nebulisation until Day 15 in organs (lungs, liver and spleen) 
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after administration of encapsulated drugs, whilst free drugs stay 
at or above the MIC90 up to Day 1only irrespective of dose. 
Clinical trials envisaged in the future. 
RIF , INH 
and PYZ 
 
Nebuilised SLNs 
Prepared from 
nanocryalline lipid 
suspension in water 
Inhaled Emulsion solvent 
Diffusion Technique 
Size: Favourable mass median aerodynamic diameter suitable for 
bronchoalveolar drug delivery 
In vivo Studies: Theraputic experimental TB drug concentrations 
were maintained in the plasma for 5 days and in the the organs for 
7 days whreas free drugs were cleared  by  1-2 days 
Modification: Imparted negative charge (DCP) or by coating 
them with alveolar macrophage specify ligands (MBSA and 0-
SAP). 
RIF 
 
Aerosoliposme 
formulated  using Egg 
PC- and Chol-based 
Liposomes 
 
Inhaled Neutral Liposomes 
were prepared by case 
film method 
Size: Netural and negatively charged liposomes composed of 
PC:Chol:DCP  had average vesicle size of 2.32±0.48 µm, 
respectively. MBSA-Coated liposomes size: 3.64±0.65µm, 0-
SAP-coated vesicles size: 3.85±059µm. 
DEE: 47.4±2.7%. 
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In vivo studies: Precent viability of mycobocterum smegnatis 
inside macrophages  (invitro) after administration od drug (in 
vivo) was 7-11% (ligand-anchoraed liposomal aerosols), 45.7 and 
31.6% case of plain Drug and plain neutral liposomal 
aerosol(based on PC: Chol) – treated macrophages. Preferential 
accumulation of MBSA-and 0-Sap- coated formulations in 
alveolar macrophages. Drug was estimated in the lung in high 
concentration (even after 24 h). 
INH 
 
Implementaion from 
PLGA 
 
Depot 
 
PLGA polymer rods 
 
In vivo studies: Rods implanted in the back of rabbits under 
anaesthesia. Concentations of INH and acetyl isoniazid in serum 
and urine determined by HPLC. Concentrations of INH≥ 0.2 
µg/ml were found both in serum and urine up to 63 days after 
implant. Urine specimen obtained at 6 weeks after implant 
inhibited the growth of M. tuberculosis in vitro measured by 
radiometric (Bactec) Method. 
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INH, PYZ Single implants prepared 
from PLGA 
Depot Depot drug preparation In vivo Studies : 3 times the daily dose of PYZ contained in 
single PLGA polymer implant – no burst levels of the drug evident 
after administration – sustained levels up to 54 days. 
Chemotherapeutic activity Investigated in mice of the single 
PLGA Polymer Implants similar to standard oral treatment with 
the two drugs given daily for 8 weeks, determined by mortality 
and CFU counts of tubercle bacilli from lungs and spleen. 
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Chol = Cholesterol, DCP = Dicetylphosphate, DEE= Drug entrapment efficiency, 
HPLC= High performance liquid chromatography, HPMC = Hydroxy propyl methyl 
cellulose,MIC -Minimum inhibitory concentration, NaCMC = Sodium carboxy 
methyl cellulose, PBS= Phosphate-buffered saline, PC= Phosphatidylcholine, 
MBSA = Methylated bovine serum albumin, and O-SAP=O-sterile amylopectin, 
ROA= Route of administration, SC=Subcutaneous, SLN=Solid lipid nanoparticles. 
3.4 Causative factors for poor bioavailability of rifampicin 
3.4.1 Drug adsorption by the excipients 
When rifampicin is administered along with p-amino salicylic acid, which is 
also an anti-tubercular drug, its absorption is delayed and the Cmax and the AUC 
values are reduced to a half, than that obtained by the administration of rifampicin 
alone
60
. This observation has been attributed to the adsorption of rifampicin on 
bentonite, which was used as an excipient in the manufacture of p-amino salicylic 
acid granules
61
. The bioavailability of rifampicin is also reported to reduce 
significantly when it is administered along with antacids
62
. The effect of antacids on 
the bioavailability of rifampicin is shown to be in the order of magnesium trisilicate 
> aluminium hydroxide > sodium bicarbonate, and is ascribed to the combined 
effects of gastric pH elevation, chelation of drug by aluminium ions and binding of 
rifampicin with magnesium trisilicate. The drug is also bound to an extent of        
16–20% by the partially neutralized magnesium silicate at pH 5. 
It is unlikely that drug adsorption is the cause, in particular, for poor 
bioavailability of rifampicin from FDC products. First of all, the FDC formulations 
(tablets or capsules) contain excipients in amounts much lower than drugs present. 
Secondly, the solid formulations generally do not contain adsorbents as excipients in 
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significant quantities. The only likelihood in that situation could be the inadvertent 
administration of antacids to patients along with the FDC products. But as this 
would happen even in formulations containing rifampicin alone, this reason even 
does not explain the typical poor bioavailability of rifampicin from FDC products. 
3.4.2 Formulation factors 
The formulation factors certainly can be a cause of variable bioavailability, 
as the performance of the formulation per se depends upon the quality of active 
ingredient(s), quality and combination of excipients, the process used in the 
manufacture, and the packaging. During development of formulations, several trials 
with different excipients and/or process are made, before the formulation of desired 
characteristics and stability is obtained. It means that intermediate formulations exist 
that do not conform to desired specifications. In case the person involved in 
formulation is not fully experienced and trained, and is not in knowledge of the 
intricacies of the formulation development, the end product might be a half-baked 
poor-performing formulation, which might get into the market.  
Many pharmaceutical companies in several parts of the world do not have 
quality control measures available with them, and the performance of the 
formulations so produced cannot be judged before release. This problem is 
compounded by the absence of a simple in vitro test that can act as an effective 
substitute to in vivo bioavailability evaluation, which is a costly proposition. In such 
situations, formulation-to-formulation and batch-to-batch variations are bound to 
happen. The variations have been observed practically, for example, bioavailability 
of nine different single-drug  rifampicin formulations of three pharmaceutical forms, 
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syrups (2), tablets (4) and capsules (3), was evaluated by Mannisto
63 
(1976) and both 
inter- and intra-formulation differences were observed. 
Similarly, in a recent study, variations were reported in bioavailability of 
multiple marketed FDC products
64
. Evidently, the variations due to formulation 
factors occur both in single rifampicin and the FDC products, suggesting that there 
is a still more specific reason that is responsible for the typical overall poor 
bioavailability of rifampicin from FDC products, as compared with the formulations 
containing rifampicin alone. 
3.4.3 Drug decomposition 
The decomposition of RIF has varied from 8.5 to 50% in the acidic 
environment of the stomach in the time range corresponding to the gastric residence 
time for most dosage forms in humans (≈15 minutes to 105 ± 45 minutes)65,3. 
However, the gastric-emptying time for some single-unit dosage forms may reach 6 
hours. The use of substandard FDC will ultimately result in drug resistant TB and 
treatment failure
43
. The factors proposed for this variation in the bioavailability of 
RIF from different FDC formulations include the particle size and crystalline form 
of the drug, manufacturing process and the excipients employed
66
. The effect of 
these factors, however, has not been convincingly explained in previous studies. 
RIF is known to undergo hydrolysis in acidic medium to the insoluble 3-
formyl rifamycin SV (3FRSV). INH accelerates degradation of RIF into this poorly 
absorbed derivative (3 FRSV) in the acidic environment of the stomach via 
reversible formation of the isonicotinyl hydrazones of 3-FRSV with INH
4
.      
Shishoo et al (2001)
3
 has indicated that RIF in the presence of INH as a FDC may 
undergo greater decomposition in the acidic conditions of the stomach, as compared 
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to when RIF is administered (orally) alone. Thus, less RIF will be available for 
absorption from FDCs as compared to RIF administered as a separate formulation. 
This will be reflected in the poor bioavailability from the former formulation.  
There is thus an urgent need to modify or segregate the FDC formulation in 
such a way that RIF and INH are not released simultaneously in the stomach. 
Alternatively both drugs need to be administered separately after an interval 
corresponding to average gastric residence time, which is somewhat unpredictable 
due to high intra- and inter-subject variability
65,3,67
.  
 Fairly recently, Chen proposed a mechanism for this apparent degradation of 
RIF. 3-FRSV and INH could possibly undergo Schiff's reaction to form a complex. 
The carbonyl groups and amine groups may rearrange to yield an ammonium ion. 
The C-4 hydroxyl group enhances the complex formation by possibly forming a 
hydrogen bond with the hydrogen atom attached to the nitrogen. This is a basic 
requirement of the Schiff's reaction. In addition, carboxylic acids and alcohols can 
also undergo carbonyl condensation reactions. INH could react with RIF in this 
manner, which could account for the instability of RIF when present together with 
INH .This interaction could also occur between RIF and PYZ, however, it has 
frequently been observed that INH caused further RIF stability reduction compared 
to PYZ. The reason for this could be due to the fact that the carboxylic acids and 
alcohol further undergo Fischer's esterification
68
. The hydroxyl groups of RIF are 
readily able to react with the aqueous carboxylic acid degradants yielded by INH 
and PYZ to form an ester. However, as PYZ lacks the electron-withdrawing group, 
such as the secondary nitrogen found on the hydrazine group of INH, there are fewer 
tendencies for this reaction to be expected between PYZ and RIF.  
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Permeability studies have demonstrated that RIF is well absorbed from the 
stomach due to its solubility, which has been shown to be maximal between pH 1–2. 
INH, although demonstrating solubility in the gastric environment, is comparatively 
well absorbed from all three segments of the small intestine. RIF and INH thus 
exhibit regional specific permeability, and the bioavailability problems associated 
with RIF could be overcome by developing an FDC in which the delivery of the two 
drugs is segregated, with RIF released in the stomach and INH in the small 
intestine
69
. A FDC multi particulate oral system, which boasts ease of manufacture 
and directly attacks RIF bioavailability concerns and poor patient compliance with 
existing FDC anti-TB formulations, is yet to be globally developed. 
3.5 Methods adopted to minimize/prevent the degradation of rifampicin 
Rifampicin is a first line antituberculous drug as oral dosage form. It is 
primarily absorbed from the stomach due to its solubility in the gastric pH, however 
undergoes degradation in the gastric environment and the degradation is further 
influenced by concurrently administered isoniazid. So it remains a concern for the 
bioavailability of rifampicin from a number of FDC anti TB formulations. 
Rifampicin is well absorbed from the stomach due to its solubility, which is 
maximum between pH 1-2. Isoniazid is poorly absorbed from the stomach, but is 
well absorbed from all three segments of the intestine. In combination, rifampicin 
disappearance was enhanced in the presence of isoniazid in the stomach and 
jejunum, but isoniazid disappearance was not influenced by rifampicin. The study 
shows higher in situ rifampicin disappearance in the presence of isoniazid, 
attributable to drug degradation due to catalysis by isoniazid. As the two drugs show 
regional specific permeability, FDCs without reduced rifampicin bioavailability 
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resulting from its decomposition in the presence of isoniazid can be designed by 
segregating delivery of the two drugs by around 3-4hrs. Rifampicin should be 
released in the stomach and isoniazid in the intestine
69
. 
The problem with rifampicin is its poor/variable bioavailability of rifampicin 
in anti-tubercular fixed-dose combination (FDC) products. They determined that 
rifampicin decomposition is enhanced by the presence of isoniazid in stomach after 
ingestion. 80–90% of rifampicin was dissolved in 0.1 N HCL within 10 min, and all 
samples showed an overlapping dissolution profile
4
. Degradation of rifampicin in 
0.1N HCl, and simulated gastric fluid (SGF) at 37°C in 45 min (USP dissolution test 
conditions) in the absence and presence of isoniazid has been documented. 
Rifampicin alone decomposes in the described conditions to an average extent of 
6.33%, while the loss of rifampicin in the presence of isoniazid increases on an 
average to 16.32%
3,70
. 
The stability of rifampicin in plasma kept at an ambient temperature for 
24hrs or stored at -20ºc for 2 weeks, the possible protective effect of adding ascorbic 
acid is possible. Rifampicin degrades rapidly in plasma at ambient temperature, and 
54% loss was observed within 8hrs. This degradation can be effectively prevented 
by adding ascorbic acid, thus prolonging the stability for upto 12hrs. Rifampicin 
occurs after storage for 1 week at -20
0
c. However samples supplemented with 
ascorbic acid before freezing, no degradation was observed within 14 days
16
. 
    Rifampicin oxidizes in solution to form rifampicin quinone. Ascorbic acid is 
often added to solutions of RIF to slow down this oxidation and explained on short 
term stability studies in plasma, no degradation was observed in thawed samples up 
to 9 hrs. The response after 9hr were 93.7% and 96.1% of the response at t=0hr at 
RIF concentrations. Degradation was observed at lower concentration of the drug 
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(0.5µg/ml) in the freeze thaw samples. However, at high concentration (20 µg/ml), 
this degradation was less evident
71
. 
Contact between rifampicin and isoniazid can decrease the degradation of 
rifampicin. Delay of rifampicin release in the acidic medium was achieved by 
preparing the Rifampicin-Sodium lauryl sulphate mixture in the ratio of 1:1 by co-
grinding method which is a relatively simple and effective method. Thus this 
approach is beneficial for the segregation of release pattern of rifampicin in alkaline 
environment and isoniazid in the acidic environment of the GI tract, which will lead 
to prevent the degradation of rifampicin alone and its interaction with isoniazid
72
. 
3.6 The rationale for the development of a novel fixed dose combination anti-  
 TB drug delivery System 
Drug delivery, which takes into consideration the carrier, the route and the 
target, has evolved into a strategy of processes or devices designed to enhance the 
efficacy of therapeutic agents through modified or controlled release. This may 
involve enhanced bioavailability, improved therapeutic index, or improved patient 
acceptance or compliance. Drug delivery has been defined by Flynn as 'the use of 
whatever means possible, be it chemical, physicochemical or mechanical, to regulate 
a drug's access rate to the body's central compartment, or in some cases, directly to 
the involved tissues. The underlying principle that drug delivery technology can 
bring both therapeutic and commercial value to health care products has been widely 
accepted. This has created an intense need for presenting 'old' drugs, such as those 
encompassed in the anti-TB regimen, in new forms utilizing novel modes of 
delivery and dosage forms
73
. Patient failure to take the prescribed medications at the 
required intervals results in significant morbidity and mortality. The need for 
research into an oral anti-TB drug delivery system is thus warranted as the efficacy 
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of the current regimen may be improved if the delivery rate, biodegradation, and 
site-specific targeting can be predicted, monitored and controlled.  
From a financial and a global health care perspective, finding new ways to 
administer the anti-TB drugs in oral form and delivering the multiple doses, long-
term therapy in inexpensive, potent, forms with improved bioavailability is needed. 
The provision of an administration method, embodied by a dosage form that 
addresses FDC bioavailability concerns, that will allow patients to safely treat 
themselves and enhance their compliance with the anti-TB regimen is a significant 
health care development, particularly in developing countries where access to 
doctors, clean syringes, sterile needles, and sophisticated treatments are few and far 
between.  
As mentioned, the major route of drug administration is through the oral 
cavity. This route provides the greatest comfort and convenience of dosing. In 
addition to avoiding the patient discomfort associated with the parentral route, the 
accidental overdosing of the drug can be corrected by withdrawing the unabsorbed 
drug from the stomach. An anti-TB dosage form that can be orally administered 
once daily would be optimal for patient compliance
42
. In addressing oral 
bioavailability concerns, chemical modification or pro drug formation may well be 
successfully implemented to alter the pharmacokinetics of RIF and INH. Prodrug 
strategies have successfully improved the oral bioavailability of numerous 
compounds. In many cases, this involves masking a polar group by esterification to 
increase lipophilicity and enhance the extent of absorption from the gastrointestinal 
tract. After absorption, the ester is enzymatically hydrolysed to release the parent 
drug. 
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RIF was developed in the Dow-Lepetit Research Laboratories (Milan, Italy) 
as part of an extensive program of chemical modification of the rifamycins, the 
natural metabolites of Nocardia mediterranei as the hydrazone with N-amino-N'-
methyl piperazine that was the most active in the oral treatment of infections in 
animals and, after successful clinical trials, was introduced into therapeutic use in 
1968
74
. To date, no form of RIF has been widely clinically applied that significantly 
improves on its oral bioavailability. There is little solubility advantage associated 
with polymorphic forms, which are in consequential from a clinical and regulatory 
point of view
75
. A piperine composition for the improvement of gastrointestinal 
absorption and systemic utilization of nutrients and nutritional supplements 
comprising an extract from the fruit of Piper containing a minimum of 98% of pure 
alkaloid piperine, has been added to multi-drug formulations for the treatment of TB 
and leprosy. A formulation, containing RIF, INH and PYZ and the said composition, 
has been tested in human volunteers (Indian Patent No.1232/DEL/89). In the 
majority of cases, the comparative levels and peak concentration of the drugs in the 
presence of piperine were higher.  
The applicability of these results to bioavailability enhancement, which aims 
to lower dosage levels and shorten the treatment course, is apparent but presently 
cost prohibitive in developing countries. INH was synthesized in 1912 from ethyl 
isonicotinate and hydrazine by Meyer and Malley as part of their doctoral work in 
Prague. In 1945, its anti-TB properties were elucidated when nicotinamide was 
discovered to have anti-TB effects. Being a pro-drug itself, activated through 
endogenous mycobacterial catalysis, various additional chemical modifications have 
been investigated to alter INH pharmacokinetics. 
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 Gianolla et al (1992)
76
 attached various acyl groups to the amine (-NH2) 
function of INH for improved lipophilicity and afforded good yields in prodrugs, 
which were characterised by spectroscopic and analytical methods. Crooks et al 
(2004)
77
 proposed the fabrication of an INH prodrug through the formation of 
covalent conjugates of INH with mono-di- and polyoxy alkanoic ortho alkanoic 
acids. The conjugation is purported to provide covalent compounds having a 
chemotherapeutic effect, with enhanced permeation of biological membranes, which 
remain intact until enzymatically cleaved.  
As reported, Zhou et al (2005)
15
 developed an ionizable prodrug of INH, 
INHMS, for sustained delivery of INH to alveolar macrophages. The charged 
prodrug was ion paired with two different hydrophobic cations: tetra pentyl 
ammonium-and tetra heptyl ammonium-bromide. The prodrug required loading into 
microparticles for realization of the targeted sustained effect. Prodrug formation is 
clinically relevant in altering in vivo disposition kinetics and in attaining sustained 
release, but developments have not necessarily addressed the deleterious RIF-INH 
interaction upon oral administration. Shishoo et al (2001)
3
 have promoted the need 
for the development of a stable formulation containing the RIF-INH combination for 
differentiated GI release and have suggested enteric-coated tablets or alternative 
multilayered dosage forms. 
In developing an oral modified-release system, cognizance must be taken of 
the increase in popularity of multiparticulate solid dosage forms (e.g. micro 
particles, nanoparticles, beads, pellets, granules) in the area of oral controlled drug 
delivery
78
. Formulation of an anti-TB dosage form as an oral multiparticulate drug-
delivery system would furnish many biopharmaceutical advantages when compared 
with solid single-unit dosage forms in terms of a more even and predictable 
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distribution and transportation in the gastrointestinal tract that is fairly independent 
of the nutritional state, predictable gastrointestinal transit time, less localized 
gastrointestinal disturbances and greater product safety; as well as having an 
application in the improvement of patient compliance. In view of the many benefits 
offered by multiple unit dosage forms, it is speculated that such systems are 
particularly useful for site-specific targeting within the gastrointestinal tract
79,80
.  
 In order to manufacture an oral system as cheaply and efficiently as possible 
in developing countries, intrinsic drug delivery principles may be implemented, 
employing readily available polymeric and other formulatory excipients to segregate 
the delivery of the pure drugs. Agrawal et al (2004)
75
 have indicated that RIF release 
in the acidic medium is critical for RIF bioavailability. There is thus the requisite to 
deliver RIF in a highly available form that will be readily absorbed from the gastric 
environment. The intended delivery system exemplifies the requirements of small 
intestinal INH delivery and immediate gastric availability of RIF. 
3.7 Nanotechnology 
Nanotechnology, the term derived from the Greek word Nano, meaning 
dwarf, applies the principles of engineering, electronics, physical and material 
science, and manufacturing at a molecular or submicron level. The materials at nano 
scale could be advice or a system or these could be supra molecular structures, 
complexes or composites
81
.  
An early promoter of nanotechnology, Albert Franks, defined it as ‘that area 
of science and technology where dimensions and tolerances are in the range of 
0.1nm to 100nm. Nano technology is expected to make significant advances in the 
mainstream biomedical applications, including in the areas of gene therapy, drug 
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delivery, imaging, and novel drug discovery techniques
82
. Nanotechnology is hailed 
as a new generation of technology with the potential to revolutionize many facts of 
the world we live in. This includes virtually all aspects of daily life, including health 
and health care, the manufacturing and use of materials and equipment, the 
environment and protection thereof. It is said to be able to massively increase 
manufacturing production at significantly reduced costs. Products of 
nanotechnology will be smaller, cheaper, lighter yet more functional and require less 
energy and fewer raw materials to manufacture. However, the ‘revolution’ will not 
happen overnight and very large investments in research and development will be 
required in the process. 
Nanotechnology includes a bewildering array of activities including: 
molecular manufacturing, supra molecular and self assembly/organization; 
biomimicry; nanoparticles (e.g. Bucky balls and carbon nano tubes), nanospheres, 
nanocups and nanorods, nanobots (nanorobots), colloids, micelles, vesicles and 
nano-emulsions, clathrate complexes and intercalation compounds. 
The National Science Foundation in the USA predicts that the global 
marketplace for goods and services using nanotechnologies will grow to $1 trillion 
by 2015, and there are already over 500 products being sold that claim they are 
made with nanoscale or engineered nanomaterials. These include products like self-
cleaning windows, automobile paint, sunscreens, and tennis rackets. In the future, a 
marriage of nano- and biotechnology will likely create a whole new generation of 
drugs, biomedical devices, and other solutions to some of our most challenging 
medical problems
83
. 
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3.7.1 Nanotechnology in drug delivery 
The development of delivery systems for small molecules, proteins and DNA 
has been impacted to an enormous degree over the past decade by nanotechnology, 
and has led to the development of entirely new and somewhat unpredicted fields. 
For the pharmaceutical industry, novel drug delivery technologies represent a 
strategic tool for expanding drug markets. The technology can address issues 
associated with current pharmaceuticals such as extending product life (line 
extension), or can add to their performance and acceptability, either by increasing 
efficacy or improving safety and patient compliance
84
. This technology is permitting 
the delivery of drugs that are highly water- insoluble or unstable in the biological 
environment.  
Advantages of nano sizing of drugs has the potential to: Increase surface 
area, enhance solubility, increase rate of dissolution, increase oral bioavailability, 
more rapid onset of therapeutic action, decrease the dose needed, decrease fed/fasted 
variability and decrease patient to patient variability. 
3.7.2 Significance of drug delivery and targeting 
Although opportunities to develop nanotechnology based efficient drug 
delivery systems extend into all therapeutic classes of pharmaceuticals, the 
development of effective treatment modalities for the respiratory, central nervous 
system and cardiovascular disorders remains a financially and therapeutically 
significant need. 
Many therapeutic agents have not been successful because of their limited 
ability to reach to the target tissue. In addition, the faster growth opportunities are 
expected in developing delivery systems for anti cancer agents, hormones and 
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vaccines because of safety and efficacy shortcomings in their conventional 
administration modalities. For example, in cancer chemotherapy, cytostatic drugs 
damage both malignant and normal cells alike. Thus, a drug delivery strategy that 
selectively targets the malignant tumor is very much needed. Additional problems 
include drug instability in the biological milieu and premature drug loss through 
rapid clearness and metabolism.  
Similarly, high protein binding of certain drugs such as protease inhibitors 
limits their diffusion to the brain and other organs. However, nanotechnology for 
drug delivery applications may not be suitable for all drugs, especially those drugs 
that are less potent because the higher dose of the drug would make the drug 
delivery system much larger, which would be difficult to administer. 
3.7.3 Role of nanotechnology in tuberculosis  
3.7.3.1 Nanotechnology in diagnosis of tuberculosis  
The diagnosis tools are required to meet the needs of the WHO’s expansion 
of the Directly Observed Treatment Short-course, MDR and co-infection with HIV. 
In India, the country with the highest estimated number of TB cases, research is 
underway into the role nanotechnology can play in addressing such concerns. The 
Central Scientific Instruments Organization of India designed a nanotechnology-
based TB diagnostic kit, which is currently in the clinical trials phase. This kit does 
not require skilled technicians for use and offers portability, efficiency, user-
friendliness and availability for less than US$1. The research is also ongoing for an 
optical biosensor for rapid TB detection in the Medical Sciences division of the U.S. 
Department of Energy. Another group at RMIT University, in Australia, is 
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conducting research into the application of novel tethered nanoparticles as low-cost, 
colour based assays for TB diagnosis
85
.  
3.7.3.2 Nanotechnology in treatment of tuberculosis  
Treatments with improved sustained release profiles and bioavailability can 
increase compliance through reduced drug requirements and there in minimize 
MDR-TB. Chemotherapy of TB is complex due to the requirement of multi drug 
regimens that need to be administered over long periods. The poor patient 
compliance is the single most common reason for chemotherapy failure in TB
86
.  
The micro-encapsulation of pharmaceutical substances in biodegradable 
polymers used in controlled drug delivery has seen as an emerging technology. 
Carrier or delivery systems such as liposomes and microspheres have been 
developed for the sustained delivery of anti-TB drugs and have found better 
chemotherapeutic efficacy when investigated in animal models (e.g. mice)
5
.  
The following are among the important technological advantages of 
nanoparticles as drug carriers: high stability (i.e., long shelf life); high carrier 
capacity (i.e., many drug molecules can be incorporated in the particle matrix); 
feasibility of incorporation of both hydrophilic and hydrophobic substances; and 
feasibility of variable routes of administration, including oral administration and 
inhalation. These carriers can also be designed to enable controlled (sustained) drug 
release from the matrix
87
.   
3.7.4 Nanoparticles 
Nanoparticles are defined as particulate dispersions or solid particles with a 
size in the range of 10-1000nm. The drug is dissolved, entrapped, encapsulated or 
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attached to a nanoparticle matrix. Depending upon the method of preparation, 
nanoparticles, nanospheres or nanocapsules can be obtained. Nanocapsules are 
systems in which the drug is confined to a cavity surrounded by a unique polymer 
membrane, while nanospheres are matrix systems in which the drug is physically 
and uniformly dispersed. In recent years, biodegradable polymeric nanoparticles, 
particularly those coated with hydrophilic polymer such as poly (ethylene glycol) 
(PEG) known as long-circulating particles, have been used as potential drug delivery 
devices because of their ability to circulate for a prolonged period time, target a 
particular organ, as carriers of DNA in gene therapy, and their ability to deliver 
proteins, peptides and genes
88
. 
The major goals in designing nanoparticles as a delivery system are to 
control particle size, surface properties and release of pharmacologically active 
agents in order to achieve the site-specific action of the drug at the therapeutically 
optimal rate and dose regimen. Though liposomes have been used as potential 
carriers with unique advantages including protecting drugs from degradation, 
targeting to site of action and reduction of toxicity or side effects, their applications 
are limited due to inherent problems such as low encapsulation efficiency, rapid 
leakage of water-soluble drug in the presence of blood components and poor storage 
stability. On the other hand, polymeric nanoparticles offer some specific advantages 
over liposomes. For instance, they help to increase the stability of drugs/proteins and 
possess useful controlled release properties
89
. 
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The Advantages of using nanoparticles as a drug delivery system are  
 Particle size and surface characteristics of nanoparticles can be easily 
manipulated to achieve both passive and active drug targeting after 
parenteral administration.  
 They control and sustain release of the drug during the transportation and at 
the site of localization, altering organ distribution of the drug and subsequent 
clearance of the drug so as to achieve increase in drug therapeutic efficacy 
and reduction in side effects.  
 Controlled release and particle degradation characteristics can be readily 
modulated by the choice of matrix constituents. Drug loading is relatively 
high and drugs can be incorporated into the systems without any chemical 
reaction; this is an important factor for preserving the drug activity.  
 Site-specific targeting can be achieved by attaching targeting ligands to 
surface of particles or use of magnetic guidance. 
 The system can be used for various routes of administration including oral, 
nasal, parenteral, intra-ocular etc.  
In spite of these advantages, nanoparticles do have limitations. For example, 
their small size and large surface area can lead to particle-particle aggregation, making 
physical handling of nanoparticles difficult in liquid and dry forms. In addition, small 
particles size and large surface area readily result in limited drug loading and burst 
release. These practical problems have to be overcome before nanoparticles can be 
used clinically or made commercially available. Table 4 illustrate the therapeutic 
applications of nanoparticles and their marketed   products
89
. 
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Table 4 Therapeutic applications of nanoparticles 
 Applications Material Purpose 
Cancer therapy Poly (alkylcyanoacrylates) 
nanoparticles with anticancer 
agents, oligonucleotides. 
Targeting, reduced toxicity, 
enhanced uptake of anti 
tumors agents, improved in-
vitro and in- vivo stability. 
Intercellular 
targeting 
Poly (alkylcyanoacrylates) 
Polyester nanoparticles with 
anti- parasitic or antiviral 
agents. 
Targeting reticuloendothelial 
System for Intra cellular 
infections. 
Prolonged 
systemic 
circulation 
Polyesters with adsorbed 
polyethylene glycols or 
pluronics or derivatized 
polyesters 
Prolong systemic drug effect, 
avoid uptake by the 
reticuloendothelial system. 
Vaccine adjuvant Poly (methylmethacrylate) 
nanoparticles with vaccines 
(oral and intramuscular 
immunization) 
Enhanced immune response, 
alternate acceptable adjuvant 
Per oral 
absorption 
Poly (alkyalcyanoacrylate) 
nanoparticle with proteins and 
therapeutic agents 
Enhanced bioavailability, 
Protection from 
gastrointestinal enzymes 
Ocular delivery Poly (alkylmethacrylate) 
nanoparticles with steroids, 
anti-inflammatory agents, Anti 
bacterial agents for glaucoma 
Improved retention of 
drug 
DNA delivery DNA-alginate nanoparticles, 
DNA –chitosan nanoparticles, 
PDNA-poly(DL-lactide-co 
glycolide) Nanoparticle 
Enhanced delivery and 
significantly higher 
expression levels 
Other 
Applications 
Nanoparticles with adsorbed 
enzymes Nanoparticles with 
radioactive or contrast agents 
Enzyme immunoassays radio 
imaging 
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3.7.5 Pharmaceutical approaches to nanoparticulate system  
 Nanoparticles (NPs) belong to the class of multiphase systems in which one 
or more micro phases are dispersed in a continuous matrix of different composition 
or physical state. The main characteristic of colloidal dispersions is their extremely 
large interface area between the dispersed phase and the continuous phase. Colloidal 
dispersions are metastable or unstable, since minimization of interface free energy 
between two different phases is dictated by thermodynamic constraints. However, in 
some cases colloids display significant kinetic stability that prevents their 
aggregation. Hence, production of microparticles (MPs) and NPs relies essentially 
upon the chemical production of colloidal dispersions, their kinetic stabilization, and 
effective recovery of the final formulates. Polymeric materials are constituted by 
large molecules whose peculiar solution characteristics often allow for the 
preparation of stable and size-controlled colloidal dispersions, which in turn can be 
converted into NPs. In addition, several polymers can be used as stabilizers of 
colloidal dispersions, since they provide a surface coating of the meta stable micro 
phase, thus lowering its tendency to phase-aggregation. The common feature of all 
methods for the preparation of MPs and NPs is the externally-induced separation of 
at least two phases. This process is better known as coacervation, and it may be 
promoted by a number of different techniques. 
3.7.5.1 Solvent evaporation method 
 
In this method, the polymer is dissolved in an organic solvent such as 
dichloromethane, chloroform or ethyl acetate, which is also used as the solvent f 
dissolving the hydrophobic drug. The mixture of polymer and drug solution is then 
emulsified in an aqueous solution containing a surfactant or emulsifying agent to 
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form oil in water (o/w) emulsion. After the formation of stable emulsion, the organic 
solvent is evaporated either by reducing the pressure or by continuous stirring. 
Particle size was found to be reducing the pressure or by continuous stirring. Particle 
size was found to be influenced by the type and concentrations of stabilizer, 
homogenizer speed and polymerconcentration. In order to produce small particle 
size, often a high-speed homogenizationor ultrasonication may be employed
90
. 
3.7.5.2 Spontaneous emulsification or solvent diffusion method 
This is a modified version of solvent evaporation method. In this method, the 
water miscible solvent along with a small amount of the water immiscible organic 
solvent is used as an oil phase. Due to the spontaneous diffusion of solvents an 
interfacial turbulence is created between the two phases leading to the formation of 
small particles. As the concentration of water miscible solvent increases, a decrease 
in the size of particle can be achieved. Both solvent evaporation and solvent 
diffusion methods can be used for hydrophobic or hydrophilic drugs. In the case of 
hydrophilic drug, a multiple w/o/w emulsion needs to be aqueous phase
91
. 
3.7.5.3 Polymerization method 
In this method, monomers are polymerized to form nanoparticles in an 
aqueous solution. Drug is incorporated either by being dissolved in the 
polymerization medium or by adsorption onto the nanoparticles after polymerization 
completed. The nanoparticle suspension is then purified to remove various 
stabilizers and surfactants employed for polymerization by ultracentrifugation and 
re-suspending the particles in an isotonic surfactant-free medium. This technique has 
been reported for making poly butyl cyano acrylate or poly (alkyl cyano acrylate) 
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nanoparticles. Nanocapsules formation and their particle size depend on the 
concentration of the surfactants and stabilizers used
92
. 
3.7.5.4 Production of nanoparticles using supercritical fluid technology 
Conventional methods such a solvent extraction-evaporation, solvent 
diffusion and organic phase separation methods require the use of organic solvents 
which are hazardous to the environment as well as to physiological systems. 
Therefore, the supercritical fluid technology has been investigated as an alternative 
to prepare biodegradable micro and nanoparticles because supercritical fluids are 
environmentally safe. A supercritical fluid can be generally defined as a solvent at a 
temperature above its critical temperature, at which the fluid remains a single phase 
regardless of pressure. Supercritical CO2 (SC CO2) is the most widely used 
supercritical fluid because of its mild critical conditions (Tc = 31.10C, Pc = 73.8 
bars), non-toxicity, non-inflammability, and low price. The most common 
techniques involving supercritical fluids are supercritical anti-solvent (SAS) and 
rapid expansion of critical solution. The process of SAS employs a liquid solvent, 
e.g. methanol, which is completely miscible with the supercritical fluid to dissolve 
the solute to be micronized; at the process conditions, because the solute is insoluble 
in the supercritical fluid, the extract of the liquid solvent by supercritical fluid leads 
to the instantaneous precipitation of the solute, resulting the formation of 
nanoparticles
93
.  
3.7.5.5 Polyelectrolyte complex (PEC)  
Polyelectrolyte complex or self assemble polyelectrolyte is a term to describe 
complexes formed by self-assembly of the cationic charged polymer and plasmid 
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DNA. Mechanism of PEC formation involves charge neutralization between cationic 
polymer and DNA leading to a fall in hydrophilicity as the polyelectrolyte 
component self assembly. Several cationic polymers (i.e. gelatin, polyethylenimine) 
also possess this property. Generally, this technique offers simple and mild 
preparation method without harsh conditions involved. The nanoparticles 
spontaneously formed after addition of DNA solution into Chitosan dissolved in 
acetic acid solution, under mechanical stirring at or under room temperature. The 
complexes size can be varied from 50 nm to 700 nm
94
. 
3.7.5.6 Microemulsion method 
Chitosan NP prepared by microemulsion technique was first developed by 
Maitra et al 1999)
 95
. This technique is based on formation of chitosan NP in the 
aqueous core of reverse micellar droplets and subsequently cross-linked through 
glutaraldehyde. In this method, a surfactant was dissolved in N-hexane. Then, 
chitosan in acetic solution and glutaraldehyde were added to surfactant/hexane 
mixture under continuous stirring at room temperature. Nanoparticles were formed 
in the presence of surfactant. The system was stirred overnight to complete the 
cross-linking process, which the free amine groups of chitosan conjugate with 
glutaraldehyde. The organic solvent is then removed by evaporation under low 
pressure. The yields obtained were the cross-linked chitosan NP and excess 
surfactant. The excess surfactant was then removed by precipitation with CaCl2 and 
then the precipitant was removed by centrifugation. The final nanoparticles 
suspension was dialyzed before lyophilization. This technique offers a narrow size 
distribution of less than 100 nm and the particle size can be controlled by varying 
the amount of glutaraldehyde that alters the degree of cross-linking. Nevertheless, 
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some disadvantages exist such as the use of organic solvent, time-consuming 
preparation process, and complexity in the washing step. 
3.7.5.7 Ionic gelation method 
 In the ionic gelation method, Chitosan (CS) is dissolved in aqueous acidic 
solution to obtain the cation of CS. This solution is then added drop wise under 
constant stirring to poly anionic tripolyphosphate (TPP) solution. Due to the 
complexation between oppositely charged species, CS undergoes ionic gelation and 
precipitates to form spherical particles. The method is schematically represented in 
Fig.3 However, TPP/CS micro particles formed have poor mechanical strength thus, 
limiting their usage in drug delivery 
 
 
Figure 3. Schematic representation of preparation of chitosan particulate 
systems by ionic gelation method. 
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Insulin-loaded CS nanoparticles have been prepared by mixing insulin with 
TPP solution and then adding this to CS solution under constant stirring
96
 .Two 
types of CS in the form of hydrochloride salt (SeacureR 210 Cl and ProtasanR 110 
Cl), varying in their molecular weight and degree of deacetylation, were utilized for 
nanoparticle preparation. For both types of CS, TPP concentration was adjusted to 
get a CS/TPP ratio of 6:1. Chitosan nanoparticles thus obtained were in the size 
range of 300–400 nm with a surface charge ranging from ±54 to ±25 mV. Using this 
method, insulin loading was modulated reaching the values up to 55%. Efficiency of 
the method was dependent upon the deacetylation of CS, since it involves the 
gelation of protonated amino groups of CS. 
There are many ongoing investigations, which demonstrate the improved 
oral bioavailability of peptide and protein formulations. Bioadhesive polysaccharide 
CS nanoparticles would seem to further enhance their intestinal absorption. Pan et al 
(2002)
97
 prepared the insulin-loaded CS nanoparticles by ionotropic gelation of CS 
with TPP anions. Particle size distribution and zeta potential were determined by 
photon correlation spectroscopy. The ability of CS nanoparticles to enhance the 
intestinal absorption of insulin and the relative pharmacological bioavailability of 
insulin was investigated by monitoring the plasma glucose level of alloxan-induced 
diabetic rats after the oral administration of various doses of insulin-loaded CS 
nanoparticles. The positively charged, stable CS nanoparticles showed particle size 
in the range of 250–400 nm. Insulin association was up to 80%. The in vitro release 
experiments indicated initial burst effect, which is pH-sensitive. The CS 
nanoparticles enhanced the intestinal absorption of insulin to a greater extent than 
the aqueous solution of CS in vivo. After administration of 21 I.U/kg insulin in the 
CS nanoparticles, hypoglycemia was prolonged over 15h. The average 
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pharmacological bioavailability relative to s.c. injection of insulin solution was up to 
14.9%. 
Xu and Du
98
 have studied different formulations of CS nanoparticles 
produced by the ionic gelation of TPP and CS. TEM indicated their diameter 
ranging between 20 and 200 nm with spherical shape. FTIR confirmed 
tripolyphosphoric groups of TPP linked with ammonium groups of CS in the 
nanoparticles. Factors that affect the delivery of bovine serum albumin (BSA) as a 
model protein have been studied. These include molecular weight and deacetylation 
degree of CS, concentrations of CS and BSA, as well as the presence of 
polyethylene glycol (PEG) in the encapsulation medium. Increasing molecular 
weight of CS from 10 to 210 kDa, BSA encapsulation efficiency was enhanced 
nearly twice. The total release of BSA in phosphate buffered saline pH 7.4 in 8 days 
was reduced from 73.9% to 17.6%. Increasing deacetylation degree from 75.5% to 
92% promoted the encapsulation efficiency with a decrease in release rate. 
Encapsulation efficiency decreased greatly by increasing the initial concentration of 
BSA and CS. Higher loading capacity of BSA enhanced the BSA release from 
nanoparticles. However, adding PEG hindered the BSA encapsulation and increased 
the release rate.  
Ko et al (2002)
99
 prepared CS micro particles with TPP by the ionic cross-
linking method. Particle sizes of TPP-CS micro particles varied from 500 to 710 Am 
with drug encapsulation efficiencies more than 90%.Morphologies of TPP-CS micro 
particles have been examined by SEM.As the pH of TPP solution decreased and 
molecular weight of CS increased, micro particles acquired better spherical shape 
having smooth surface. Release of felodipine as a model drug was affected by the 
preparation method. Chitosan micro particles prepared at lower pH or higher 
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concentration of TPP solution resulted in a slower release of felodipine. With a 
decreasing molecular weight and concentration of CS solution, the drug release 
increased. The release of drug from TPP-CS microparticles decreased when the 
cross-linking time was increased. 
3.7.6 Oral administration of nanoparticle-based TB drugs 
Stability of nanoparticles offers the possibility of oral administration. The 
fate of nanoparticles in the gastrointestinal tract has been investigated in a number of 
studies
100,101,102
. In general, the uptake of nanoparticles occurs as follows: (1) by 
transcytosisvia M cells, (2) by intracellular uptake and transport via the epithelial 
cells lining the intestinal mucosa, (3) by uptake via Peyer’s patches. Pandey and 
colleagues
48
 demonstrated that the nanoparticles provided sustained release of the 
anti-TB drugs and considerably enhanced their efficacy after oral administration.  
Three frontline drugs, rifampin (RMP), isoniazid (INH), and pyrazinamide 
(PZA) were co encapsulated in poly (lactide-co-glycolide) (PLG) nanoparticles. 
After a single oral administration of this formulation to mice, the drugs could be 
detected in the circulation for 4 d (RMP) and 9 d (INH and PZA); therapeutic 
concentrations in the tissues were maintained for 9 to 11 d. In contrast, free 
(unbound) drugs were cleared from the plasma within 12 to 24hrs after 
administration.  
Treatment of M. tuberculosis–infected mice with the nanoparticle-bound 
drugs (five oral doses every10th day) resulted in complete bacterial clearance from 
the organs. Free drugs were able to produce bacterial clearance only after daily 
administration of 46 doses. Similar efficacy of the nanoparticle-bound drugs was 
also observed in guinea pigs
103
. At the same time, incorporation in microparticles 
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was less effective: their drug-loading capacity was lower as well as the plasma half-
life of the bound drugs
15,53
.  
The behavior of polymeric nanoparticles in the gastrointestinal tract is 
influenced by their bioadhesive properties; adhesion of nanoparticles to the mucosa 
enhances the absorption of the associated drug, thus increasing its bioavailability. 
Thus, lectin shave been shown to improve mucoadhesion of the drug due to the bio 
recognition of the lectin-grafted carriers by glycosylated structures in the 
intestine
105
. Accordingly, the efficacy of PLG-based formulations of anti-TB drugs 
was further improved by covalent attachment of wheat germ agglutinin
105
.  
Oral administration of wheat germ agglutinin–coated PLG nanoparticles 
loaded with RIF, INH, and PZA in mice produced considerably extended serum half 
life :detectable RIF serum levels were observed for 6 to 7 d and INH and PZA for 13 
to 14 d (vs. 4–6 d and 8–9 d for non modified nanoparticles). All three drugs were 
present in lungs, liver, and spleen for 15 d. The lectin-modified formulations 
produced bacterial clearance in these organs after three oral doses administered 
every 14 d (45 daily doses of free drugs). As suggested by the authors, the prolonged 
circulation of drugs encapsulated in wheat germ agglutinin–grafted nanoparticles 
might be attributed to the fact that lectins enhance prolonged adhesion of the 
particles to the intestinal surface to allow (1) an increase in the time interval 
available for absorption and (2) a localized increase in the concentration gradient 
between luminal and aerosal sides of the membrane. Table 5 illustrate release of 
drug and therapeutic efficacy of the nanoparticle-based formulations of the first-line 
antituberculous drugs
87
. 
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Table 5 Drug release and therapeutic efficacy of the nanoparticle-based 
formulations of the first-line antituberculous drugs — Rifampicin, 
Isoniazid, and Pyrazinamide 
 
Delivery 
system 
Animal 
model 
Administration 
route 
Duration of drug 
release (d) 
Regimen 
producing 
sterilizing effect in 
lungs and spleen Plasma Organs 
PLG 
nanoparticles 
 
 
 
 
 
 
 
 
 
 
 
Lectin –
functionalized 
PLG 
nanoparticles 
 
Solid lipid 
nanoparticles 
Mice 
 
Mice 
 
Guinea Pigs 
 
 
Guinea Pigs 
 
 
Guinea Pigs 
 
 
Guinea Pigs 
 
 
 
Guinea Pigs 
Oral 
 
Subcutaneous 
 
Aerosol 
 
 
Oral 
 
 
Oral 
 
 
Aerosol 
 
 
 
Aerosol 
6-9 
 
32 
 
4-9 
 
 
4-9 
 
 
7-13 
 
 
6-14 
 
 
 
5 
9-11 
 
36 
 
Up to 10 d  
(each drug) 
 
Up to 10 d 
 (each drug) 
 
Up to 15 d 
 (each drug) 
 
Up to 15 d 
 (each drug) 
 
 
7 
5 doses ever 10 d  
 
Single injection 
 
5 doses every 10 d 
 
 
5 doses every 10 d 
 
 
3 doses fortnightly  
 
 
3 doses fortnightly 
 
 
 
7 doses weekly 
 
 
PLG –poly (lactide-co-glycolide), The drug-to-polymer ratio is 1:1 for each drug 
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3.7.7 Criteria for ideal polymeric carriers for nanoparticles and nanoparticle 
delivery systems
106
 
Polymeric carriers 
  Easy to synthesize and characterize 
  Inexpensive 
  Biocompatible 
  Biodegradable 
  Non-immunogenic 
  Non-toxic 
  Water soluble 
Nanoparticle delivery systems 
 Simple and inexpensive to manufacture and scale-up 
 No heat, high shear forces or organic solvents involved in their preparation    
process. 
 Reproducible and stable 
 Applicable to a broad category of drugs; small molecules, proteins and poly  
nucleotides 
 Ability to lyophilize 
 Stable after administration 
 Non-toxic 
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Table 6, 7 illustrate polymers used for the preparation of nanoparticles and polymeric 
nanoparticles for antimicrobial drug delivery 
107,108
.  
Table 6 Polymers used for the preparation of nanoparticles 
Technique Candidate Drug Polymer used 
Heat denaturation and cross 
linking in w/o emulsion 
Hydrophilic Hydrophilic Albumin Gelatin 
Desolvation and cross 
linking in water 
Hydrophilic and protein 
affinity 
Hydrophilic Albumin, Gelatin 
Cross – linking in water Hydrophilic and protein 
affinity 
Hydrophilic Alginates and 
chitosan 
Polymer precipitation in an 
organic solvent 
Hydrophilic Hydrophilic Dextran 
Emulsion polymerization Hydrophilic Hydrophilic 
Poly(alkylcyanoacrylates) 
Interfacial w/o 
polymerization 
Hydrophilic Hydrophilic 
Poly(alkylcyanoacrylates) 
Solvent extraction 
evaporation 
Hydrophilic and 
Hydrophilic Soluble in 
polar solvent 
Polyester Poly (Lactic acid), 
poly(Caprolactone) 
Solvent displacement Hydrophilic and 
Hydrophilic Soluble in 
polar solvent 
Polyester Poly (Lactic acid), 
poly(lactide-co-glycolide)  
Salting out Soluble in polar solvent Polyester Poly (Lactic acid), 
poly(lactide-co-glycolide)  
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Table 7 Polymeric nanoparticles for antimicrobial drug delivery 
 Formulation Drug Targeted 
microorganism 
Activity 
Poly(D, Lactide)PLA 
Nanospheres 
arjunglucoside Leishmania Reduced toxicity 
Polylactic co glycolic 
acid(PLGA)nanoparticles 
Phosphorothioate 
antisense 
oligoneucleotide 
HIV Protection of 
olegonucleotide 
from degradation 
Poly(ethylene oxide) (PEO)- 
modified poly (epsilon-
carprolactone) (PCL) 
nanoparticle 
Saquinavir HIV 1)Protect the drug 
from cytochrome O 
metabolish 
2)bypass P-gp 
efflux pump 
Alginate nanoparticles Rifampicin, 
isoniazid, 
pyrazinamide and 
ethambutol. 
Mycobacterium 
tuberculosis 
1)High drug 
payload 
2) improved 
pharmacokinetics 
3) High 
therapeutics 
efficacy 
Poly-lactide-co-
glycolide(PLG) 
nanoparticles 
Rifampicin, 
isoniazid, 
pyrazinamide and 
ethambutol. 
Mycobacterium 
tuberculosis 
1)Enhanced 
bioavailability 
Improved 
pharmacodynamics 
Polaxamer 188 coated 
poly(epsilon-
caprolactone)(PCL) 
nanosphere 
Amphotericin B Candida 
albicans 
Lower in vivo 
toxicity due to 
reduced 
accumulation in 
kidney and liver 
Polyethylene glycol   
(PEG)-PLA nanocapsules 
Halofantrine Plasmo 
diamberghe 
Prolonged 
circulation half life 
Poly(isohexylcyanoacrylate)
(PIHCA) nanospheres 
Primaquine and 
ampicillin 
Leishmania 
donovant, 
Salmonella 
typhynurium 
and listeria 
monocytogenes 
Particle itself 
exhibits 
antimicrobial 
activity 
Glycosylated  
polyacrylate nanoparticles 
Beta-lactum 
ciprofloxacin 
Staphylococcus 
aereus and 
Bacillus 
anthracis 
Improved 
bioavailability, 
Higher therapeutic 
efficacy 
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3.8 Ultrasonication 
Ultrasonication is a common tool for the preparation and processing of 
polymer nanoparticles. It is particularly effective in breaking up aggregates and in 
reducing the size and polydispersity of nanoparticles
109
. The physical stability and in 
vivo distribution of nanoparticles are affected by their mean size, polydispersity, and 
surface charge density
110
. Despite the wide-spread applications of ultrasonication in 
nanotechnology, its effects on chitosan nanoparticles are not well understood, 
although there have been several reports on the ultrasonication of the chitosan 
polymer.  
It is generally agreed that ultrasonication causes main chain scissions at the 
1,4-glycosidic bond
111
 without affecting the degree of deacetylation (DD) of 
chitosan samples. The process has, therefore, been conveniently applied to produce 
chitosan samples of lower molecular weights of the same DD
112,113,114
. It was 
hypothesized that ultrasonic-mediated depolymerization of chitosan would influence 
the properties of the chitosan nanoparticles. The complexity of the chitosan 
nanoparticle system may further render it more vulnerable to chemical modifications 
by ultrasonication. High-intensity ultrasonication produces acoustic cavitation, 
which generates hot spots of short lifetimes with intense local heating of ∼5000◦C, 
pressures of ∼1000 atm, and heating and cooling rates above 1010 K/s115. These, 
together with free-radical formation, may mediate redox reactions and intra 
molecular regroupings in the samples 
116
. Cavitation also generates rapid streaming 
of solvent molecules around the cavitation bubble, as well as shock waves during 
bubble collapse, which in turn generate very large shear forces
115
. In addition, rare 
fractions and compressions of the liquid media can cause dispersive (particle 
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separation) and coagulative (collision and adhesion of particles) phenomena, 
respectively
117
.  
Ultrasonic treatments were administered using an ultrasonic probe with 
diameter of 3mm and a 130 Whigh-intensity ultrasonic processor (VC130, Sonics 
and Materials Inc., USA) operating at 20 kHz. The converter was made of 
piezoelectric lead zirconate crystals. Samples (24 ml) in glass universal bottles 
(Beatson and Co., UK) were equilibrated to 25
◦
C and ultrasonicated under 
continuous mode at ambient conditions. The probe was immersed 4 cm into the 
sample during ultrasonication, which was carried out at specified amplitudes (20, 40, 
60, 80) over durations of 2–10 min. For simplicity, the ultrasonication conditions are 
denoted as AxTy where x represents the amplitude and y the duration. Amplitudes of 
20, 40, 60, and 80 corresponded to intensities of approximately 14, 42, 70, and 99 
W/cm2, respectively, the intensity calculated by taking the difference between the 
output Watts delivered into the sample and in air, divided by the area of the probe 
tip. Ultrasonication produced similar heating effects in the chitosan solution and 
chitosan nanoparticle samples. In both cases, temperature increased linearly from 25 
to 45
◦
C for samples ultrasonicated for 5 min at increasing amplitudes from 0 to 80, 
and from 25 to 41
◦
C for samples ultrasonicated at the amplitude of 40 with 
increasing duration from 0 to 10 min. Treated samples were cooled to ambient 
temperature and analyzed immediately. Some samples were lyophilized (FD3, 
Dynavac Engineering, Australia) before analysis. 
3.9 Freeze drying of nanoparticles 
 
Protective excipients, such as carbohydrates, are widely used in freeze-
drying to ensure redispersibility and to avoid aggregation or size changes of 
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nanoparticles
118
. Glucose and lactose were evaluated as cryo- and lyo protectants for 
the L- PLA nanoparticles because these nanoparticles could not survive during the 
drying process without protectants. Even the smallest tested amount of glucose 
(weight ratio glucose: nanoparticles 1:4) was found to protect the nanoparticles, 
although the appearance of the dried material was translucent and sticky, and its 
redispersibility was poor. When lactose was used as a protectant, it enhanced the 
appearance of the cake (the dried material) as a white powder, eligible for a freeze-
dried formulation. Redispersion of the nanoparticle was possible, but as a form of 
visible aggregates. Further freeze-thawing experiments revealed that already the 
freezing step (with lactose) destroyed the particles. Next, the two carbohydrates 
were used together to combine the cryoprotective functionality of glucose and the 
lyoprotective functionality of lactose. The best result, prolonged Tyndall effect 
(opalescence in the dispersion) after redispersion of the dried formulation and good 
quality nanoparticles were obtained, when the amount of lactose was double the 
amount of glucose. The weight ratios of glucose and lactose to the nanoparticles 
were 1:2 and 1:1, respectively. Additionally, when an extra stabilizer, Tween 80, 
was used during the nanoparticle preparation or during the redispersion, the freeze-
dried cake could be redispersed more easily with increased stability (prolonged 
Tyndall effect). 
The good cryoprotective results with glucose probably arise from its ability 
to bind water molecules to the amorphous phase which it forms during the freezing 
step. Part of the water in the frozen glucose remained non-frozen (even 32% w/w). 
That water acted as a plasticizer and as a spacing matrix reducing the pressure of ice 
crystals against the nanoparticles and preventing harmful aggregation caused by 
freeze concentration, respectively. At the same time, insufficient cryoprotective 
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function of lactose derived most likely from its lower water binding activity. 
However, as a combination with glucose, lactose reduced the amount of water to a 
level where the interaction of glucose with water was reduced and, thus, the 
formation of ice crystal was slightly promoted. This enabled sufficient evaporation 
of water during the drying and formation of a proper cake. Tween 80 improved the 
freeze-drying result as it acted as a steric stabilizer and increased the hydrophilicity 
of the nanoparticles. A hydrophilic surface enhances the redispersion properties of 
the freeze-dried nanoparticles
119,120
. 
This technique involves the freezing of the nanoparticle suspension and 
subsequent sublimation of its water content under reduced pressure to get a free 
flowing powdered material following advantages are cited for the freeze drying of 
nanopartilces: 
 Prevention from degradation and/or solubilization of the polymer. 
 Prevention from drug leakage, drug desorption and/or drug degradation.  
 Easy to handle and store and helps in long-term prevention/conservation of 
nanoparticles.  
 Readily dispersible in water without modification in their physicochemical 
properties. 
3.10 Chitosan 
Chitosan [(1 → 4) 2-amino 2-deoxy -d-glucan] is a linear polyamine with a 
high ratio of glucosamine to acetyl-glucosamine units. The percentage of 
glucosamine units in the polymer is known as its degree of deacetylation (DD)
121
. 
Protonation of the amino group allows the polymer to be solubilized in aqueous 
acids and to interact with negatively charged materials
122
. It is this functional group 
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that enables the formation of chitosan nanoparticles by crosslinking and desolvation 
with cationic salts
105
. Chitosan nanoparticles are attractive non-viral carriers for the 
delivery of peptides, proteins, oligonucleotides, and plasmids
123
. They have the 
capacity to protect sensitive bioactive macromolecules from enzymatic and chemical 
degradation in vivo and during storage
125
 and to facilitate the transport of charged 
macromolecules across absorptive epithelial cells
125
. 
Chitosan possesses some ideal properties of polymeric carriers for 
nanoparticles such as biocompatible, biodegradable, nontoxic, and inexpensive. 
Furthermore, it possesses positively charge and exhibits absorption enhancing effect. 
These properties render Chitosan a very attractive material as a drug delivery carrier. 
In the last two decades, Chitosan nanoparticles have been extensively developed and 
explored for pharmaceutical applications
106
.  
The efficacy of many drugs is often limited by their potential to reach the site 
of therapeutic action. In most cases (conventional dosage forms), only a small 
amount of administered dose reaches the target site, while the majority of the drug 
distributes throughout the rest of the body in accordance with its physicochemical 
and biochemical properties. Therefore, developing a drug delivery system that 
optimizes the pharmaceutical action of a drug while reducing its toxic side effects in 
vivo is a challenging task. 
One approach is the use of colloidal drug carriers that can provide site 
specific or targeted drug delivery combined with optimal drug release profiles. The 
idea of using submicron drug delivery systems for drug targeting was conceived and 
developed after Paul Ehrlich originally proposed the idea of tiny drug-loaded magic 
bullets over a hundred year ago. Among these carriers, liposomes and 
micro/nanoparticles have been the most extensively investigated. Liposomes present 
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some technological limitations including poor reproducibility and stability, and low 
drug entrapment efficiency. Nevertheless, several low molecular weight drugs are 
now commercially available which employ this technology. Polymeric 
nanoparticles, which possess a better reproducibility and stability profiles than 
liposomes, have been proposed as alternative drug carriers that overcome many of 
these problems. The details of Chitosan-based drug delivery systems prepared by 
different methods for various kinds of drugs were given in Table 8
126
. 
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Table 8 Chitosan-based drug delivery systems prepared by different methods for 
various kinds of drugs 
Type of system 
Method of 
preparation 
Drug 
Tablets 
 
Matrix coating 
 
Diclofenac sodium, Pentoxyphylline, Salicylic 
acid, Theophylline, Propranolol HCL. 
Capsules Capsule shells Insulin, 5-amino salicylic acid. 
Microsphere/ 
Microparticles 
 
Emulsion cross- linking 
 
Theophylline, cisplatin, pentazocine, 
phenobarbitone, insulin, 5-fluorouracil, 
declofenac sodium, griseofulvin, aspirin, 
diphtheria toxoid, pamidronate, suberolbis 
phosphonate, mitoxantrone, progesterone. 
 Coacervation/ 
precipitation 
Spray drying 
 
Prednisolone, interleukin-2, propranol-HCL 
Cimetidine, famotidine, nizatidine, vitamin D-2, 
diclofenacsodium, ketoprofen, metoclopromide-
HCL, bovine serum albumin, ampicillin, 
cetylpyridinium chloride, oxytetracycline, 
betamethazone. 
 Ionic gelation 
Seiving method 
Felodipine,Clozapine. 
Gadopentetic acid. 
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Nanoparticles 
 
Emulsion-droplet 
coalescence 
Coacervation/ 
precipitation 
Ionic gelation 
DNA, doxorubicin 
Indulin, riein, bovin serum albumin, 
cyclosporine A,  
Doxorubicin. 
 
 Reverse micellar 
method 
Adriamycin, nifedipine, bovin serum albumin,s 
albutamol sulfate, lidocaine-HCL, Riboflavin. 
Beads 
 
Coacervation/ 
precipitation 
 
Isosorbide dinitrate, cholorhexidine gluconate, 
trypsin, Granulocyte-macrophages, colony 
stimulating factor, acyclovir. 
Films 
 
Solution casting 
 
riboflavine, testosterone, progesterone, beta-
oestradiol, Chlorpheniraminemaleate, aspirin, 
theophylline, caffeine. 
Gel 
 
Cross-linking lidocaine-HCL, hydrocortisone acetate,5-
flourouracil. 
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3.10.1 Characteristics of nanoparticles on drug delivery 
Table 9 illustrate different parameters and characterizaton methods of nanopaticles
89
 
Table 9 Different parameters and characterizaton methods of nanopaticles  
 
 
Parameter Characterization method 
Particle size and distribution 
Photo correlation spectroscopy (PCS) 
Laser defractometry 
Transmission electron microscopy(TEM) 
Scanning electron microscopy(SEM) 
Mercury porositometry 
Charge determination 
Laser Doppler anemometry 
Zeta potentiometer 
Surface hydrophobicity 
Water Doppler Anemometry 
Rose Bengal (dye) binding 
Hydrophobic interaction chromatography 
X-ray photoelectron spectroscopy 
Chemical analysis of surface Static secondary ion mass spectroscopy 
Carrier-drug interaction Differential scanning calorimetry (DSC) 
Nanoparticles dispersion stability Critical flocculation temperature (CFT) 
Release profile 
In vitro release characteristics under 
physiologic and sink conditions 
Drug stability 
Bioassay of drug extracted from 
nanoparticles / chemical analysis of drug 
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3.11 Characterization of nanoparticles 
3.11.1 Morphology 
Nanoparticles possess a variety of shapes and their names are characterized 
by their different shapes. For example, there are nanospheres that are spherical, 
nanoreefs, nanoboxes, nanoclusters, nanotubes etc. These shapes or morphologies 
sometimes arise spontaneously as an effect of a templating or directing agent during 
synthesis for example during miscellar emulsions or anodized alumina pores, or from 
the iniate crystallographic growth patterns of the materials themselves. 
The morphologies of nanoparticles help serve their various purposes such as 
long carbon nanotubes being used to bridge an electrical junction. Amorphous 
particles usually adopt a spherical shape or nanospheres and anisotropic 
microcrystalline whiskers correspond to their particular crystal shape. Small 
nanoparticles usually form clusters. These may be of various shapes like rods, fibers, 
and cups etc. The study of fine particles is called micromeritics. 
Controlling the morphology of nanoparticles is of key importance for 
exploiting their properties for their use in several emerging technologies. Optical 
ﬁlters and bio-sensors are among the many applications that use optical properties of 
gold nanoparticles and it requires anisotropy of the particle shape as larger shapes 
produce greater plasmon losses.  
Despite the great importance of the morphology of nanoparticles, it is 
generally not well characterized and practically never controlled. However, this is of 
prime importance. For example, this is important in magnetic devices where well-
defined magnetization axes and switching fields are required to store or to process 
information
127
.  
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3.11.2 Particle size 
Particle size and size distribution are the most important characteristics of 
nanoparticle systems. They determine the in vivo distribution, biological fate and 
targeting ability of nanoparticle systems. In addition they can also influence the drug 
loading, drug release and stability of nanoparticles. 
Many studies have demonstrated that nanoparticles of sub-micron size have a 
number of advantages over microparticles as a drug delivery system
128
. Generally 
nanoparticles have relatively higher intracellular uptake compared to microparticles 
and available to wider range of biological targets due to their small size and relative 
mobility. 100nm nanoparticles had a 2.5 fold greater uptake than 1µm microparticles 
and 6 fold greater uptakes than 10µm microparticles in a CACO-2 cell line
129
. In a 
subsequent study, the nanoparticles penetrated throughout the sub mucosal layers in 
a rat in situ intestinal loop model, while microparticles were predominantly localized 
in the epithelial lining. It was also reported that nanoparticles can cross the blood-
brain barrier following the opening of tight junctions by hyper osmotic mannitol, 
which may provide sustained delivery of therapeutic agents for difficult-to-treat 
diseases like brain tumors. Tween 80 coated nanoparticles have been showed to 
cross the blood-brain barrier. In some cell lines, only submicron nanoparticles can 
be taken up effectively but not the larger size microparticles. The recent literature 
shows ophthalmic nanosuspension that proves to be boon for drugs that exhibit poor 
soluble in lachrymal fluid. 
Drug release is affected by particle size. Smaller particles have larger surface 
area; therefore, most of the drug associated would be at or near the particle surface, 
leading to fast drug release. The particle surface, leading to fast drug release. 
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Whereas, larger particles have large cores which allow more drug to be encapsulated 
and slowly diffuse out
130
. Currently, the fastest and most routine method of 
determining particle size is by photon-correlation spectroscopy or dynamic light 
scattering. Photon-correlation spectroscopy requires the viscosity of the medium to 
be known and determines the diameter of the particle by Brownian motion and light 
scattering properties
131
. The results obtained by photon-correlation spectroscopy are 
usually verified by scanning or transmission electron microscopy (SEM or TEM). 
3.11.3 Surface properties of nanoparticles 
When nanoparticles were administered intravenously, they are easily 
recognized by the body immune systems, and are then cleared by phagocytes from 
the circulation. Apart from the size of nanoparticles, their surface hydrophobicity 
determines the amount of adsorbed blood components, mainly proteins. This is turn 
influences the in vivo fate of nanoparticles. Binding of these opsonins onto the 
surface of nanoparticles called opsonization acts as a bridge between nanoparticles 
and phagocytes. The association of a drug to conventional carriers leads to 
modification of the drug biodistribution profile, as it is mainly delivered to the 
mononuclear phagocytes system such as liver, spleen, lungs and bone marrow. 
Indeed, once in the blood stream, surface non-modified nanoparticles are rapidly 
opsonized and massively cleared by the macrophages of mononuclear phagocytes 
system rich organs. Generally, it is IgG, compliment C3 components that are used for 
recognition of foreign substances, especially foreign macromolecules. 
Hence, to increase the likelihood of the success in drug targeting by 
nanoparticles, it is necessary to minimize the opsonized and to prolong the 
circulation of nanoparticles in vivo. This can be achieved by surface coating of 
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nanoparticles with biodegradable copolymers with hydrophilic segments such as 
polyethylene glycol (PEG) polyethylene oxide, polyoxamer, poloxamine and 
polysorbate 80 (Tween 80). 
The zeta potential of a nanoparticle is commonly used to characterize the 
surface charge property of nanoparticles
132
. It reflects the electrical potential of 
particles and is influenced by the composition of the particle and the medium in 
which it is dispersed. Nanoparticles with a zeta potential above (+/-) 30 mV have 
been shown to be stable in suspension, as the surface charge prevents aggregation of 
the particles. The zeta potential can also be used to determine whether a charged 
active material is encapsulated within the centre of the nanocapsule or adsorbed 
onto the surface.  
3.11.4 Drug-polymer interactions 
 
Drug loading can be performed during the preparation of nanoparticles or by 
adsorbing/absorbing in preformed particles. Within the particle-forming polymer, 
drug can be present as a solid solution (individual drug molecules) or as a solid 
dispersion (amorphous/crystalline drug). It can be adsorbed on the particle surface or 
bound chemically within the nanoparticles .The preparation process can also modify 
the crystal structure of the drug. The polymer is usually amorphous or semi-
crystalline. Differential scanning calorimetry (DSC), (powder) X-ray diffractometry 
(XRPD) and FTIR are commonly used techniques to reveal the physicochemical 
state and possible interactions of the drug and the polymer in pharmaceutical micro- 
and nanoparticles. Polymer MW is determined e.g. by size exclusion 
chromatography (SEC) the term gel permeation chromatography (GPC) is 
interchangeably used. 
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 DSC detects phase transitions such as glass transition, (exothermic) 
crystallization and (endothermic) melting: the nanoparticle sample is heated and 
changes in heat flow, compared to reference, are registered. 
Crystallinity/amorphicity properties are obtained from XRPD analysis when 
diffraction pattern of the x-ray from the sample is determined as a function of 
scattering angle. In FTIR, a vibrational spectrum, characteristics for a given crystal 
structure, is obtained. 
Absence of the drug melting peak and diffraction peaks of the crystal 
structure of the drug in DSC thermo gram and XRPD pattern, respectively, are 
usually signs of amorphous or molecularly dispersed drug within the polymer .It can 
also indicate that the amount of drug is lower than the detection limit of the 
instrument. Drug polymer interactions (e.g. plasticizing effect of drug on polymer) 
or polymorph change of the drug can be detected as peak shifts in DSC thermogram, 
band shifts in FTIR spectra or as new reflections in XRPD pattern. Correspondingly, 
smoothened XRPD pattern, increased cold crystallization exotherms (DSC) or some 
band shifts to higher wave numbers (FTIR) indicate increased amorphicity of the 
polymer
133
. 
3.11.5 Drug loading 
 
Ideally, a successful nanoparticulate system should have a high drug-loading 
capacity thereby reduce the quantity of matrix materials for administration. Drug 
loading can be done by two methods 
 Incorporating at the time of nanoparticles production (incorporation 
method)  
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 Absorbing the drug after formation of nanoparticles by incubating the 
carrier with a concentrated drug solution (adsorption /absorption 
technique)
 137
.  
Drug loading and entrapment efficiency very much depend on the solid-state 
drug solubility in matrix material or polymer (solid dissolution or dispersion), which 
is related to the polymer composition, the molecular weight, the drug polymer 
interaction and the presence of end functional groups (ester or carboxyl). The PEG 
moiety has no or little effect on drug loading. The macromolecule or protein shows 
greatest loading efficiency when it is loaded at or near its isoelectric point when it 
has minimum solubility and maximum adsorption  For small molecules, studies 
show the use of ionic interaction between the drug and matrix materials can be a 
very effective way to increase the drug loading
135
. 
3.11.6 In-vitro drug release
 
 To develop a successful nanoparticulate system, both drug release and 
polymer biodegradation are important consideration factors. In general, drug release 
rate depends on: (1) solubility of drug; (2) desorption of the surface bound/adsorbed 
drug; (3) drug diffusion through the nanoparticle matrix; (4) nanoparticle matrix 
erosion/degradation; and (5) combination of erosion/diffusion process. Thus 
solubility, diffusion and biodegradation of the matrix materials govern the release 
process. In the case of nanospheres, where the drug is uniformly distributed, the 
release occurs by diffusion or erosion of the matrix under sink conditions. If the 
diffusion of the drug is faster than matrix erosion, the mechanism of release is 
largely controlled by a diffusion process. The rapid initial release or ‘burst’ is 
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mainly attributed to weakly bound or adsorbed drug to the large surface of 
nanoparticles
136
. It is evident that the method of incorporation has an effect on 
release profile. If the drug is loaded by incorporation method, the system has a 
relatively small burst effect and better sustained release characteristics. If the 
nanoparticle is coated by polymer, the release is then controlled by diffusion of the 
drug from the core across the polymeric membrane. The membrane coating acts as a 
barrier to release, therefore, the solubility and diffusivity of drug in polymer 
membrane becomes determining factor in drug release. Furthermore release rate can 
also be affected by ionic interaction between the drug and addition of auxiliary 
ingredients. When the drug is involved in interaction with auxillary ingredients to 
form a less water soluble complex, then the drug release can be very slow with 
almost no burst release effect; whereas if the addition of auxillary ingredients e.g., 
addition of ethylene oxide-propylene oxide block copolymer (PEO-PPO) to 
chitosan, reduces the interaction of the model drug bovine serum albumin (BSA) 
with the matrix material (chitosan) due to competitive electrostatic interaction of 
PEO-PPO with chitosan, then an increase in drug release could be observed
137
. 
Various methods which can be used to study the in vitro release of the drug 
are: (1) side-by-side diffusion cells with artificial or biological membranes; (2) 
dialysis bag diffusion technique; (3) reverse dialysis bag technique; (4) agitation 
followed by ultracentrifugation/centrifugation; (5) Ultra-filtration or centrifugal 
ultra-filtration techniques. Usually the release study is carried out by controlled 
agitation followed by centrifugation. Due to the time-consuming nature and 
technical difficulties encountered in the separation of nanoparticles from release 
media, the dialysis technique is generally preferred.  
Review of Literature 
77 
 
From the above mentioned literature, it is clearly understood that 
nanoparticulate approach is beneficial to overcome the disadvantage of poor 
bioavailability of drugs.Ascorbic acid has been reported to stabilize rifampicin from 
degradation in the dissolution medium or in the plasma sample; however, its 
usefulness in protecting rifampicin from degradation in the acidic environment of 
stomach has not been addressed. Ascorbic acid administration (1000mg/day p.o) is 
recommended in the clinical practice to suppress tuberculous infection by activating 
the immunity. Among the polymers, chitosan has been reported advantageous for 
development of nanoparticles used in the treatment of chronic infections like TB. 
Based on the above considerations, the present study aimed to develop chitosan 
loaded rifampicin-ascorbic acid nanoparticles and evaluate their physicochemical, 
in-vitro dissolution stability, in-vitro diffusion and in-vivo bioavailability in 
comparision with their respective control formulations.  
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3.12 Background of the study 
Bioavailability of rifampicin from fixed dose products containing isoniazid, 
pyrazinamide, and ethambutol remains challenging owing to its degradation in the 
acidic environment of the stomach following oral administration. Previous studies 
reveal that different approaches such as controlled release system, microspheres and 
nanoparticles were attempted to improve the efficacy of anti TB drugs in animal 
model; however no approach has yielded beneficial results.  It has been well 
documented that any attempt that protects rifampicin degradation with improved 
absorption in the stomach is most beneficial to effectively control TB. 
  Recently nanoparticle delivery of drugs that are poorly bioavailable has 
assumed significance because nanosizing of drugs has the potential to improve 
surface area, enhance solubility, increase rate of dissolution, increase oral 
bioavailability, more rapid onset of therapeutic action, decrease the dose needed, 
decreased fed/fasted variability and decrease patient-patient variability.  It has also 
been documented that ascorbic acid used to stabilize rifampincin in this dissolution 
media as well as in the plasma sample against degradation. Furthermore daily intake 
of ascorbic acid/day is also recommended to improve immunity against tuberculous 
infection. The possible effect of ascorbic acid in stabilizing rifampicin against 
gastric degradation has not been established. 
Polymer plays a critical role in the development of ascorbic acid 
nanoparticles with desired characteristics. It has been recommended that natural 
polymer such as chitosan is advantageous for development of nanoparticles for 
chronic infection such as TB. Besides chitosan has also been reported to improve 
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absorption of drugs because of its mucoadhesive property which provides prolonged 
contact of the drug with the biological membrane at the site of delivery. 
Based on the above factors the present study was directed to investigate 
whether ascorbic acid and nanoparticulate delivery of rifampicin together can 
address the poor bioavailability of rifampicin in the presene or absence of isoniazid. 
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5. DRUG PROFILE 
 
5.1 RIFAMPICIN 
Rifampin is a bactericidal antibiotic drug of the rifamycin group
138
. It is a semi 
synthetic compound derived from Amycolatopsis rifamycinica
139
 (formerly known 
as Amycolatopsis mediterranei and Streptomyces mediterranei).  
 
Molecular formula: C43H58N4O12 
Chemical structure 
 
Generic name:  
5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl- 8-[N-
(4-methyl-1-piperazinyl)formimidoyl]-
2,7epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-1, 11(2H)-dione 21-acetate. 
Molecular weight: 822.94 
Solubility:  
Freely soluble in chloroform and DMSO; soluble in ethyl acetate, methanol, 
tetrahydrofuran; slightly soluble in acetone, water, carbon tetrachloride 
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Polarity: (Log P) 3.719 
Acidity/ basicity : pKa 1.7 for the 4-hydroxy and pKa 7.9 for the 3-piperazine 
nitrogen 
Stability : Very stable in DMSO; rather stable in water 
Melting point: 183ºC 
Optimal human dosage 
Dose 10 mg/kg, in a single daily administration, not to exceed 600 mg/day,  
oral or i.v 
In vitro potency For M. tuberculosis: H37Rv, MIC is 0.4 mg/ml
138
. 
Mechanism of action 
Rifampicin inhibits the essential rpoB gene product b-subunit of DNA 
dependent RNA polymerase activity, acting early in transcription
139
. It is thought to 
bind to the ß-subunit, close to the RNA/DNA channel, and physically blocks the 
transit of the growing RNA chain after nucleotides have been added
139,140
. 
Spectrum of activity 
Rifampicin is bactericidal with a very broad spectrum of activity against 
most grampositive and some gram-negative organisms (including Pseudomonas 
aeruginosa) and M. Tuberculosis. Rifampicin has clinical efficacy against a wide 
variety of organisms, including Staphylococcus aureus, Legionella pneumophila, 
Group-A Streptococcus, Brucella spp., Haemophilus  nfluenzae, and Neisseria 
meningitidis, as well as in vitro activity against penicillin-resistant S. pneumoniae, 
N. gonorrhoeae, Chlamydia trachomatis, H. ducreyi, and many gram-negative rods. 
Due to rapid emergence of resistant bacteria it is restricted to treatment of 
mycobacterial infections, where the customary use of combination drugs delays 
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resistance development, and the treatment of asymptomatic meningococcal 
carriers
141
. 
Pharmacokinetics of Rifampicin 
Absorption 
Rifampicin is well absorbed from the gastrointestinal tract, with peak plasma 
levels achieved within 1 to 4 h after oral administration, although food may delay its 
absorption
142,143
. After intravenous dose administration the plasma levels in adults 
are about 9 μg/ml (300mg infusion) over 30 min. after infusion. 
Distribution 
Rifampicin readily diffuses into most organs, tissues, bones and body fluids, 
including exudates into tuberculosis infected lung cavities
144
. Therapeutic 
concentrations are achieved in saliva reaching 20% of serum concentrations. High 
concentrations appear in the lachrymal glands and tears. The urine is coloured 
orange to brick red. It is reported that rifampicin is highly protein bound to an extent 
of 84-91%
145
. Tissue distribution occurs at a relatively fast rate. At physiological pH 
only about 25% of the drug is ionized while the molecule as a whole is lipid soluble. 
Levels of rifampicin in the cerebrospinal fluid are approximately one tenth of those 
achieved in the blood, although this may be increased in inflammatory states 
146,147
. 
Metabolism 
The principal pathways of metabolism of rifampicin involve desacetylation 
and hydrolysis. Desacetylation at the C-25 position results in a more polar and 
equally active compound, 25- desacetyl rifampicin (DAR), with increased capacity 
for biliary excretion. Depending on the dose of rifampicin, one-third to one-eighth 
may be excreted in the bile, either as a 25-DAR or as unchanged rifampicin. The 
unchanged rifampicin is reabsorbed, creating an enterohepatic circulation, whereas 
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the 25-DAR is poorly absorbed
148
. The half-life of rifampicin is 3-5 h. Rifampicin, 
stimulates its own metabolism in liver and the biliary excretion of desacetyl 
rifampicin 
149
. On first dose administration on an empty stomach of 300 mg 
rifampicin, the serum concentration curves are similar to those following 
intravenous dosing, indicating little presystemic metabolism, but repeated 
administration induces hepatic endoplasmic reticular enzymes. Rifampicin induces 
certain cytochrome P450s, mainly 3A4 isozyme. The bioavailability of the active, 
orally administered rifampicin decreased from 93% after the first single oral dose to 
68% after 3 weeks of oral and intravenous rifampicin therapy. This is attributed to 
both, an increased hepatic metabolism and an induction of a prehepatic “first-pass” 
effect resulted from multiple rifampicin doses 
150
. 
Excretion 
Rifampicin is mainly eliminated in bile, gets reabsorbed and undergoes 
enterohepatic circulation. Amount excreted in urine increases with increasing doses 
and upto 30% of dose of 900 mg may be excreted in urine, about half of it within    
24 h
145,151,152
. About 40% is excreted in bile. About 60-65% dose appears in feces. 
Within 24 h, 3-30% of unchanged drug and active metabolite get excreted in urine 
(600 mg single dose oral administration). 6-15% of dose is excreted in urine and 
15% of dose appears as active metabolite (25-DAR) in urine. 7% of dose is excreted 
as inactive 3-FRSV
152
. 
Drug-Drug interactions 
Rifampicin induces certain cytochrome P450s, mainly 3A4 isozyme. The 
rifampicin dose of 600 mg/day was established partly to limit the CYP3A induction 
potential
153
. The drug affects the metabolism of the following drugs: acetaminophen, 
astemizole, carbamazepine, corticosteroids, cyclosporin, dapsone, ketoconazole, 
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methadone, phenobarbital, phenytoin, quinidine, terfenadine, theophylline, 
verapamil and warfarin
149
. 
Adverse effects of Rifampicin 
Human adverse reactions: Hepatitis and serious hypersensitivity reactions 
including thrombocytopenia, hemolytic anaemia, renal failure have been reported. 
Asymptomatic elevations of serum transaminase enzymes, increase in serum bile 
acids and bilirubin concentrations can occur. Marked elevation of serum alkaline, 
phosphatase and bilirubin suggests rifampicin liver toxicity. 
Cardiovascular: Hypotension and shock. 
Respiratory: Shortness of breath. 
CNS: Rare cases of organic brain syndrome have been reported (i.e. confusion, 
lethargy, ataxia, dizziness and blurring of vision). 
Gastrointestinal: Nausea, vomiting, diarrhoea. Rifampicin causes orange-red 
staining of all body fluids 
154,141
. 
Indications 
The primary indications for rifampicin are for treatment of tuberculosis 
(pulmonary andextrapulmonary lesions) and for leprosy. It has recently been used 
for brucellosis
141
. 
Contraindications 
Rifampicin is contraindicated in known cases of hypersensitivity to the drug. 
It may be contraindicated in pregnancy (because of teratogenicity noted in animal 
studies and since the effects of drugs on foetus have not been established) except in 
the presence of a disease such as severe tuberculosis. It is contraindicated in 
alcoholics with severely impaired liver function and with jaundice 
141
. 
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5.2 ISONIAZID 
 
Molecular formula: C6H7N3O  
Chemical structure 
 
Generic Name: Isonicotinic acid hydrazide; isonicotinoyl hydrazine; isonicotinyl 
                           Hydrazine. 
Molecular weight: 137.14 
Solubility: Soluble in water (~14% at 25ºC, ~26% at 40ºC) ethanol: (~2%at 25ºC), 
                   boiling ethanol (~10%), chloroform (~0.1%). Practically insoluble in  
                   ether, benzene. 
Polarity: (Log P) 0.64 
Acidity / basicity: pH of a 1% aqueous solution 5.5 to 6.5 
Stability: Very stable in DMSO; rather stable in water 
Melting point: 171.4ºC 
Optimal human dosage 
5 mg/kg for adults, 10-20 mg/kg for children. Adult dosing generally 300 mg 
capsule administered orally, once daily; or 15 mg/kg up to 900 mg/day, two or three 
times/week, ideally dose administered 1 h before or 2 h after a meal. Concomitant 
administration of pyridoxine (B6) recommended for malnourished patients, 
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adolescents, and those predisposed to neuropathy (e.g.diabetic).Can also be given 
intramuscularly or intravenously
29
. 
In-vitro potency For M. tuberculosis: H37Rv, MIC is 0.025 mg/ml. 
Mechanism of action 
Isoniazid is a prodrug activated by catalase-peroxidase hemoprotein, KatG. 
Isoniazid inhibits InhA, a nicotinamide adenine dinucleotide (NADH)-specific 
enoyl-acyl carrier protein (ACP) reductase involved in fatty acid synthesis
141
. 
Spectrum of activity 
Isoniazid is a bactericidal agent active against organisms of the genus 
Mycobacterium, specifically M. tuberculosis, M. bovis and M. kansasii. Isoniazid is 
bactericidal to rapidly-dividing mycobacteria, but is bacteristatic if the 
mycobacterium is slow growing. Isoniazid is highly specific, being active against 
only a subset of the mycobacteria and largely ineffective against other 
microorganisms; this is in part due to several unusual aspects of metabolism, 
exemplified in M. tuberculosis, including unusually high KatG activity and a 
defective drug efflux mechanism
155
. 
Pharmacokinetics of isoniazid 
Absorption 
Isoniazid is readily absorbed when administered either orally or parentrally. 
Peak plasma concentrations of 3-8 μg/ml develop 1-2 h after fasting dose of 300 mg 
orally. Aluminium containing antacids may interfere with the absorption of 
isoniazid
156,157
. 
Distribution 
Isoniazid diffuses readily into all body fluids and cells. Isoniazid is not 
considered to be bound appreciably to plasma proteins. The concentration of the 
Drug profile 
88 
 
drug is initially higher in the plasma and muscle than in the infected tissue, but the 
latter retains the drug for long time in quantities well above those required for 
bacteriostatis 
158,159
. 
Metabolism 
The plasma half-life of isoniazid ranges from 1-4 hrs, those who are fast 
acetylators because of genetic variations, having short half-lifes. The primary 
metabolic route is acetylation of isoniazid to acetylisoniazid by N-acetyltransferase, 
form in the liver and small intestine. Acetyl isoniazid is then hydrolyzed to 
isonicotinic acid and monoacetylhydrazine, isonicotinic acid is conjugated with 
glycine to isonicotinyl glycine and monoacetylhydrazine is further acetylated to 
diacetylhydrazine. Some unmetabolized isoniazid is conjugated to hydrazones. The 
metabolites of isoniazid have no tuberculostatic activity and are non-toxic
157
. 
Excretion 
Elimination of isoniazid from the body is dependent upon its genetically 
controlled rate of acetylation. Excretion is primarily renal. From 75% to 95% of 
dose of isoniazid is excreted in the urine within 24 h, mostly as metabolites. In 
patients with normal renal function, over 70% of a dose appears in the urine in 24 h. 
Of this amount, 93% of the isoniazid excreted in urine in fast acetyltors in the form 
of N-acetylisoniazid and 63% in slow acetylators as N-acetylisoniazid
159
. Small 
amounts of drug are also excreted in faeces
157
. 
Drug-drug interactions 
Isoniazid interacts with the cytochrome P-450 system, especially CYP2E1, 
where it shows a biphasic inhibition induction; it causes increases in serum 
concentrations of various drugs, especially phenytoin and carbamazepine, increases 
the effects of warfarin and theophylline, inhibits metabolism of benzodiazepines, 
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and inhibits monoamine oxidase and histaminases. Isoniazid should not be 
administered with food, as studies have shown that this significantly reduces its 
bioavailability
141
. 
Adverse effects of isoniazid 
Central Nervous System (CNS) effects: Peripheral neuropathy is the most 
common CNS related toxic effect. It is dose-related, occurs most often in the 
malnourished and in those predisposed to neuritis (e.g., alcoholics and diabetics), 
and is usually preceded by paraesthesias of the feet and hands. The incidence is 
higher in “slow acetylators”. Other neurotoxic effects, which are uncommon with 
conventional doses, are convulsions, toxic encephalopathy, optic neuritis and 
atrophy, memory impairment and toxic psychosis. 
Hepatic effects: Isoniazid does carry a specific warning of the potential for 
liver toxicity. Liver toxicity and hepatitis risks are increased with concomitant use of 
carbamazepine, phenobarbital, rifampicin, and alcohol abuse. Elevated serum 
transaminase (SGOT, SGPT), bilirubinaemia, bilirubinuria, jaundice, and 
occasionally severe and sometimes fatal hepatitiscan occur with normal dosing 
regimens. The common prodromal symptoms of hepatitis are anorexia nausea, 
vomiting, fatigue, malaise, and weakness. Mild hepatic dysfunction, evidenced by 
mild and transient elevation of serum transaminase levels appears in the first 1-3M 
of treatment but can occur at any time during therapy. In most instances enzyme 
levels return to normal, and generally there is no necessity to discontinue medication 
during the period of mild serum transaminase elevation. The frequency of 
progressive liver damage increases with age. It is rare in persons under 20, but 
occurs in up to 2.3% of those over 50 years of age
141,155
. 
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Gastrointestinal effects: Nausea, vomiting, epigastric distress and dark urine can 
occur but are rare.  
Haematological effects: agranulocytosis; hemolytic, sideroblastic, or aplastic 
anaemia, thrombocytopenia; and eosinophilia can occur
141
. 
Endocrine and metabolic: Pyridoxine deficiency, pellagra, hyperglycaemia, 
acidosis and gynecomastia can occur
155
. 
Hypersensitivity: Fever, skin rashes, lymphadenopathy and vasculitis can occur
160
. 
Indications 
The primary indications for isoniazid is for the treatment of tuberculosis 
(pulmonary and extrapulmonary lesions
157
. 
Contraindications 
Isoniazid is contraindicated in known cases of hypersensitivity to the drug. It 
is contraindicated in alcoholics with severely impaired liver function and with 
jaundice
155
. 
 
 
 
Polymer profile 
  
 
91 
6. POLYMER PROFILE 
 
6.1 CHITOSAN 
Chitosan is a natural cationic biopolymer consequent commencing the 
hydrolysis of chitin. One perceptible improvement of this substance is that it can be 
obtained from ecologically sound natural sources, namely crab and shrimp shell 
wastes. Together with chitin, Chitosan is well thought-out the second most profuse 
polysaccharide subsequent to cellulose. However contrasting cellulose, the employ 
of Chitosan as an excipient in pharmaceutical formula is a pretty new development. 
But Chitosan has been widely premeditated in the biomedical field and has been 
found to be highly biocompatible. In addition to the good biocompatibility of 
Chitosan and the abundance of natural sources of the material, Chitosan has a 
number of enviable properties that put together study of it attention-grabbing
161
. 
Origin of Chitosan 
Chemist always plays molecules. Chitin did not escape from it. Chemist did 
not spare chitin, the polymer either and made Chitosan. Chitin is the primary 
structural component of the outer skeletons of crustaceans, and of many other 
species such as molluscs, insects and fungi. Chitosan is most commonly obtaining 
from crustacean chitin, from crab and shrimp shells wastes. Chitin accounts for 
approximately 70% of the organic components in such shells. It is a reinforcing 
material, which occurs in three polymorphic forms, a-, b- and g-chitin. Where 
hardness in needed a-chitin is found, where flexibility is required b- and g-chitin 
occur. Chitin is inert in aqueous environment. Chitosan is prepared from chitin to 
obtain a more reactive polymer. The term Chitosan is used when chitin could be 
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dissolved in weak acid. When chitin is heated in a strong solution of sodium 
hydrochloride (>40%)  at high temperature (90-120
o
)
161
. 
Scope for chitin/ chitosan production in India 
The international shrimp industry from harvest through various 
processingoperations produces a vast amount of potentially recoverable 
proteinaceous by-productsin the form of shrimp heads and shells which is one of the 
major raw materials for chitin/ Chitosan production. Shells of other crustaceans viz. 
crabs, lobsters, squilla, and cuttle fish bones also could be profitably utilized.In 
India, it is estimated that more than one lakh tonne of shrimp processing wasteis 
being wasted annually which could be gainfully utilized for manufacturing chitin 
ahigh value industrial product. Another raw material for chitin is squilla. It is 
estimated that a potential of around 50,000 tonne of squilla is available of which 
nearly 5,000 tonne is being thrown back into the sea. This is an important trawl by 
catch especially in Mangalore and could be used for chitin/chitosan production. Crab 
shells and lobster shells are also raw materials for chitin/chitosan production. The 
estimated availability of crab shells is 30,000 - 40,000 tone in the Indian waters
161
. 
Chemistry 
Chitosan (Poly [-(1,4)-2-amino-2-deoxy-D-glucopiranose] ) is a natural 
carbohydrate polymer prepared by the partial N-deacetylation of chitin .Chitin is 
isolated from shells of crustacean( for example shrimp, crab and lobster ) by treating 
the shells with 2.5 N NaOH at 75 
o
C and with 1.7 N HCl at room temperature for 6 
hours Deacetylation can be done by alkaline treatment or by enzymatic reaction. The 
alkaline deacetylation is carried out by treating chitin with NaOH at high 
temperature. The degree of deacetylation increases with increasing temperature or 
NaOH concentration. 
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Structure of Chitosan 
Important properties of chitosan 
 Medical grade micronised Chitosan is biodegradable, non allergic, 
haemostatic, non toxic and wound healing accelerator. 
 Chitosan films are flexible, tough, transparent, clear and oxygen permeable 
with good tensile strength. 
 Chitosan could be used to make single and biopolymer membranes, non 
woven fabrics and sponges for surgical applications. 
 It is resistant to alkali, digestive enzymes and urine. 
 Chitosan also could be cross linked. 
Solubility 
Chitosan is soluble in organic acids like formic, acetic, prop ionic. oxalic, 
malonic, succinic, adipic, lactic, pyruvic, malic, tartaric and citric acid
162
. 
Process 
Technology  
Central Institute of Fisheries Technology (CIFT) Kochi has the distinction of 
perfecting the technology for chitin and Chitosan production in the country. The 
institute is imparting training to entrepreneurs who are interested in setting up such 
units. They also provide technical support on a turnkey basis. 
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Raw material 
 Dried/wet shells of prawns, squilla, crabs, lobsters etc., could be utilized. 
The shells thus used should be thoroughly free from sand and extraneous matter, so 
as to reduce the ash content of the final product to less than 2%. 
Deproteinisation 
The shells are boiled with 3% sodium hydroxide for 30minutes in a mild 
steel vessel to remove protein stuck to head and shell. The boiled raw material is 
allowed to cool and it is washed with water to remove all traces of alkali (could be 
tested with a pH paper). 
Demineralisation 
The deproteinised shells are transferred to a mild steel vessel lined with fiber 
glass and is treated with 3% hydrochloric acid. This is kept for 30minutes with 
occasional stirring till the reaction is complete. The excess acid is decanted and the 
residue is washed till the pH is normal. 
Removal of water 
Excess water is removed using a screw press till the moisture is below 60%. 
The product thus obtained is called chitin. 
Deacetylation of Chitin 
It is the process of conversion of chitin to Chitosan. Chitin is heated at 90-95 
0 C for about one and a half hour with 40% caustic soda in amild steel vessel. 
Excess alkali is drained off and the mixture is washed with water several times till it 
is free from alkali. Eighty percent of the alkali, thus removed could be reused in 
subsequent cycles. 
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Drying 
The above product is sun dried for 6-8 hours or in drier till the moisture 
content is less than 5%. Care should be taken not to exceed the drier temperature 
beyond 60 
0
 C. chitosan thus obtained is in the form of flakes. 
Powdering and Packing 
The Chitosan flakes obtained could be powdered and packed in lots of 10, 
20, and 25 kg in HDP/ Polyethylene lined non woven sacks in a dry place. Chitin 
can be stored for one year whereas chitosan can be stored for nearly three months 
only. 
Yield 
Chitin represent 14-27% and 13-15% of the dry weight of shrimp and crab 
processing waste respectively and squilla yields 15% chitin. On a conservative basis 
the yield is estimated as dry raw material chitin 14% by wt Chitosan 10% by wt
163
. 
Product characterization 
 Chitosan can be described in general by the following parameters: 
 Degree of deacetylation in %, 
 Dry matter in %, 
 Ash in %, 
 Protein in %, 
 Viscosity in Centipoises, 
 Intrinsic viscosity in ml/g, 
 Molecular weight in g/mol, and 
 Turbidity in NTU units 
All of these parameters can be adjusted to the application for which chitosan 
is being used. The deacetylation is very important to get a soluble product. In 
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general, the solubility of heteroglucans are also influenced by the distribution of the 
acetyl groups, the polarity and size of the monomers, distribution of the monomers 
along the chain, the flexibility of the chain, branching, charge density, and molecular 
weight (50,000 to 2,000,000 Da) of the polymer. Viscosity (10 to 5000 cp) can be 
adjusted to each application by controlling the process parameters
164
. 
Chemical and biological properties of chitosan 
 Cationic polyamine Biocompatibility 
 High charge density at pHs < 6.5 Natural polymer 
 Adheres to negatively charged surfaces Safe and non-toxic 
 Forms gels with polyanions Haemostatic 
 High molecular weight linear polyelectrolyte 
 Biodegradable to normal body constituents 
 Viscosity, high to low Bacteriostatic / Fungistatic 
 Chelates certain transitional metals Spermicidal 
 Amiable to chemical modification Anticancerogen 
 Reactive amino/hydroxyl groups Anticholestermic 
Specification of pharmaceutical-grade chitosan parameters description 
 Appearance (powder or flake) White or yellow 
 Particle size < 30μm 
 Viscosity A ≤ 5 cps 
 Density between 1.35 to 1.4 g/cm3 
 PH 6.5 to 7.5 
 Moisture content > 10% 
 Ash value > 2% 
 Mater insoluble in water ≤ 0.5% 
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 Degree of deacetylation 66 to 99.8% 
 Heavy metal (Pb) < 10 ppm 
 Heavy metal (As) < 10 ppm 
 Protein content < 0.3% 
 Loss on drying ≤ 10 % 
 Glass transition temperature 203 0C 
Uses of chitosan 
Clarification and purification 
The property of long chain molecules of dissolved Chitosan to wrap the solid 
particles suspended in liquids and to bring them together and agglomerate makes it 
suitable as a coagulant aid. It is used in treatment of sewage effluents, purification of 
drinking water etc. 
Chromatography 
The presence of free amino acid hydroxyl groups in Chitosan is a good 
chromatographic support. 
Paper and textiles 
The high molecular weight, poly cationic linear film forming and hydrogen 
bonding ability makes chitosan an ideal polymer applicable in the paper industry. 
The chelating ability, adhesive property and ionic bond forming characteristic of 
chitosan find potential application in textiles. Fabrics seized with chitosan have good 
stiffness, improved dye uptake, added luster and improved laundering resistance. 
Photography 
Due to the resistance of chitosan to abrasion, optical characteristic film 
forming ability and behaviors with silver complexes chitosan has important 
application in photography. 
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Food and nutrition 
Chitosan supplemented chick feed and fish feed improved the weight gain in 
chicken and fish
165
. 
Agriculture  
It has potential application in agriculture such as germination and culturing 
to enhance self protection against pathogenic organisms in plants and suppress them 
in soil, to induce chitinase activity, in encapsulation of fertilizers, in liquid fertilizers 
and incontrolled release of herbicides. 
Medical and pharmaceutical uses
166
 
 Disintegrant 
 Bioadhesive polymer Diluents in direct compression of tablets. 
 Binder in wet granulation 
 Slow-release of drugs from tablets and granules 
 Drug carrier in microparticle systems 
 Films controlling drug release 
 Preparation of hydrogels, agent for increasing viscosity in solutions. 
 Wetting agent, and improvement of dissolution of poorly soluble drug 
substances 
 Site-specific drug delivery (e.g. to the stomach or colon) 
 Absorption enhancer (e.g. for nasal or oral drug delivery) 
 Biodegradable polymer (implants, microparticles) 
 Carrier in relation to vaccine delivery or gene therapy. 
 Bacteriostatic agent 
 Enzyme immobilization 
 Film / membrane for dialysis 
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 Artificial skull sponge for mucosal haemostatic agent wound dressing 
 Anti cholesteremic material 
 Anti sore composition 
 Antibillirubinemia agent 
 Preparation of self regulated drug delivery system 
 Sustained release / direct compression 
 Buccal and sublingual drug delivery 
 Ophthalmic drug delivery 
 Gastrointestinal drug delivery 
 Transdermal drug delivery 
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7. EXCIPIENT PROFILE 
 
7.1 ASCORBIC ACID 
 
Category: Water Soluble Vitamin 
Empiricalformula:C6H8O6 
Structure: 
        
   
Chemical name: L-ascorbic acid 
Molecular weight: 176.1 
Melting point: About 190°C (with decomposition) 
Colour: White to slightly yellowish crystalline powder 
Taste: Slight acidic taste. 
Solubility: Freely soluble in water; sparingly soluble in alcohol; insoluble in 
chloroform, in ether, and in benzene. 
Dosage and Administration 
Ascorbic acid (vitamin c) is usually administered orally. When oral 
administration is not feasible or when malabsorption is suspected, the drug may be 
administered IM, IV, or subcutaneously. When given parentrally, utilization of the 
vitamin reportedly is best after IM administration and that is the preferred parentral 
route. 
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The average protective dose of vitamin C for adults is 70 to 150 mg daily. In 
the presence of scurvy, doses of 300 mg to 1 g daily are recommended. However, as 
much as 6 g has been administered parentrally to normal adults without evidence of 
toxicity. 
Toxicity 
 Unpleasant diarrhea167 
 Gastrointestinal disturbances168 
 Hyperoxaluria 169 
 Haemolysis 170 
Mechanism of antioxidants 
 
Ascorbic acid is a mild reducing agent. For this reason, it degrades upon 
exposure to oxygen, especially in the presence of metal ions and light. It can be 
oxidized by one electron to a radical state or doubly oxidized to the stable form 
called dehydroascorbic acid. 
Ascorbate usually acts as an antioxidant. Typically it reacts with oxidants 
such reactive oxygen species, such as the hydroxyl radical formed from hydrogen 
peroxide. Such radicals are damaging to animals and plants at the molecular level 
due to their possible interaction with nucleic acids, proteins, and lipids. Sometimes 
these radicals initiate chain reactions. Ascorbate can terminate these chain radical 
reactions by electron transfer. Ascorbic acid is special because it can transfer a 
single electron, owing to the stability of its own radical ion called 
"semidehydroascorbate". dehydroascorbate. The net reaction is: 
RO• + C6H7O6
−
 → ROH + C6H6O6-•. 
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The oxidized forms of ascorbate are relatively unreactive, and do not cause 
cellular damage. 
However, being a good electron donor, excess ascorbate in the presence of 
free metal ions can not only promote, but also initiate free radical reactions, thus 
making it a potentially dangerous pro-oxidative compound in certain metabolic 
contexts. 
Functions 
 Antioxidant which helps defend cells from the effects of smoke, pollution 
and other highly reactive substances called free radicals 
 Controls blood cholesterol levels 
 Converts folic acid into active form folinic acid 
 Essential for the formation of intercellular material, bone and teeth 
 Essential for the absorption of iron
171
 
 Fights bacterial and viral  infections 
 Helps in healing
172
 
 Maintains healthy reproductive organs 
 May help protect against certain cancers, cataracts and heart disease 
 Necessary in production of red blood cells 
 Prevents allergic reactions (antihistamine activity) 
 Prevents hemorrhaging 
USES 
 Bone viral and bacterial infections 
 Allergic reactions (due to its antihistamine qualities) 
 Arthritis 
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 Atherosclerosis 
 Colds and influenza 
 Gastro-intestinal hemorrhages  
 Iron-deficient anemia
173,174
 
 Reducing high blood cholesterol levels 
 Reducing leg cramps during pregnancy 
 Treating lead, mercury and cadmium poisoning 
 Treating loose teeth
167
 
 Treatment of scurvy
175,176
 
 Great antioxidant 
175,176
  
 Bleeding gums
167
  
 Adjuvant in cancer
175
 
 Reduces gastric cancer
177
 
 Stabilizes food and plasma 
 Coronary heart diseases
172
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7.2 SODIUM TRIPOLYPHOSPHATE 
 
 
Sodium tri phosphate (STP, sometimes STPP or sodium tripolyphosphate or TPP,) is 
an inorganic compound with formula Na5P3O10. It is the sodium salt of the 
polyphosphate penta-anion, which is the conjugate base of triphosphoric acid. It is 
produced on a large scale as a component of many domestic and industrial products, 
especially detergents
178
. 
Chemical structure 
 
Chemical and physical properties 
 White powder 
 Melting point 622 degree centigrade 
 Easily soluble in water 
 Can soften hard water 
 Slightly alkaline 
Specifications 
 Molecular Formula : Na5P3O10 
  Molecular weight : 367.86 
Uses 
 Manufacturing of ceramic tile 
 Gum synthesis 
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 Food industry 
 Poultry process 
 Metal industry 
 Pharmaceutical industry 
Storage 
 Avoid Moisture 
 Should not be put in the open air 
Table 10 Details of sodium tripolyphosphate 
Indexes Industrial Grade Food Grade 
Na5P3O10 94.0%Min 94.0%Min 
P2 O 5 57.0%Min 57.0%Min 
Water Insoluble Matter 0.15%Max 0.04%Max 
Iron(Fe) 0.015%Max 0.006%Max 
PH value (1% water 
solution)  
9.2-10.0 9.5-10.0 
Heavy Metal (as Pb) 70 PPM Max. 0.001%Max 
Arsenic (As) - 0.0003%Max 
Fluoride (F) - 0.003%Max 
Whiteness 92%Min 92%Min 
Ignition loss 1.0 - 
density (g/cm3) 0.35-0.9 0.35-0.9 
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8. MATERIALS 
Table 11 List of materials 
Drugs and Chemicals Supplier/ Manufacturer 
Rifampicin  - Astha laboratories Pvt Ltd, Hyderabad. 
Isoniazid - Astha laboratories Pvt Ltd, Hyderabad. 
Chitosan (85% deacetylation)  
(M.W-150kDa, 400KDa, 600KDa)   
- Central Institute of Fisheries Technology, 
- Cochin.                                                                                         
Glacial acetic acid (Analytical grade)                                         - S.D Fine chem. Ltd, Mumbai. 
Ascorbic acid (Analytical grade) - Qualigens fine Chemicals, Mumbai. 
Potassium chloride (Analytical 
grade) 
- Loba chemicals, Mumbai. 
Hydrogen chloride (Analytical 
grade) 
- Loba chemicals, Mumbai. 
HPLC water (Analytical grade) - Merck  Pvt Ltd, Mumbai. 
Sodium Hydroxide (Analytical 
grade) 
- Spectrum Reagents & Chemicals, Cochin. 
Potassium Di hydrogen Phosphate 
(Analytical grade)            
- Spectrum Reagents & Chemicals, Cochin. 
Tween 80(Analytical grade) - Loba chemicals, Mumbai. 
Sodium Tri Poly Phosphate  
(Analytical grade) 
- S.D Fine chem. Ltd, Mumbai 
Dialysis membrane 
(M.WCO 12,000-15,000Da) 
- Himedia Laboratory, Mumbai 
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9. INSTRUMENTS 
Table 12 List of Instruments 
               Instruments                                     Model / Manufacturer 
FT-IR spectrophotometer - Perkin Elmer Spectrum RX 1, USA. 
Scanning electron microscope - Joel model JSM 6400, Tokyo. 
UV-Visible Spectrophotometer - Perkin Elmer Lambda 25, USA 
Dissolution apparatus - Electro lab No.2 (USP XXIII) 1995, 
                                                                Chennai. 
Single pan digital balance - Shimadzu BL220H , Koyoto, Japan. 
Microscope - Unilab, Ambala cantt, Haryana, India. 
Digital pH meter - Hanna instruments, Italy HI98. 
Magnetic stirrer - Eltek MS 2012, India. 
Sonicator - Bandelin Sono plus Model HD, 2070. 
Freeze Drier - Labconico, USA 
Research cooling centrifuge         - Remi Centrifuge R4C-DX, USA 
Differential Scanning Colorimetry - DSC CA 60 Shimadzu, Japan 
Zeta potential analyzer - Zetasizer 3000HS, Malvern instrument, 
   UK. 
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10. METHODS 
Estimation of pure rifampicin 
Rifampicin was estimated spectrophotometrically at 475 nm
 179,180,181,182,183
 in 
the range of 2-10 µg/ml as per Beer Lambert’s law184. 
Preparation of buffer pH 1.2 
50ml 0f 0.2M KCl was mixed with 85ml of 0.2M HCl and made upto 200ml 
with water. 
Preparation of 0.2M potassium chloride 
14.911gm of KCl was dissolved in distilled water and diluted with distilled 
water and made up to 1000ml
185
 
Preparation of 0.2M hydrochloric acid 
17ml of HCl was mixed with 1000ml 0f H2O
185
. 
10.1 Preparation of standard graphs 
Preparation of standard solution 
100mg of rifampicin was dissolved in 100ml of buffer pH 1.2 so as to get a 
stock solution of 1000 μg/ml concentration. From this 2 ml of stock solution was 
diluted to 100ml with pH 1.2 phosphate buffer thus giving a concentration of 20 
μg/ml of the drug. Aliquot of standard drug solution ranging from 1ml to 9ml were 
transferred  to 10ml volumetric flask and were diluted up to the mark with pH 1.2 
buffer. Thus the final concentration ranges from 2-10μg/ml as per Beer 
Lambert’slaw184. Absorbance of each solution was measured at 
475nm
179,180,181,182,183
 against buffer pH 1.2 as a blank and the concentrations of drug 
vs absorbance were plotted. 
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Table 13 Absorbance of rifampicin at 475nm in pH 1.2 buffer 
S.No Concentration (µg/ml) Absorbance 
1. 0 0 
2. 2 0.18 
3. 4 0.41 
4. 6 0.62 
5. 8 0.84 
6. 10 1.02 
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Preparation of standard graph of rifampicin with ascorbic acid (125, 250, 500, 
1000mg) 
Preparation of standard solution 
100mg of rifampicin and ascorbic acid (125, 250,500, 1000mg) were 
dissolved in 100ml of buffer pH 1.2 so as to get a stock solution of 1000 μg/ml 
concentration. From this 2 ml of stock solution was diluted to 100ml with pH 1.2 
phosphate buffer thus giving a concentration of 20 μg/ml of the drug. Aliquot of 
standard drug solution ranging from 1 to 9ml were transferred  to 10ml volumetric 
flask and were diluted up to the mark with pH 1.2 buffer. Thus the final 
concentration ranges from 2-10 μg/ml as per Beer Lambert’s law. Absorbance of 
each solution was measured at 475 nm against buffer pH 1.2 as a blank and the 
concentrations of drug vs absorbance were plotted. 
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Table 14 Absorbance of rifampicin with ascorbic acid (125mg) 
at 475nm in pH 1.2 buffer 
S.No 
 
Concentration (µg/ml) Absorbance 
1. 0 0 
2. 2 0.21 
3. 4 0.42 
4. 6 0.64 
5.  8 0.86 
6.    10 0.99 
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Table 15 Absorbance of rifampicin with ascorbic acid (250mg) 
at 475nm in pH 1.2 buffer 
S.No Concentration(µg/ml) Absorbance 
 
1. 0 0 
2. 2 0.23 
3. 4 0.40 
4. 6 0.59 
5. 8 0.74 
6. 10 0.92 
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Table 16 Absorbance of rifampicin with ascorbic acid (500mg) 
at 475nm in pH 1.2 buffer 
S.No Concentration (µg/ml) Absorbance 
 
1. 0 0 
2. 2 0.21 
3. 4 0.41 
4. 6 0.61 
5. 8 0.82 
6. 10 0.98 
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Table 17 Absorbance of rifampicin with ascorbic acid (1000 mg) 
at 475nm in pH 1.2 buffer 
S.No Concentration(µg/ml) Absorbance 
1. 0 0 
2. 2 0.22 
3. 4 0.41 
4. 6 0.62 
5. 8 0.81 
6. 10 0.99 
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Preparation of standard graph for isoniazid 
100mg of isoniazid was dissolved in 100ml of buffer pH 1.2 so as to get a 
stock solution of 1000 μg/ml concentration. From this 2 ml of stock solution was 
diluted to 100ml with pH 1.2 phosphate buffer thus giving a concentration of 20 
μg/ml of the drug. Aliquot of standard drug solution ranging from 1ml to 9ml were 
transferred  to 10ml volumetric flask and were diluted up to the mark with pH 1.2 
buffer. Thus the final concentration ranges from 2-10 μg/ml as per Beer Lambert’s 
law. Absorbance of each solution was measured at 263 nm
186
 against buffer pH 1.2 
as a blank and the concentrations of drug vs absorbance were plotted.                                                                      
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Table 18 Absorbance of isoniazid at 263nm in pH 1.2 buffer 
 
 
S.No Concentration(µg/ml) Absorbance 
1. 0 0 
2. 2 0.21 
3. 4 0.43 
4. 6 0.64 
5. 8 0.85 
6. 10 0.97 
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Procedure for simultaneous estimation of rifampicin and isoniazid 
Procedure for determining the sampling wavelength for simultaneous 
analysis. 
By appropriate dilution of two standard drug solutions with ethanol, 
solutions containing 10 μg/ ml of rifampicin and 10 μg/ml of isoniazid were scanned 
separately in the range of 500-200 nm to determine the wavelength of rifampicin 
and isoniazid showed absorbance maxima at 475
179,180,181,182,183
 and 263
186
 nm 
respectively as shown in Fig. 8 and 9. 
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Figure  10. Absorption spectrum of rifampicin in buffer pH 1.2 (10 μg/ml) 
showing  max 475nm 
Methods 
118 
 
          
200.0 250 300 350 400 450 500 550 600 650 700.0
0.00
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.00
nm
A 
266.33
235.74
214.77
 
 
Figure 11. Absorption spectrum of rifampicin in buffer pH 1.2 (10 μg/ml) 
showing  max 263nm 
Selection of method and wavelength 
For estimation of rifampicin, simultaneous equation method employing 475 
nm as analytical wavelength was used. For estimation of isoniazid, 263 nm was 
selected as the analytical wavelength. In the simultaneous equation method 
developed for simultaneous estimation of rifampicin and isoniazid, the wavelengths 
were selected from the overlain spectra as shown in Fig 10. 
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Figure 12.   Overlain spectra of isoniazid and rifampicin in buffer pH 1.2              
(10 μg/ml) showing  max 263nm and 475nm in standard solution 
Preparation of Standard Stock Solution 
The standard stock solution containing rifampicin and isoniazid were prepared by 
dissolving 100 mg of rifampicin and 100mg of isoniazid separately in 20 ml of buffer pH 
1.2. It was then sonicated for 10 minutes and the final volume of both the solutions were 
made up to 100 ml with buffer pH 1.2 to get stock solutions containing 1000 μg/ ml each 
of rifampicin and isoniazid in two different 100 ml volumetric flasks. From this 2 ml of 
stock solution was diluted to 100ml with pH 1.2 phosphate buffer thus giving a 
concentration of 20 μg/ml of the drug. Aliquot of standard drug solution ranging from 1 to 
9ml were transferred to 10ml volumetric flask and were diluted up to the mark with pH 
1.2 buffer. Thus the final concentration ranges from 2-10 μg/ml as per Beer Lambert’s 
law. Absorbance of each solution was measured at 215 nm against buffer pH 1.2 as a 
blank and the concentrations of drug vs absorbance were plotted. 
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Table 19 Absorbance of rifampicin and isoniazid at 215nm in pH 1.2 buffer 
S.No Concentration(µg/ml) Absorbance 
1. 0 0 
2. 2 0.164 
3. 4 0.282 
4. 6 0.579 
5. 8 0.882 
6. 10 1.209 
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Preparation of standard graph for rifampicin and isoniazid with ascorbic acid 
(125, 250,500, 1000mg) 
100mg of rifampicin, 100mg of isoniazid, and ascorbic acid (125, 250,500, 
1000mg) were dissolved in 100ml of buffer pH 1.2 so as to get a stock solution of 
1000 μg/ml concentration. From this 2 ml of stock solution was diluted to 100ml 
with pH 1.2 phosphate buffer thus giving a concentration of 20 μg/ml of the drug. 
Aliquot of standard drug solution ranging from 1ml to 9ml were transferred to 10ml 
volumetric flask and were diluted up to the mark with pH 1.2 buffer. Thus the final 
concentration ranges from 2-10 μg/ml as per Beer Lambert’s law. Absorbance of 
each solution was measured at 215 nm against buffer pH 1.2 as a blank and the 
concentrations of drug vs absorbance were plotted. 
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Table 20 Absorbance of rifampicin and isoniazid with ascorbic acid (125 mg) 
at 215nm in pH 1.2 buffer 
 
S.No Concentration (µg/ml) Absorbance 
1. 0 0 
2. 2 0.17 
3. 4 0.37 
4. 6 0.56 
5. 8 0.74 
6. 10 0.90 
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Table 21 Absorbance of rifampicin and isoniazid with ascorbic acid (250 mg) 
at 215nm in pH 1.2 buffer 
 
S.No Concentration (µg/ml) Absorbance 
1. 0 0 
2. 2 0.27 
3. 4 0.43 
4. 6 0.63 
5. 8 0.84 
6. 10 0.99 
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Table 22 Absorbance of rifampicin and isoniazid with ascorbic acid (500mg) 
at 215nm in pH 1.2 buffer 
 
S.No Concentration (µg/ml) Absorbance 
1. 0 0 
2. 2 0.20 
3. 4 0.38 
4. 6 0.67 
5. 8 0.73 
6. 10 0.91 
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Table 23 Absorbance of rifampicin and isoniazid with ascorbic acid (1000mg) 
at 215nm in pH 1.2 buffer 
 
S.No Concentration (µg/ml) Absorbance 
1. 0 0 
2. 2 0.2 
3. 4 0.41 
4. 6 0.62 
5. 8 0.78 
6. 10 0.95 
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10.2 Preparation of rifampicin loaded chitosan nanoparticles 
Rifampicin loaded chitosan nanoparticles were prepared according to the 
procedure first reported by Calvo et al (1997b)
187 
based on the ionic gelation of  
chitosan with sodium tri polyphosphate anions (STPP) in the presence of tween 80 
as a suspending agent to prevent aggregation, at ambient temperature. Rifampicin 
and chitosan with different molecular weight (150, 300, 450KDa) were dissolved in 
1% acetic acid in aqueous solution under magnetic stirring at room temperature in 
the presence of tween 80 at various concentrations (0.25, 0.5, 1.0%). Nanoparticles 
were prepared by adding STPP aqueous solution drop wise to chitosan solution 
under magnetic stirring with different speed (400,800,1200rpm) at room temperature 
for 45 min. The nanosuspensions were cold centrifuged at 12000g, in a glucose bed 
for 30 min using Remi centrifuge (R4C-DX, USA). The supernatant liquid was 
analyzed by spectrophotometer at 475 nm
179,180,181,182,183 
to calculate the percentage 
drug entrapment and drug loading. The final suspensions were then frozen and 
lyophilized at 0.4 mbar and -40 ºC for 5 hrs using sucrose and glucose (1:1) as 
cryoprotective agents. The lyophilized nanoparticles were stored in desiccators at 
4ºC. The formula for preparation of nanoparticles is given in Table 23. 
10.3 Preparation of rifampicin-ascorbic acid nanoparticles 
The chitosan molecular weight and ascorbic acid concentration were chosen 
based on maximum diffusion and dissolution stability characteristics respectively for 
the preparation of rifampicin-ascorbic acid loaded chitosan nanoparticles. The 
nanoparticles were prepared as described before under preparation of nanoparticles 
(10.2). 
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Table 24 Formulation of rifampicin loaded chitosan nanoparticles 
 
 
 
Formula 
code 
 
Composition 
 Chitosan Mwt 
(KDa) 
(%) Tween 80     Stirring speed(rpm) 
F1           0.25 400 
F2           0.5 400 
F3           1.0 400 
F4 150 (Low)          0.25 800 
F5           0.5 800 
F6           1.0 800 
F7           0.25   1200 
F8           0.5   1200 
F9           1.0   1200 
F10           0.25 400 
F11           0.5 400 
F12           1.0 400 
F13           0.25 800 
F14 300 (Medium)          0.5 800 
F15           1.0 800 
F16           0.25  1200 
F17           0.5  1200 
F18           1.0  1200 
F19           0.25 400 
F20           0.5 400 
F21           1.0 400 
F22           0.25 800 
F23       600 (High)          0.5 800 
F24           1.0 800 
F25           0.25   1200 
F26           0.5  1200 
F27 
F28 
 
     150 (Low) 
 
         1.0 
         0.5 
 1200 
  1200 
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10.4 Evaluation of rifampicin loaded chitosan nanoparticles 
10.4.1 Drug and carrier interaction by Fourier transform infra red spectroscopy 
          (FTIR) 
FTIR Spectroscopy (Perkin Elmer RX1) was performed on pure drug, 
polymer and nanoparticles. The pellets were prepared by gently mixing 1mg sample 
with 200mg potassium bromide at high compaction pressure. The scanning range 
was 450 to 4000  cm
-1
 and the resolution was 4 cm
-1
. The pellets thus prepared were 
examined and the spectra of all the samples were compared. 
10.4.2 Thermal analysis by differential scanning calorimetry (DSC) 
Differential scanning calorimetric measurement of nanoparticles was carried 
out by using a thermal analysis instrument (DSC CA 60 Shimadzu. Japan) equipped 
with liquid nitrogen sub ambient accessory. Samples were accurately weighed in 
aluminum pans thematically sealed and heated at a rate of 10ºC min
-1
 in a 30 to 
300ºC temperature under nitrogen flow of 40 ml/min. The experiment was repeated 
for pure rifampicin, chitosan, ascorbic acid and physical mixture. 
10.5 Physicochemical properties and release of nanoparticles 
10.5.1 Morphology by scanning electron microscopy  
The morphology of nanoparticles was analyzed by scanning electron 
microscope (JEOL MODEL JSM 6400). The nanoparticles were mounted directly 
on the SEM stub, using double –sided, sticking tape and coated with platinum and 
scanned in a high vacuum chamber with a focused electron beam. Secondary 
electrons, emitted from the samples were detected and the image formed. 
10.5.2 Surface characteristics by zetasizer 
The particle size, and particle size distribution of nanoparticles were 
measured with a malvern instrument (Zetasizer 3000 HS U.K).The particle size 
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distribution is reported as poly dispersity index. The samples were placed in the 
analyzer chamber and readings were performed at 25°c with a detected angle of 90 
degrees. The zeta potential of nanoparticles was measured with a malvern 
instrument (Zetasizer 3000 HS U.K). The samples were diluted with pH 7.4 buffer, 
and placed in eletrophoretic cell and measured in the automatic mode. 
10.5.3 Rifampicin encapsulation efficiency and loading capacity of 
nanoparticles 
The encapsulation efficiency and loading capacity of nanoparticles were 
determined by the separation of nanoparticles from the supernatant liquid containing 
non associated rifampicin obtained after cold centrifugation at 12000g for 30 
minutes .The amount of free rifampicin in the supernatant liquid was measured by 
spectrophotometer at 475 nm. The rifampicin encapsulation efficiency (EE) and 
loading capacity (LC) of the nanoparticles were calculated from the following 
equations
188
. 
                                               Total amount of rifampicin – Free rifampicin  
Encapsulation efficiency = -------------------------------------------------------- x 100 
                                                          Total amount of rifampicin       
 
                                                 Total amount of rifampicin – Free rifampicin 
Loading capacity            = --------------------------------------------------------- × 100 
                                                            Weight of nanoparticles 
 
10.6 In-vitro dissolution stability study 
In-vitro dissolution stability was performed on rifampicin, rifampicin 
nanoparticles and rifampicin – ascorbic acid nanoparticles in 0.1 N HCL. The study 
was carried out by the method described by Shisoo et al., (1999)
19
. A solution of 
0.1N HCL (200 ml) was placed in the vessel of the USP dissolution apparatus No.2 
(USP XXIII, 1995) and the medium was equilibrated at 37±0.1°C with stirring at 50 
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rpm. Rifampicin (100mg) and ascorbic acid (drug to ascorbic acid ratio at 100:125, 
100:250, 100:500,100:1000mg) were accurately weighed, dissolved in and diluted to 
100 ml with 0.1N HCL. The resulting solution was transferred immediately to the 
dissolution vessel at once and 1 ml of sample was withdrawn immediately from a 
zone midway between the surface of the dissolution medium and bottom of the 
vessel (0-min sample). This experiment was done in the presence and absence of 
isoniazid in a concentration proportionate to the strength in FDC products taken in 
the medium. Samples were withdrawn at 0, 15, 30, 45, 60min intervals and filtered 
through 0.1µm membrane filter immediately and 1 ml fresh 0.1N HCL solution was 
added in to the system. An aliquot, 1 ml was diluted to 10 ml of 0.1N HCL         
using cyclomixer (3min). Samples were measured at 475nm in 
spectrophotometer
179,180,181,182,183
. The experiment was run in triplicate and the mean 
values were recorded as percent drug degradation. The percentage degradation of 
drug was calculated from the difference between the values of sample drawn           
at 0 and appropriate time intervals
69
.  
10.7 In-vitro diffusion study 
The studies were performed on rifampicin, rifampicin nanoparticles and 
rifampicin – ascorbic acid nanoparticles in 0.1 N HCL. Sample equivalent to 100mg 
of rifampicin was redispersed in 10ml 0.1N HCL solution and placed in a dialysis 
membrane bag with a molecular cut-off of (MWCO 12,000-15,000Da, Himedia, 
India) which acts as a donor compartment, tied and placed into 10 ml 0.1N HCL 
solution in a beaker which acts as a receptor compartment .The entire system was 
kept at 37ºC±0.1°C with continuous magnetic stirring at a rotation speed of 50 rpm. 
At appropriate time intervals (0, 15, 30, 45, 60min) 1 ml of the release medium was 
removed through 0.1µm membrane filtered immediately and 1 ml fresh 0.1N HCL 
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solution was added in to the system. This experiment was done in the presence and 
absence of isoniazid taken in the medium. The amount of rifampicin in the release 
medium was determined by spectrophotometer at 475nm and the percentage release 
of rifampicin recorded. The experiment was run in triplicate and the mean values 
were recorded as percent release of rifampicin
189
. 
10.8 Pharmacokinetics study 
Animals 
New Zealand white rabbits weighing 1.5 to 2.5kg were obtained from the 
animal house, Swamy Vivekananda College of Pharmacy. The animals were fed 
with cabbage and water. They were maintained in standard laboratory conditions at 
21±2 
0
C and relative humidity of 55-60%. The animals are overnight fasted before 
the experiment. The study protocol was approved by the Institutional Animal Ethical 
Committee and the protocol number is SVCP/IAEC/Ph.D /03/2011. 
Drugs: Rifampicin and isoniazid were obtained from Astha Laboratories Pvt. 
Ltd, Hyderabad, Andhra Pradesh, India. Ascorbic acid was obtained from Qualigens 
Fine Chemicals, Mumbai. 
Chemicals: 1% CMC from Loba Chem Pvt Ltd, Mumbai, 95% v/v alcohol. 
Requirements:  Cotton, Surgical blade, 26G needle, Blood collecting tubes 
(EDTA tubes),   Plasma sample collecting tubes 
Sex: Both Male/Female         
No. of animals: 24 
Animal dose:  
Rifampicin     : 31mg/kg/p.o 
Isoniazid        : 15mg/kg/p.o 
           Ascorbic acid  : 26mg/kg/p.o 
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Collection of blood from marginal ear vein 
 The animal was placed in a retainer. Hair of the ear was shaved smoothly 
with blade without disturbing the blood vessels. Ear was cleaned with 95% v/v 
alcohol on the collection site and rapid rubbing on the ear to  dilate blood vessels 
which is easy to collect the blood. 2G needle was inserted in vein to collect the 
blood from marginal ear vein. After collecting blood, clean sterile cotton was kept 
on the collection site and finger pressure was applied to stop the bleeding
190
. 
Rabbits were classified into 8 different groups each group consisting of 3 animals. 
Group I       -   Control (Rifampicin) 
Group II      -   Rifampicin + Isoniazid 
Group III     -   Rifampicin - ascorbic acid 
Group IV     -   Rifampicin + Isoniazid - ascorbic acid 
Group V       -   Rifampicin nanoparticles 
Group VI      -   Rifampicin nanoparticles + Isoniazid 
Group VII     -   Rifampicin - ascorbic acid nanoparticles   
Group VIII    -   Rifampicin - ascorbic acid nanoparticles + Isoniazid 
Procedure 
Preparation of samples 
The samples were suspended in water using 1% CMC as a suspending agent 
and used for this study. Each group of animals (three rabbits) was administered the 
samples as shown above through an intra gastric tube after a overnight fasting. 
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Blood samples     (1 ml) were collected in to heparinized tubes from the marginal ear 
vein at 0, 0.5, 1, 2, 4, 6, 9 and 12 h after drug administration and plasma was 
separated by using centrifugation and stored at -20°C. Samples were analyzed by 
high performance liquid chromatography (HPLC)
 191
.
 
Bioanalytical work
 
Extraction of rifampicin from plasma 
The method described by Rafig et al., (2010)
 192
 was followed. The mobile 
phase consisted of acetonitrile, 0.05 M sodium citrate buffer adjusted to pH 4.0 with 
0.05 M hydrochloric acid (42:58) and pumped at a flow-rate of 2.3 ml/min an 
ambient temperature. Buffer was filtered through Whatman filter paper. Mobile 
phase was filtered (cellulose acetate filter diameter 47 mm, pore size 0.45 µm, 
Sartorius AG. 370700) and sonicated (EYELA-Sonicator) for 12 min. 
An aliquot of 200 µl of plasma samples was pipetted into an eppendrof’s 
tube of 1.5ml capacity. Acetonitrile (300 µl) was added, vortexed for one minute and 
micro centrifuged at 10,000 rpm for 5min. Then 300 µl of the supernatant was taken 
into another micro centrifuge tube and vacuum dried in the HETO vacuum 
centrifuge. The residue obtained was reconstituted in 100 µl of mobile phase. 
Plasma was filtered through 0.22 µm membrane (13 mm) and 20 µl volumes were 
injected
193
. 
HPLC analysis 
Rifampicin was analyzed at ambient temperature on a Kromasil C18 column 
Phenomenex, UK, 100mm×3.2mm i.d., 3µm particle size) with an ODS 
Securigard® guard column 4mm×3mm (Phenomenex, Macclesfield, UK). The 
mobile phase ammonium acetate buffer was adjusted to pH 4.0 with 0.05 M 
hydrochloric acid and acetonitrile (20:90). The analytes were detected by a UV –
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Visible detector at 475 nm
194
. The injection volume for each sample was 20µl to 
column. The peak was found at 2.52 min, which was probably the 25-
desacetylrifampicin metabolite. HPLC analyses showed that the assay method is 
linear in the ranges 0.1-1µg/ml for plasma. The chromatograms were recorded 
according to the “Area normalization method” with the measurement of peak 
area
195
. 
Extraction efficiency 
The extraction efficiency was calculated by comparing the peak heights of 
rifampicin spiked-pooled blank plasma samples with that of respective standard 
rifampicin samples. 
Calibration curve for rifampicin 
A calibration curve of rifampicin was obtained by plotting the concentration 
of rifampicin against the respective spiked-pooled blank plasma samples peak area. 
Concentration of rifampicin was calculated by using the following equation. 
Y = MX+ C 
Peak plasma concentration (Cmax) and the time to attain the peak plasma 
concentration (Tmax) were calculated from the actual plasma data. The elimination 
rate constant (Kel) was calculated from the log-linear decline of concentration. 
Elimination half life (t1/2) was obtained from t1/2 el=0.693/ Kel. Absorption rate 
constant (ka) was calculated by the residual method and absorption half life (t1/2 a) 
was obtained from the formula t1/2 a=0.693/Ka. Area under the plasma drug 
concentration versus time curve (AUC 0-12 h) was calculated by trapezoidal rule. 
Extension of the AUC data to infinity (AUC 0-) was done by dividing the last 
observed concentration of drug in plasma by Kel
196
. 
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Statistical analysis 
The data were analyzed by one way ANOVA followed by Tukey’s multiple 
comparison tests with the help of Graph Pad Instat software, version 3.01. All the 
data were presented as a mean value with its standard deviation (mean±S.D). P<0.05 
was considered as statistically significant. 
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11. RESULTS AND DISCUSSION 
11.1 Preparation of rifampicin nanoparticles 
The present study followed ionic gelation method for preparation of 
rifampicin nanoparticles using the natural and biodegradable polymer chitosan of 
different molecular weights. Natural polymers are more desirable for nanoparticles 
used in chronic infections like tuberculosis as they are free from polymer induced 
toxicity
28
 and therefore chitosan was chosen in the study. Ionic gelation is simple to 
process and nanoparticles of desirable size are easily obtained. Chitosan with 
different molecular weight, tween 80 in variable concentrations and variable stirring 
speed were used in order to examine their influence on the physicochemical and 
release characteristics of the drug. Lyophillization was followed for preparation of 
nanoparticles using sucrose and glucose (1:1) as cryoprotective agent to yield stable 
amorphous solid with the desired property such as high redispersion speed, 
acceptable storage stability and also residual moisture content. Formulation of 
rifampicin loaded chitosan nanoparticles are given in Table 24.  
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11.2 Drug and carrier interaction by Fourier Transform Infra Red 
Spectroscopy 
The FTIR spectra of drug, polymer, ascorbic acid and nanoparticles are 
shown in Figures 18, 19. The infrared spectra are recorded on Fourier Transform 
Spectrometer in the mid–infrared region (MIR) within the range (400-4000 cm-1) 
and the study was carried out separately to check the compatability between drug 
and polymer used for the preparation of nanoparticles. There are three characteristic 
peaks of chitosan of different grades; 3318 cm
-1 
of (OH),1078cm-1 of (C-O-C) 
and 1621cm
-1
 of (NH2) for low molecular weight chitosan; 3267 cm
-1 
of 
(OH),1078cm-1 of (C-O-C) and 1675cm-1 of (NH2) for medium molecular 
weight chitosan;3324 cm
-1 
of (OH),1317cm-1 of (C-O-C) and 1578cm-1 of (NH2) 
for high molecular weight chitosan;  The peaks of chitosan at 1621cm
-1
 (low 
molecular weight), and at 1675cm
-1
 (medium molecular weight), 1578cm
-1 
(high 
molecular weight) disappeared and new sharp peaks at 1664 cm
-1
, 1421cm
-1
,1378 
cm
-1
  were observed in the chitosan-TPP nanoparticles. These changes indicate that 
amino groups of chitosan were cross linked with tripolyphosphate groups of TPP in 
the nanoparticles
197
. Rifampicin showed characteristic peaks at 1719cm
-1 
(acetoxyl 
C=O), 1746cm
-1 
(furanone C=O) and 2898cm
-1
(amyl NH-C=O) and ascorbic acid 
showed characteristic peaks at 1012cm
-1 
; O-H, 1750cm
-1 
; C=O and at 1640cm
-1
; 
C=C and these peaks were also observed in the rifampicin, rifampicin-ascorbic acid 
loaded chitosan nanoparticles (Figures.18h, 18i, 18j, 18k) indicating the absence of 
chemical interaction between the drug and polymer and thus safe use of ionic 
gelation method for development of rifampicin nanoparticles using chitosan as 
polymer.  
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11.3 Thermal analysis by differential scanning calorimetry (DSC) 
The thermogram of rifampicin, chitosan, chitosan-TPP nanoparticles, 
rifampicin-chitosan nanoparticles are shown in Figures 20, 21. DSC analysis reveals 
the physical state of drug in the formulation which influences the release 
characteristics of the drug from the system. The drug and the polymer may co-exist 
in the polymeric carrier as a) amorphous drug either in amorphous or in crystalline 
polymer or b) crystalline drug either in amorphous or in crystalline polymer. The 
DSC thermogram of rifampicin showed endothermic peaks at 189.0
o
C, 238.16
o
C 
and exothermic peak at 272.02
o
C (Figure.20a). The DSC of polymer showed 
characteristic endothermic and exothermic   peaks at 101.42
o
C and 290.03
o
C for low 
molecular weight (Fig.20b), at 178.18
o
C and 312.04
o
C for medium molecular 
weight (Figure.20c), and at 182.49
o
C and 338.4
o
C for high molecular weight 
(Fig.20d) chitosan. The endothermic and exothermic peaks of chitosan of 101.42
o
C 
and 290.03
o
C (low Mwt), 178.18
o
C and 312.04
o
C (medium Mwt), 182.49
o
C and 
338.4
o
C (high Mwt) were shifted to 113.72
o
C and 310.12
o
C, 180.98
o
C and 320.1
o
C, 
182.49 and 340.2
o
C respectively in chitosan-TPP nanoparticles (Figures. 20 e, f, g). 
Similarly the endothermic peaks of rifampicin at 189.0
 o
C and 238.16
o
C and 
272.02
o
C were shifted to 124.32 and 325.16
o
C, 215.65 and 342.33
o
C, and 198.35 
and 363.64
o
C (Figures. 21 a, b, c)   in the rifampicin loaded chitosan nanoparticles. 
These findings indicate that physical state of rifampicin and chitosan has changed 
from crystallinity to amorphous state that help improved dissolution of the drug in 
the environment. 
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11.4 Morphology by scanning electron microscopy 
Figures (22-49) shows the morphology of nanoparticles. All nanoparticle 
formulations prepared with different grades of chitosan at variable stirring speed and 
concentration of tween 80 were spherical with smooth surfaces and solid dense and 
showed no aggregation due to the result of stable zeta potential on the surface of the 
nanoparticles that prevent the agglomeration process. The morphology of all 
formulations was almost identical and was not affected by the molecular weight of 
polymer, concentration of tween 80 and stirring speed. 
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11.5 Surface characteristics by zetasizer 
Table 25 shows the results data of zeta potential, zeta size, PDI of 
nanoparticles. Commonly, zeta potential is an index of the stability of the 
nanoparticles. Under  most  conditions,  the  higher the  absolute value  of  the  zeta  
potential  of  the  nanoparticles,  the  larger the  charge on their  surface, leading  to  
stronger repulsive  interaction  between  the  dispersed  nanoparticles  and higher 
stability and more uniform size
198
. A high potential value of above ±25mV, ensures 
a high energy barrier that stabilizes the nano suspension
199
.
 
The zeta potential of all 
formulations ranged from  +32mV to +42mV with a positive surface charge possibly 
due to the presence of amino groups in the polymer and zeta potential of all the 
formulations was above +25mV, the limit for the stability of nanoparticles. The zeta 
potential of nanoparticles was affected by molecular weight of chitosan, stirring 
speed, tween 80 concentration.  
The zeta potential decreased significantly with increase in molecular weight 
of chitosan (Figure 50); conversely, the zeta potential of nanoparticles increased 
with increase in stirring speed and tween 80 concentrations (Figure 51).  The 
possible mechanism may be formation of fine particles by increased stirring speed 
that may facilitate greater interaction between the drug and the polymer and 
therefore increased zeta potential of the nanoparticles. These formed nanoparticles 
with higher zeta potential were better stabilized with higher concentration of tween 
80. Higher molecular weight chitosan may probably hinder fine particles formation 
by ionic gelation method and thus reduced zeta potential. Zeta potential values 
obtained in the present study allow predicting good colloidal stability due to high 
energy barrier between particles. These findings suggest chitosan molecular weight, 
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stirring speed, tween 80 concentrations need to be optimized for the development of 
stable nanoparticles.  
Poly dispersity index is another factor that represents the dispersion 
homogeneity; the range for the PDI is from 0-1.Values close to 0 indicates the 
homogenous dispersion and those greater than 0.5 indicate high heterogeneity. The 
PDI for all formulations was between 0.2-0.5 which indicates a relative homogenous 
dispersion
200
. Further, the homogeneity of the dispersion was influenced by the 
molecular weight of polymer, stirring speed and concentration of the stabilizing 
agent; however maintained homogeneous dispersion with PDI at or lower than 0.5. 
Figure 50 shows the influence of molecular weight on particles size. Particle 
size plays a critical role in influencing the physicochemical and biological 
characteristics of nanoparticles. Smaller particles less than 400nm are most preferred 
in pharmaceutical product development. In the present study the particle size of all 
formulations ranged from 202nm-513nm, and increased significantly with increase 
in molecular weight of polymer. The decrease in particle size with low molecular 
weight chitosan is possibly due to the increased solubility of the polymer that may 
aid in the colloidal solubility of nanoparticles in the solution
201
.
 
Furthermore, higher 
molecular weight chitosan is less soluble, and as a result an increase in particle 
diameter or even aggregation may be obtained.  
Tween 80 as a stabilizing agent is adsorbed on to the surface of the 
nanoparticles, thereby slowing down the growth of crystal phases by reducing the 
surface free energy. It was found in the study that the nanoparticles prepared in the 
presence of tween 80 were much smaller, spherical particles, however the size of 
these particles decreased significantly as the concentration of tween 80 increased 
(Fig 53). Our finding is consistent with earlier report that higher concentration of 
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tween 80 reduces the surface free energy to a great extent and hence stabilization of 
the smaller particles formed
202
. Besides, stirring speed also has produced the same 
effect of tween80 on the particle size of nanoparticles in our study. As the stirring 
speed increased the particle size of the nanoparticles decreased significantly    
(Figure 54). This effect is due to the occurrence of external energy and thus the 
shear stress causing droplet breakdown increased with increased stirring speed 
203
. 
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11.6 Rifampicin encapsulation efficiency and loading capacity of nanoparticles 
Results data of rifampicin encapsulation efficiency and loading capacity of 
the nanoparticles are given in Table 26. The drug encapsulation efficiency and 
loading capacity of the nanoparticles depend upon the molecular weight of the 
polymer, the interaction between the drug and the polymer, the stirring speed used 
and also the concentration of the stabilizing agent added in the development of 
nanoparticles. Figures 55, 56 shows that the increase in the molecular weight of 
chitosan, the stirring speed and the concentration of tween 80 (stabilizing agent), all 
resulted increase in the encapsulation efficiency and loading capacity significantly. 
Rifampicin having carboxyl group resulted in electrostatic interaction with the 
amino group of chitosan and therefore influenced the encapsulation efficiency and 
loading capacity of nanoparticles. High molecular weight chitosan has more reaction 
sites and therefore more electrostatic interaction with rifampicin. Our findings 
consistent with earlier observation that longer chains of high molecular weight 
chitosan can entrap greater amount of drug when gelated with tripolyphosphate
204
. 
Further increasing stirring speed or concentration of tween 80 brings about breaking 
down of the particles to smaller size caused by increased shearing stress and 
consequently stabilization of the formed nanoparticles by higher concentration of the 
stabilizing agent which promotes greater interaction between the drug and polymer 
and therefore increased encapsulation efficiency and loading capacity of the 
nanoparticles (Figure. 57).  
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11.7 In-vitro dissolution stability 
The results of in-vitro percentage degradation of rifampicin with isoniazid       
/ ascorbic acid and of nanoparticles are shown Table 43. Rifampicin degraded 33.1% 
at 15 min, and the degradation increased overtime and reached 42.7% at 60min and 
our finding supports  the view that  rifampicin undergoes degradation in the acidic 
environment of the stomach and the degradation has varied from 8.5%-50% during 
the gastric emptying time for most dosage form in humans
4
. Rifampicin degrades to 
3-formyl rifampicin SV (3FRSV) and 1-amino 4 methyl piperazine under acidic 
pH
69
 and at the same time it is more soluble at low pH and therefore well absorbed 
from the stomach because of its high solubility between pH1 and 2
205
. The 
degradation of rifampicin increased to 74% in the presence of isoniazid in the 
simulated gastric fluid and this increase was statistically significant (P<0.01) and in 
consistent with earlier claim that decomposition of rifampicin is further influenced 
by the presence of isoniazid after ingestion
16
. Ascorbic acid as an antioxidant 
protects rifampicin from degradation to 3FRSV in the plasma sample
3
. In the present 
study ascorbic acid in different concentrations (125mg, 250mg, 500mg, and 
1000mg) was used to examine its protective effect against degradation in the 
simulated gastric fluid. Ascorbic acid addition reduced the rifampicin degradation at 
all time point intervals and the percent drug degradation decreased significantly as 
the concentration of ascorbic acid increased and drug degradation reached minimum 
(20.40%) with 500mg ascorbic acid and there was no further significant decrease in 
drug degradation beyond this concentration of ascorbic acid. At 60min, the 
degradation of drug decreased from 42.7% to 20.40% significantly (P<0.01) in the 
presence of ascorbic acid (500mg). Besides ascorbic acid also minimized rifampicin 
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degradation in the presence of isoniazid from 74% to 25.6% and this effect was 
statistically significant (P<0.001).  
Nanoparticles being small in size can help enhanced dissolution and improve 
the bio-availability of the drugs. Applying this factor the present study attempted to 
examine whether nanoparticle system can help reduce the degradation of rifampicin 
in the simulated gastric fluid (without enzyme). Rifampicin nanoparticles degraded 
significantly less than rifampicin at all time point intervals and at 60min it degraded 
32.15% as compared to rifampicin (42.7%) (P<0.05). Nanoparticle delivery of 
rifampicin reduced rifampicin degradation from 74% to 56.76% in the presence 
isoniazid at 60min.  Ascorbic acid significantly reduced degradation of rifampicin 
nanoparticles at all time intervals and, at 60min from 32.15% to 25.92%.   
Rifampicin – ascorbic acid nanoparticles showed enhanced degradation of drug 
(25.92%) as compared to rifampicin - ascorbic acid (20.4%), possibly, nanoparticles 
give rise to larger surface area becoming available for interaction with acidic 
environment that may facilitate degradation of rifampicin. However nanoparticulate 
delivery of rifampicin along with ascorbic acid has reduced degradation from 42.7% 
to 25.92% and ascorbic acid addition to rifampicin nanoparticle in the presence of 
isoniazid reduced rifampicin degradation significantly from 25.6% to 20.87% and 
this finding supports the view that nanopaticle approach seems beneficial in 
overcoming degradation of rifampicin in the acidic environment of the stomach. 
Additionally ascorbic acid could further protect rifampicin from degradation in the 
acidic environment. Though the literatures report that ascorbic acid can stabilize 
rifampicin against degradation either in the plasma sample or in the dissolution 
medium, the underlying mechanism of protection by ascorbic acid against 
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rifampicin degradation in the presence of isoniazid in the acidic environment is not 
clearly established. In the present study too the results obtained with ascorbic acid 
co-administration could not explore the underlying mechanism of stabilization of 
rifampicin by ascorbic acid. However it has been documented that rifampicin, a 
zwiterionic compound at low pH the basic piperezine nitrogen group of rifampicin 
become protenated with positive charge leading to cationic nitrogen having strong 
tendency to form ion pair with sodium lauryl sulphate
72
. It is hypothesized whether 
such a mechanism is feasible where in the rifampicin possibly forms a soluble 
complex with ascorbic acid and thus protects rifampicin against degradation in the 
acidic environment. 
To support the above said mechanism the following points need to be 
addressed: Rifampicin is freely soluble at pH 1-2 and the solubility decreases with 
increase in pH. In clinical practice rifampicin is recommended to be taken on empty 
stomach in order to ensure the bioavailability of rifampicin. On addition of ascorbic 
acid, the shift in pH less than 1-2 is more likely by the effect of ascorbic acid. The 
mechanism underlying improved stability of rifampicin in the acidic environment 
either by ascorbic acid or by nanoparticles and ascorbic acid together cannot be 
clearly ascertained. 
Results and discussion 
147 
 
11.8 In-vitro diffusion study 
The results of in-vitro diffusion study are shown in Table 52. The release of 
rifampicin was 32.4% at 15 min and increased over time and reached 48.6% at 60 
min. Ascorbic acid significantly improved the release of rifampicin at all time point 
intervals, and at 60 min, from 48.6% to 67.21%. This finding is consistent with our 
observation in the dissolution stability study and suggests that ascorbic acid may 
overcome the degradation and enhance the absorption of rifampicin by further 
lowering the acidic pH at which the drug is more soluble. The percentage release of 
rifampicin was 48.6% which was reduced significantly to 18.1% in the presence of 
isoniazid due to promotion of degradation by isoniazid. Ascorbic acid significantly 
increased percentage release of rifampicin in the presence of isoniazid from 18.1% 
to 60% indicating the stabilizing effect of ascorbic acid against rifampicin 
degradation in the acidic environment, besides protecting rifampicin from isoniazid 
induced degradation of rifampicin. Rifampicin nanoparticles increased release of 
rifampicin significantly over time as compared to rifampicin and released 67.23% at 
60 min as compared to rifampicin (48.6%), possibly, rifampicin when presented in 
nanosize may improve the transmucosal transport of the drug through the membrane 
at a rate faster than rate of degradation of drug in the acidic environment, besides 
protecting the drug from the degradation in the acidic environment. This was further 
evident that nanoparticles of rifampicin increased the drug release from 18.1% to 
38.83%, thus showing the stabilization effect of nanoparticles against rifampicin 
degradation under the influence of isoniazid. The stabilizing effect of ascorbic acid 
against rifampicin degradation was further improved significantly when rifampicin 
was presented as nanoparticles, and the percentage release of rifampicin increased 
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significantly from 67.21% to 74.01% (P<0.05). Similar effect was observed with 
rifampicin-ascorbic acid nanoparticles containing isoniazid as compared to 
rifampicin-ascorbic acid containing isoniazid.  These findings propose the 
hypothesis that nanoparticles coupled with ascorbic acid may promote absorption of 
rifampicin faster than its degradation of rifampicin alone as well as in the presence 
of isoniazid. Besides, chitosan being mucoadhesive may also play a role in 
promoting absorption of rifampicin. 
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11.9 In-vivo pharmacokinetic study 
In-vivo pharmacokinetic parameters were studied on the best formulation 
(F8) selected, based on the particle size, the percentage degradation, percentage 
release and encapsulation efficiency of rifampicin nanoparticles and the results are 
shown in Table 69. The study was carried out in rabbits in order to ascertain whether 
the in-vitro release and degradation data of rifampicin and rifampicin nanoparticles 
would be truly reflected in in-vivo bioavailability. HPLC chromotograms and 
graphical representation of the data are shown in Figures 60-75. 
Isoniazid reduced C max from 5.9 µg/ml to 4.1µg/ml, AUC 0-12 (µg/mlh) from 
33.96 to 27.80 and AUC 0(µg/mlh) from 61.05 to 53.53 and these reductions are 
statistically significant (P<0.05) and these changes are due to degradation of 
rifampicin under the influence of isoniazid and therefore reduction in bioavailability 
of rifampicin. As compared to rifampicin, ascorbic acid addition improved C max, 
AUC0-12 (µg/mlh) and AUCo- (µg/mlh)  significantly from 5.9µg/ml to 9.3µg/ml 
(P<0.01), 33.96 to 66.14 (P<0.01) and 61.05 to 82.48 (P<0.01) respectively. These 
findings reveal the stabilizing effect of ascorbic acid against rifampicin degradation 
in the stomach as observed in the in-vitro dissolution stability and diffusion studies. 
Ascorbic acid also stabilized rifampicin against degradation in the presence of 
isoniazid  and the Cmax of rifampicin increased from 4.1µg/ml to 10.2µg/ml, AUC0-12 
(µg/mlh) from 27.81 to 71.42 and    AUC 0- (µg/mlh) from 53.53 to 89.54. These 
findings reveal the influence of ascorbic acid protecting isoniazid induced rifampicin 
degradation in the stomach and increasing the concentration of drug available for 
absorption. Kel of rifampicin was decreased by ascorbic acid and the cause 
underlying this could not be ascertained; whether ascorbic acid increases residence 
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time of the drug in the blood and so Kel is reduced, needs to be investigated. As 
AUC0-12 and AUC0- were increased Vd was found decreased. Tmax was increased 
due to increase in Cmax. The effect of nanoparticle approach and ascorbic acid 
addition together on the bio-availability of rifampicin was also examined. These 
findings clearly propose that ascorbic acid can improve the bio-availability of 
rifampicin irrespective of the presence and absence of isoniazid at the absorption 
site.  
 The effect of nanoparticle approach and how it was influenced by ascorbic 
acid on the bio-availability of rifampicin was also examined. Rifampicin delivery as 
nanoparticle improved Cmax AUC0-12(µg/mlh) and AUC0- (µg/mlh) significantly as 
compared to rifampicin. The Cmax, AUC 0-12(µg/mlh) and AUC0- (µg/mlh) of 
rifampicin increased significantly from 5.9µg/ml to 6.3µg/ml (P<0.05), 33.96 to 
63.69 (P<0.01) and 61.05 to 68.79 (P<0.05) significantly from the nanoparticles. 
However isoniazid reduced the stabilizing effect of nanoparticle approach as 
the Cmax, AUC0-12 (µg/mlh) and AUC0- (µg/mlh)  were significantly (P<0.01) 
reduced from 6.3µg/ml to 5.5 µg/ml, 63.69 to 53.76 and from 68.70 to 58.34 
respectively. Ascorbic acid improved the stability of rifampicin nanoparticles 
significantly as evident from the Cmax, AUC0-12(µg/mlh) and AUC0- (µg/mlh).    
The Cmax of rifampicin increased from 6.3µg/ml to 10.1µg/ml (P<0.01), AUC0-12 
from 63.69 to 70.35 (P<0.01) and AUC0- from 68.79 to 79.92 (P<0.01). Similarly 
ascorbic acid protected rifampicin from degradation under the influence of isoniazid 
enhancing the Cmax, AUC0-12 (µg/mlh) and AUC0- (µg/mlh) values. The Cmax, 
AUC0-12 (µg/mlh) and AUC0- (µg/mlh) of rifampicin with isoniazid were 5.5µg/ml, 
55.76, and 58.74 respectively and these values were increased to 10.4, 71.78, and 
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80.61µg/ml respectively. There were corresponding changes in the Kel, Ka, Vd, t1/2 
and Tmax and these changes were statistically significant (P<0.05). The results of the 
in-vivo study clearly suggest that ascorbic acid can stabilize rifampicin against 
degradation in the acidic environment following oral ingestion. Furthermore 
ascorbic acid coupled with nanoparticle delivery of rifampicin can greatly overcome 
the rifampicin degradation and improve its bio-availability significantly.  
The beneficial effect of ascorbic acid in tuberculosis has also been well 
documented. Ascorbic acid, as antioxidant and immune enhancing nutrient when 
used in conjuction with standard TB regimen accelerate healing from 
tuberculosis
206
. An ascorbate concentration of 1mg/day, which is easily reached in 
the blood, prevents the growth of cultures of M.tuberculosis
207
.
 
TB patients are 
found to have elevated MMP-9 levels
208
, which is correlated with severity of illness 
in patients with active tuberculosis
209
. MMP-9 is secreted by both the bacillus and 
host response to infection with ascorbic acid is critical for inhibiting the activity of 
plasmin and matrix mettalloproteinasses (mmp-2 and mmp-9) and for maintaining 
optimum synthesis and structure of the connective tissue which undergoes 
enzymatic destruction in TB infection. It has been demonstrated that adequate levels 
of ascorbic acid can prevent MMP-9 secretion and degradation of collagen matrix in 
various system
208
. 
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12. SUMMARY AND CONCLUSION 
 
 The present study followed two directional approaches to improve the   
disadvantage of rifampicin degradation that affects bio-availability of the drug. 
 In the first approach ascorbic acid was used to stabilize rifampicin against 
degradation in the acidic environment and the second approach is to present 
rifampicin nanoparticles along with ascorbic acid.  
 Ascorbic acid significantly reduced rifampicin degradation both in the 
presence and absence of isoniazid. Ascorbic acid and the nanoparticle 
approach together further influenced stability of rifampicin against 
degradation in the acidic environment. 
The stability of rifampicin from the above approaches was reflected in 
reduced degradation and increased release of rifampicin in the acidic 
environment. In-vivo study revealed improved pharmacokinetics of 
rifampicin from nanoparticles coupled with ascorbic acid. 
 In conclusion, the results of the present study demonstrate that degradation 
of rifampicin in combination with isoniazid in fixed dose formulations can be 
controlled by using ascorbic acid as stabilizing agent in appropriate concentration. It 
has been established that tuberculous patients are recommended supplementation of 
ascorbic acid (1000mg/day) to improve the immune system against tuberculosis and 
therefore our study justifies the recommendation of ascorbic acid addition to 
rifampicin formulations in order to control degradation and improve bioavailability 
of rifampicin following oral ingestion for effective management of tuberculosis. 
Extrapolation of the findings of the present study to humans, may address the 
clinical implications of this approach. 
  Recommendation 
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13. RECOMMENDATION 
 
 The results of the study clearly demonstrated the beneficial effects of 
ascorbic acid co-administration in improving bioavailability of rifampicin that can 
help control TB effectively. Further study is recommended for preclinical and 
clinical outcome and thus its viability in the design of fixed dose combination of 
rifampicin, isoniazid, pyrazinamide, ethambutol including ascorbic acid for better 
management of TB infection. 
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 Figure 18. FTIR of Low (a), medium(b),high(c) molecular weight chitosan,  
chitosan low(d), medium(e), high(f) molecular weight -TPP nanoparticles. 
 Figure 19. FTIR of Rifampicin (g), ascorbic acid (h) and rifampicin loaded 
low(i), medium(j), high(k) molecular weight chitosan nanoparticle, rifampicin- 
ascorbic acid loaded low molecular weight chitosan nanoparticles (l) 
 
  
 
 
Figure 20. DSC of Rifampicin (a), Low (b), medium(c), high (d) molecular 
Weight chitosan, low (e), medium (f), high(g) molecular weight chitosan 
nanoparticles 
 
  
 
 
 
Figure 21. DSC of low (a), medium (b), high (c) molecular weight chitosan- 
rifampicin nanoparticles 
 
 
Morphology by scanning electron microscopy of rifampicin loaded chitosan 
nanoparticles 
 
Figure 22.  Scanning electron microscopic (SEM) image of nanoparticles (F1) 
 
 
Figure 23.  Scanning electron microscopic (SEM) image of nanoparticles (F2) 
 Figure 24. Scanning electron microscopic (SEM) image of nanoparticles (F3) 
 
 
Figure 25. Scanning electron microscopic (SEM) image of nanoparticles (F4) 
 Figure 26.  Scanning electron microscopic (SEM) image of nanoparticles (F5) 
 
 
Figure 27. Scanning electron microscopic (SEM) image of nanoparticles (F6) 
 Figure 28. Scanning electron microscopic (SEM) images of nanoparticles (F7) 
 
 
Figure 29. Scanning electron microscopic (SEM) image of nanoparticles (F8) 
 
 Figure 30. Scanning electron microscopic (SEM) image of nanoparticles (F9) 
 
 
Figure 31. Scanning electron microscopic (SEM) image of nanoparticles (F10) 
 Figure  32. Scanning electron microscopic (SEM) image of nanoparticles (F11) 
 
 
Figure 33. Scanning electron microscopic (SEM) image of nanoparticles (F12) 
 Figure 34. Scanning electron microscopic (SEM) image of nanoparticles (F13) 
 
 
Figure 35. Scanning electron microscopic (SEM) image of nanoparticles (F14) 
 Figure 36. Scanning electron microscopic (SEM) image of nanoparticles (F15) 
 
 
Figure  37. Scanning electron microscopic (SEM) image of nanoparticles (F16) 
 Figure 38. Scanning electron microscopic (SEM) image of nanoparticles (F17) 
 
 
Figure 39. Scanning electron microscopic (SEM) image of nanoparticles (F18) 
 Figure 40. Scanning electron microscopic (SEM) image of nanoparticles (F19) 
 
 
Figure 41. Scanning electron microscopic (SEM) image of nanoparticles (F20) 
 Figure 42. Scanning electron microscopic (SEM) image of nanoparticles (F21) 
 
 
Figure 43. Scanning electron microscopic (SEM) image of nanoparticles (F22) 
 Figure 44. Scanning electron microscopic (SEM) image of nanoparticles (F23) 
 
 
Figure 45. Scanning electron microscopic (SEM) image of nanoparticles (F24) 
 
 Figure 46. Scanning electron microscopic (SEM) image of nanoparticles (F25) 
 
 
Figure 47. Scanning electron microscopic (SEM) image of nanoparticles (F26) 
 Figure 48. Scanning electron microscopic (SEM) image of nanoparticles (F27) 
 
 
Figure 49. Scanning electron microscopic (SEM) image of rifampicin- 
ascorbic acid loaded chitosan nanoparticles (F28) 
 
  Table 25 Results data of Particle size, Zeta potential, PDI (Mean±SD, n=3) 
Formula Code Particle size (nm) Zeta potential (mV) PDI  
F1        423±3.43** a +37±0.13* * a 0.429 
F2        410±2.12* *a +37±0.68* * a 0.431 
F3        432±1.23* * 
a
 +35±0.89* * 
a
 0.495 
F4        325±2.34* *
a
 +37±0.46* * 
a
 0.302 
F5 302±1.43* * a +38±0.96* * a 0.285 
F6 308±3.48* * a +39±0.65* * a 0.301 
F7   215±2.34* * *
a
   +40±0.85* * *
a
 0.285 
F8        202±2.76   +42±0.75* * *
a
 0.225 
F9   225±3.48* * *
a
   +39±0.45* * *
a
 0.285 
F10        460±2.12* * a +38±0.32* * a 0.452 
F11 442±6.43* * a   +37±0.87* * *a 0.441 
F12        496±2.34* 
a
        +32±0.14* 
a
 0.510 
F13 359±2.12* * a +37±1.01* * a 0.325 
F14 334±3.48* * a   +41±0.98* * *a 0.285 
F15 334±5.56* * 
a
   +39±0.14* * *
a
 0.323 
F16   229±4.32* * *a   +40±0.78* * *a 0.292 
F17   212±2.34* * *a   +42±0.15* * *a 0.231 
F18   240±4.67* * *a   +39±0.65* * *a 0.273 
F19        490±3.48* a +38±0.47* * a 0.494 
F20        453±5.32* * a +37±0.54* * a 0.451 
F21        513±3.48* a +38±0.36* * a 0.523 
F22 380±4.21* * a   +37±0.58* * *a 0.325 
F23 345±4.87* * a   +41±0.25* * *a 0.292 
F24 360±2.34* * a +38±0.85* * a 0.335 
F25 302±2.12* * a   +40±0.98* * *a 0.230 
F26   214±3.48* * *a   +42±0.47* * *a 0.235 
F27   250±5.98* * *a   +39±0.25* * *a 0.310 
F28   202±5.98* * *
a
   +42±0.17* * *a 0.219 
 ***P<0.001, **P<0.01, *P<0.05,
   a
Significant difference compared to formulation F8 
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Figure 50. Influence of molecular weight of chitosan on zeta potential 
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Figure 51. Influence of stirring speed on zeta potential 
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Figure 52. Influence of molecular weight of chitosan on particle size 
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Figure 53. Influence of concentration of tween 80 on particle size 
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Figure 54. Influence of stirring speed on particle size 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 26  Data of encapsulation efficiency and loading capacity and 
(%) diffusion of nanoparticles (Mean±SD, n=3) 
Formula 
Code 
(%) Encapsulation 
Efficiency± S.D 
(%) Loading 
Capacity± S.D 
(%) Diffusion ± S.D 
F1 49.82±0.34* * *
a
 25.96±0.45* * *
a
 28.75 ±0.33* * 
a
 
F2 56.96±0.35* * *
a
 29.80±0.51* * *
a
 29.93±0.16* * 
a
 
F3 57.85±0.25* * *
a
 31.76±0.52* * *
a
 30.06±0.48* * 
a
 
F4 62.85±0.32* * *a 35.91±0.32* * *a 30.81±0.11* * a 
F5 64.64±0.41* * *
a
 36.78±0.44* * *
a
 32.60±0.32* * 
a
 
F6 70.19±0.36* * *a 39.69±0.29* * *a 33.01±0.18* * a 
F7 77.67±0.24* * *
a
 43.93±0.34* * *
a
 40.05±0.15* * *
a
 
F8 80.71±0.33 45.65±0.35* * *
a
 45.09±0.33 
F9 85.00±0.32* * 
a
 48.57±0.62* * *
a
 44.16±0.25* * *
a
 
F10 50.89±0.15* * *
a
 27.66±0.35* * *
a
 26.01±0.62* * 
a
 
F11 57.85±0.45* * *a 30.56±0.42* * *a 28.30±0.25* * a 
F12 59.10±0.23* * *
a
 32.13±0.49* * *
a
 29.63±0.30* * 
a
 
F13 66.25±0.31* * *a 35.67±0.43* * *a 29.98±0.24* * a 
F14 66.96±0.12* * *
a
 37.87±0.22* * *
a
 30.46±0.19* * 
a
 
F15 72.50±0.54* * *a 41.01±0.35* * *a 31.09±0.55* * a 
F16 78.92±0.22* *
a
 44.64±0.62* * *
a
 32.64±0.51* * 
a
 
F17 82.14±0.31* * a 46.23±0.32* * *a 35.71±0.22* * a 
F18 85.71±0.52* * *
a
 48.87±0.34* * *
a
 36.43±0.11* * 
a
 
F19 53.92±0.11* * *a 28.49±0.47* * *a 21.39±0.19* a 
F20 59.28±0.32* * *
a
 31.32±0.51* * *
a
 23.11±0.30* 
a
 
F21 61.07±0.26* * *a 33.20±0.19* * *a 23.98±0.29* a 
F22 73.92±0.24* * *a 39.42±0.35* * *a 25.15±0.17* **a 
F23 68.75±0.31* * *a 38.89±0.21* * *a 28.60±0.20* * a 
F24 75.17±0.21* * *a 42.52±0.69* * * a  30.34±0.24* * a 
F25 80.00±0.24* a 45.25±0.23* * *a 30.83±0.06* * a 
F26 83.57±0.23* * a 47.27±0.22* * *a 33.98±0.16* * a 
F27 87.14±0.26* * *a 49.39±0.57* * *a 34.67±0.27* * a 
F28 82.56±0.014* * 
a
 48.38±0.189* * *
a
 49.23±0.17* * *
a
 
 
***P<0.001, **P<0.01, *P<0.05,
   a
Significant difference compared to formulation F8 
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Figure 55. Influence of molecular weight of chitosan on encapsulation efficiency 
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Figure 56. Influence of molecular weight of chitosan on loading capacity 
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Figure 57. Influence of molecular weight of chitosan on % diffusion of drug 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In-vitro dissolution stability study 
In-vitro percentage degradation of rifampicin alone and in combination with 
isoniazid using ascorbic acid in different concentrations at 475nm. 
Table 27 Percentage degradation of rifampicin alone at pH 1.2 buffer 
 
Time(min) Trial 1 Trial 2 Trial 3 Mean±SD 
0 0 0 0 0 
15 33 33.2 33.1 33.1±0.10 
30 37 38.8 37.6 37.8±0.916 
45 40 39.2 36.3 38.5±1.94 
60 44 43.6 40.6 42.7±1.85 
 
Table 28 Percentage degradation of rifampicin in the presence of isoniazid 
at pH 1.2 buffer 
 
Time(min) Trial 1 Trial 2 Trial 3 Mean±SD 
0 0 0 0 0 
15 54.8 56.3 56.6 55.9±0.96 
30 61.2 61.4 62 61.5±0.41 
45 74 73.8 74.2 74±0.207 
60 78.5 78.6 79.4 78.8±0.49 
 
Table 29 Percentage degradation of rifampicin in the presence of ascorbic acid 
(125mg) at pH 1.2 buffer 
 
Time(min) Trial 1 Trial 2 Trial 3 Mean±SD 
0 0 0 0 0 
15 23.4 24.2 23.8 23.8±0.40 
30 29.2 28.6 28.6 28.8±0.34 
45 32.3 32.2 31.9 32.1±0.16 
60 35 34.8 35.2 35.0±0.20 
 
 
Table 30 Percentage degradation of rifampicin in the presence of ascorbic acid 
(250mg) at pH 1.2 buffer 
 
Time(min) Trial 1 Trial 2 Trial 3 Mean±SD 
0 0 0 0 0 
15 15.6 15.3 14.9 15.2±0.35 
30 19.5 19.4 19.6 19.5±0.10 
45 29.2 29.4 29.0 29.2±0.20 
60 32.2 32.5 32.9 32.5±0.35 
 
Table 31 Percentage degradation of rifampicin in the presence of ascorbic acid 
(500mg) at pH 1.2 buffer 
 
Time(min) Trial 1 Trial 2 Trial 3 Mean±SD 
0 0 0 0 0 
15 14.9 14.8 15.2 14.9±0.20 
30 16.2 15.8 15.6 15.8±0.30 
45 18.5 18.8 18.6 18.6±0.15 
60 20.4 20.2 20.7 20.40±0.25 
 
 
Table 32 Percentage degradation of rifampicin in the presence of ascorbic acid 
(1000mg) at pH 1.2 buffer 
 
Time(min) Trial 1 Trial 2 Trial 3 Mean±SD 
0 0 0 0 0 
15 15.3 15 14.9 15.06±0.20 
30 16.2 16.6 16.5 16.4±0.20 
45 18.8 18.8 17.2 18.9±0.23 
60 21.0 20.8 20.6 20.8±0.20 
 
Table 33 Percentage degradation of rifampicin in the presence of   isoniazid 
and ascorbic acid (125mg) at pH 1.2 buffer 
 
Time(min) Trial 1 Trial 2 Trial 3 Mean±SD 
0 0 0 0 0 
15 35.9 35.7 35.8 35.8±0.10 
30 40 40.8 40.6 40.4±0.41 
45 48.8 49.5 49.2 49.1±0.35 
60 58.6 58.4 58.2 58.4±0.20 
 
 
Table 34 Percentage degradation of rifampicin in the presence of isoniazid and 
ascorbic acid (250mg) at pH1.2 buffer 
 
Time(min) Trial 1 Trial 2 Trial 3 Mean±SD 
0 0 0 0 0 
15 29 30 28.7 29.2±0.68 
30 40 38.9 38 38.9±1.00 
45 44 43.3 44.2 43.8±0.47 
60 52 53.7 53.3 53.0±0.88 
 
 
Table 35 Percentage degradation of rifampicin in the presence of isoniazid and  
ascorbic acid (500mg) at pH 1.2 buffer 
 
Time(min) Trial 1 Trial 2 Trial 3 Mean±SD 
0 0 0 0 0 
15 26 25.7 25 25.5±0.51 
30 37 36.9 37.3 37.0±0.20 
45 41 40.7 40 40.5±0.51 
60 45 46.3 45.1 45.4±0.72 
 
Table 36 Percentage degradation of rifampicin in the presence of isoniazid and 
ascorbic acid (1000mg) at pH 1.2 buffer 
 
Time(min) Trial 1 Trial 2 Trial 3 Mean±SD 
0 0 0 0 0 
15 24.1 25.2 25.2 24.8±0.63 
30 37.2 36.9 37.3 37.1±0.20 
45 40.1 40.7 40.1 40.3±0.34 
60 44.3 46.3 44.3 44.9±1.15 
 
 
 
  Table 37 Percentage degradation of rifampicin nanoparticles at pH 1.2 buffer 
 
Time(min) Trial 1 Trial 2 Trial 3 Mean±SD 
0 0 0 0 0 
15 14.9 15.5 15.2 15.2±0.30 
30 19.4 19.3 20 19.5±0.37 
45 29.3 29 29.4 29.2±0.20 
60 31.9 32.4 32.3 32.15±0.26 
 
 
Table 38 Percentage degradation of rifampicin nanoparticles + isoniazid  
at pH 1.2 buffer 
 
Time(min) Trial 1 Trial 2 Trial 3 Mean±SD 
0 0 0 0 0 
15 29.5 29.6 29.2 29.4±0.20 
30 33.8 34.6 34.4 34.2±0.41 
45 43 42.8 43.5 43.0±0.36 
60 56.6 56.7 57  56.76±0.20 
 
 
Table 39 Percentage degradation of rifampicin - ascorbic acid (500mg) 
nanoparticles at pH 1.2 buffer 
 
Time(min) Trial 1 Trial 2 Trial 3 Mean±SD 
0 0 0 0 0 
15 14.9 15.5 15.2 15.2±0.30 
30 17.5 17.8 17.6 17.6±0.15 
45 21.7 22 21.7 21.8±0.17 
60 26 25.6 26.2 25.9±1.30 
   
 
Table 40 Percentage degradation of rifampicin - ascorbic acid (500mg) 
nanoparticles + isoniazid at pH 1.2 buffer 
 
Time(min) Trial 1 Trial 2 Trial 3 Mean±SD 
0 0 0 0 0 
15 12.9 13.5 13.4 13.2±0.32 
30 16.7 17 16.8 16.8±0.15 
45 18.2 17.9 18 18.0±0.15 
60 20.5 21.2 20.8 20.8±0.35 
 
 
Table 41 Percentage rifampicin degradation with isoniazid and ascorbic acid at pH 1.2 buffer (mean±SD, n=3) 
 
Time 
(min) 
Rifampicin alone 
Rifampicin 
+isoniazid 
Rifampicin 
- ascorbic acid 
125mg 
Rifampicin- 
ascorbic acid 
250mg 
Rifampicin- 
ascorbic acid 
500mg 
Rifampicin- 
ascorbic acid 
1000mg 
0 0 0 0 0 0 0 
15 33.1±0.10 55.9±0.96 23.8±0.40 15.2±0.35 14.9±0.20 15.06±0.20 
30 37.8±0.92 61.5±0.41 28.8±0.34 19.5±0.10 15.8±0.30 16.4±0.20 
45 38.5±1.94 74±0.207 32.1±0.16 29.2±0.20 18.6±0.15 18.9±0.23 
60 42.7±1.85 78.8±0.49 35.0±0.20 32.5±0.35 20.40±0.25 20.8±0.20 
 
          
 
 
Table 42 Percentage rifampicin degradation with isoniazid + ascorbic acid at pH 1.2 buffer (mean±SD, n=3) 
 
Time 
(min) 
Rifampicin alone 
Rifampicin 
+isoniazid 
Rifampicin 
-ascorbic 
acid 125mg 
+isoniazid 
Rifampicin 
- ascorbic acid 250mg 
+isoniazid 
Rifampicin 
- ascorbic acid 500mg 
+isoniazid 
Rifampicin 
-ascorbic acid 1000mg 
+isoniazid 
0 0 0 0 0 0 0 
15 33.1±0.10 55.9±0.96 35.8±0.10 29.2±0.68 25.5±0.51 24.8±0.63 
30 37.8±0.92 61.5±0.41 40.4±0.41 38.9±1.00 37.0±0.20 37.1±0.20 
45 38.5±1.94 74±0.207 49.1±0.35 43.8±0.47 40.5±0.51 40.3±0.34 
60 42.7±1.85 78.8±0.49 58.4±0.20 53.0±0.88 45.4±0.72 44.9±1.15 
 
 
 
 
Table 43 Cumulative data on percentage rifampicin degradation from nanoparticles in the presence of isoniazid 
and ascorbic acid at 475nm in pH 1.2 buffer  ( mean±SD, n=3) 
 
      ***P<0.001, **P<0.01, *P<0.05
    
         a
Significant difference compared to Rifampicin alone 
         b
Significant difference compared to Rifampicin- ascorbic acid (500mg) 
         c
Significant difference compared to Rifampicin+ isoniazid 
         d
Significant difference compared to Rifampicin- ascorbic acid (500mg) + isoniazid
Time 
(min) 
Rifampicin 
Rifampicin
+ isoniazid 
Rifampicin 
-ascorbic 
acid (500mg) 
Rifampicin 
ascorbic acid 
+ isoniazid 
Rifampicin 
nps 
Rifampicin - 
ascorbic acid 
nps 
Rifampicin nps 
+ isoniazid 
Rifampicin -
ascorbic acid  
nps +isoniazid 
0 0 0 0 0 0 0 0 0 
15 33.1±0.10 55.9±0.96 14.9±0.20  25.5±0.51 15.2±0.30 * * *
a
 29.4±0.20* * *
b
 15.8±0.39* * *
c
 13.2±0.32* * *
d
 
30 37.8±0.92 61.5±0.41  15.8±0.30  37.0±0.20 19.5±0.37* * * a 34.2±0.41* * * b 17.6±0.15* * * c 16.8±0.15* * * d 
45 38.5±1.94 74±0.207 18.6±0.15 40.5±0.51 29.2±0.20* * * a 43.0±0.36* * * b 21.8±0.17* * * c 18.0±0.15* * * d 
60 42.7±1.85 78.8±0.49  20.40±0.25  45.4±0.72 32.2±0.26* * *
 a
 56.8±0.20* * *
 b
 25.9±1.30* * *
 c
 20.8±0.35* * *
 d
 
  
Figure 58. Percentage rifampicin degradation 
 
 
 
 
 
 
 
 
 
In-vitro-diffusion 
In-vitro percentage release of rifampicin alone and in combination with 
isoniazid   using ascorbic acid in different concentrations at pH 1.2 buffer 
Table 44 Percentage release of rifampicin alone at pH 1.2 
 
Time(min) Trial 1 Trial 2 Trial 3 Mean±SD 
0 0 0 0 0 
15 32.2 32.4 32.6 32.4±0.20 
30 41.3 41 41.5 41.2±0.25 
45 47 47.2 46.7 46.9±0.25 
60 48.6 48.9 48.5 48.6±0.20 
 
Table 45 Percentage release of rifampicin in the presence of isoniazid 
at pH 1.2 buffer 
 
Time(min) Trial 1 Trial 2 Trial 3 Mean±SD 
0 0 0 0 0 
15 10 10.5 10.3 10.23±0.25 
30 12.6 12.4 13 12.68±0.30 
45 14.4 14.3 14.4 14.37±0.05 
60 18 18.1 18.3 18.1±0.15 
 
Table 46 Percentage release of rifampicin in the presence of   ascorbic acid 
(500mg) at pH 1.2 buffer 
 
Time(min) Trial 1 Trial 2 Trial 3 Mean±SD 
0 0 0 0 0 
15 45.0 45.2 44.8 45±0.20 
30 56.6 56.2 56.4 56.4±0.20 
45 61.0 61.5 61 61.±0.28 
60 67.4 67.2 67 67.2±0.20 
 
Table 47 Percentage release of rifampicin in the presence of ascorbic acid  
and isoniazid buffer 
 
Time(min) Trial 1 Trial 2 Trial 3 Mean±SD 
0 0 0 0 0 
15 40 40.2 40.4 40.2±0.20 
30 42 42.3 42.3 42.1±0.15 
45 54 54.2 53.7 53.9±0.25 
60 60 60.2 60.0 60.04±0.11 
 
 
Table 48 Percentage release of rifampicin from nanoparticles 
 
Time(min) Trial 1 Trial 2 Trial 3 Mean±SD 
0 0 0 0 0 
15 47.8 48.3 48 48±0.251 
30 60.6 60.2 60.8 60.5±0.30 
45 65 64.6 65 64.8±0.23 
60 66.6 66.4 65.8 66.23±0.41 
 
 
Table 49 Percentage rifampicin release of rifampicin nanoparticles  
with isoniazid 
 
Time(min) Trial 1 Trial 2 Trial 3 Mean±SD 
0 0 0 0 0 
15 18.5 18.8 18.4 18.5±0.20 
30 22.2 22.4 21.8 22.13±0.30 
45 34.3 33.7 34.2 34.0±0.32 
60 38.6 39 38.8 38.83±0.20 
 
 
Table 50 Percentage release of rifampicin from rifampicin - ascorbic  
acid nanoparticles 
 
Time(min) Trial 1 Trial 2 Trial 3 Mean±SD 
0 0 0 0 0 
15 55.0 55.4 54.8 55.0±0.30 
30 64.1 64.4 64.0 64.1±0.20 
45 68.3 68.5 68.4 68.4±0.10 
60 73.8 74.0 74.4 74.0±1.30 
 
 
Table 51 Percentage release of rifampicin from rifampicin - ascorbic acid 
nanoparticles in the presence of  isoniazid 
 
Time(min) Trial 1 Trial 2 Trial 3 Mean±SD 
0 0 0 0 0 
15 41.8 42.4 42 42.03±0.30 
30 58.7 58.5 58.2 58.46±0.25 
45 63.8 64.2 63.9 63.9±0.20 
60 69 68.6 69.2 68.9±0.30 
 
Table 52 Cumulative data on percentage rifampicin release from nanoparticles in the presence of isoniazid and ascorbic acid at 
475nm in pH 1.2 buffer (mean±SD, n=3) 
 
***P<0.001, **P<0.01, *P<0.05,
    
a
Significant difference compared to Rifampicin alone 
b
Significant difference compared to Rifampicin- ascorbic acid (500mg) 
c
Significant difference compared to Rifampicin+ isoniazid 
d
Significant difference compared to Rifampicin- ascorbic acid (500mg) + isoniazid
Time 
(min) 
Rifampicin 
alone 
Rifampicin 
+ isoniazid 
Rifampici
n -ascorbic 
acid 
Rifampicin 
ascorbic acid 
+ isoniazid 
Rifampicin  
nps 
Rifampicin nps 
+ isoniazid 
Rifampicin - 
ascorbic acid 
nps 
Rifampicin -
ascorbic acid  
nps +isoniazid 
0 0 0 0 0 0 0 0 0 
15 32.4±0.20 10.2±0.25 45.0±0.20 40.2±0.20 48.0±0.25* * *
a
 18.5±0.20* * *
b
 55.1±0.30* * *
c
 42.0±0.30* * *
d
 
30 41.2±0.25 12.7±0.30 56.4±0.20 42.1±0.15 60.5±0.30* * *a 22.1±0.30* * *b 64.1±0.20* * *c 58.5±0.25* * *d 
45 46.9±0.25 14.4±0.05 61.0±0.28  53.9±0.25 64.8±0.23* * *a 34.0±0.32* * *b 68.4±0.10* * *c 63.9±0.20* * *d 
60 48.6±0.20 18.1±0.15 67.2±0.20 60.0±0.11 66.2±0.41* * *a 38.8±0.20* * *b 74.0±1.30* * *c 68.9±0.30* * *d 
  
 
Figure 59. Percentage rifampicin release 
 
 
 
 
 
 
 
Plasma drug concentration at various time intervals by HPLC method 
 
Table 53 Group I - Rifampicin alone (n=6, mean±SD) 
 
 
Time(hr) Concentration(µg/ml) 
 
Mean± S.D 
1 2 3 4 5 6 
0.5 
1 
2 
4 
6 
9 
12 
3.9 
4.0 
4.8 
5.6 
3.7 
0.9 
- 
3.5 
4.3 
5.1 
4.9 
3.8 
0.8 
- 
 
3.3 
4.1 
4.7 
6.0 
3.3 
1.2 
- 
4.0 
4.2 
5.0 
6.2 
3.4 
1.0 
- 
4.1 
4.1 
5.3 
7.0 
3.3 
0.7 
- 
 
3.7 
4.4 
5.2 
5.7 
3.2 
1.1 
- 
 3.80±0.18 
 4.20±0.13 
 5.10±0.20 
 5.91±0.12 
 3.40±0.16 
 1.0±0.01 
- 
 
 
 
 
 
 
 
 
 
HPLC Chromatograms 
 
GROUP I- Rifampicin alone 
 
 
    Figure 60 (a). 0.5 hr 
 
 
Figure 60(b). 1
st
hr 
 
 Figure 60(c). 2
nd
hr 
 
 
 
Figure 60(d). 4
th
 hr 
 Figure 60(e). 6
th
hr 
 
 
 
Figure 60(f).  9
th
hr 
 
 
    
Table 54 Group-II - Rifampicin + isoniazid  (n=6, mean±SD) 
 
 
Time(hr) Concentration(µg/ml) 
 
Mean± S.D 
1   2 3 4 5 6 
0.5 
1 
2 
4 
6 
9 
12 
1.9 
2.9 
3.1 
3.9 
2.9 
- 
- 
2.3 
3.0 
3.3 
4.0 
3.0 
- 
- 
2.6 
2.9 
3.4 
4.1 
2.8 
- 
- 
2.0 
3.0 
3.2 
3.7 
2.6 
- 
- 
2.1 
2.8 
3.5 
4.3 
3.1 
- 
- 
2.8 
2.9 
3.4 
4.1 
2.8 
- 
- 
2.2±0.202 
2.9±0.1155 
3.2±0.115 
4.09±0.046 
2.9±0.054 
- 
- 
 
 
 
 
 
 
 
 
 
 
 
 
HPLC Chromatograms 
 
Group-II - Rifampicin + isoniazid 
 
 
Figure 61(a).  0.5hr 
 
 
Figure 61(b).  1
st
hr 
 
  
Figure 61(c).  2
nd 
hr 
 
 
 
Figure 61(d).  4
th
 hr 
 
 
 
  
 
Figure 61(e).  6
th
 hr 
 
 
 
 
 
 
 
 
 
 
 
 
Table 55 Group-III - Rifampicin - ascorbic acid (n=6, mean±SD) 
 
 
 
 
 
 
 
 
 
 
 
 
Time(hr) Concentration(µg/ml) 
 
Mean±S.D 
1 2 3 4 5 6 
0.5 
1 
2 
4 
6 
9 
12 
6.0 
8.1 
8.7 
9.9 
8.0 
4.1 
2.7 
6.2 
8.6 
8.1 
10.2 
8.1 
4.3 
1.9 
6.4 
8.4 
8.3 
9.8 
7.9 
3.9 
2.3 
6.1 
8.5 
8.5 
10.0 
8.2 
3.8 
2.5 
6.5 
8.4 
8.3 
10.2 
7.7 
4.0 
2.6 
6.2 
8.2 
8.7 
9.7 
7.8 
3.9 
2.0 
6.2±0.115 
8.3±0.155 
8.0±0.1764 
9.28±0.020 
8.0±0.064 
4.1±0.1155 
2.3±0.2309 
HPLC Chromatograms 
 
Group-III - Rifampicin - ascorbic acid (n=6, mean±SD) 
 
Figure 62(a).  0.5hr 
 
 
Figure 62(b).  1
st
 hr 
 
  
Figure 62(c).  2
nd
hr 
 
 
Figure 62(d).  4
th
 hr 
 
 
 
 Figure 62(e).  6
th
 hr 
 
 
Figure 62(f).  9
th
hr 
 
 
 
 Figure 62(g).  12
th
 hr 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 56 Group-IV -Rifampicin - ascorbic acid + isoniazid (n=6, mean±SD) 
 
 
Time(hr) Concentration(µg/ml) 
 
Mean±S.D 
1 2 3 4 5 6 
0.5 
1 
2 
4 
6 
9 
12 
5.4 
6.9 
9.0 
10.6 
6.7 
2.8 
1.6 
5.8 
7.1 
9.1 
10.0 
6.3 
2.3 
2.1 
6.0 
7.4 
9.2 
10.8 
6.6 
2.7 
1.9 
5.2 
7.5 
9.3 
10.4 
6.8 
2.9 
1.5 
6.1 
7.2 
8.9 
10.7 
6.1 
2.1 
1.7 
5.9 
6.8 
9.1 
10.9 
6.5 
2.8 
2.4 
5.7±0.18 
7.1±0.15 
9.1±0.06 
10.2±0.12 
6.5±0.12 
  2.6±0.152 
  1.8±0.145 
 
 
 
 
 
 
 
 
 
 
 
 
HPLC Chromatograms 
 
Group-IV -Rifampicin - ascorbic acid + isoniazid (n=6, mean±SD) 
 
 
Figure 63(a).  0.5hr 
 
 
Figure 63(b).  1
st
 hr 
 
 
 Figure 63(c).  2
nd
 hr 
 
 
 
Figure 63(d).  4
th
 hr 
 
 
 
 
  
Figure 63(e).  6
th
 hr 
 
 
 
Figure 63(f).  9
th
 hr 
 
 
 
  
 
Figure 63(g). 12th hr 
 
 
 
 
 
 
 
 
 
 
 
 
Table 57 Group-V - Rifampicin nanoparticles (n=6, mean±SD) 
 
 
Time(hr) Concentration(µg/ml) 
 
Mean± S.D 
1 2 3 4 5 6 
0.5 
1 
2 
4 
6 
9 
12 
3.5 
4.8 
5.8 
6.6 
3.7 
0.9 
- 
4.2 
5.2 
5.1 
6.3 
3.5 
1.0 
- 
3.7 
5.4 
5.5 
5.7 
3.2 
1.1 
- 
3.4 
5.6 
5.6 
6.4 
3.6 
1.2 
- 
4.1 
5.1 
4.9 
5.9 
3.1 
0.7 
- 
3.9 
4.9 
5.8 
6.2 
3.7 
1.3 
- 
3.8±0.23 
5.2±0.67 
6.1±0.14 
   6.3±0.34 
3.4±0.76 
1.0±0. 57 
- 
 
 
 
 
 
 
 
 
 
 
 
 
HPLC Chromatograms 
 
Group-V - Rifampicin nanoparticles (n=6, mean±SD) 
 
Figure 64(a).  0.5hr 
 
 
 
Figure 64(b).  1
st
 hr 
 
 
 Figure 64(c) .  2
nd
 hr 
 
 
 
Figure 64(d).  4
th
 hr 
 
 
 
 Figure 64(e).  6
th
 hr 
 
 
 
 
Figure 64(f).  9
th
 hr 
 
 
 
Table 58 Group-VI- Rifampicin nanoparticles+ isoniazid (n=6, mean±SD) 
 
     
Time(hr) Concentration(µg/ml) 
 
Mean± S.D 
1 2 3 4 5 6 
0.5 
1 
2 
4 
6 
9 
12 
2.7 
4.0 
5.1 
3.9 
2.9 
1.9 
- 
2.3 
4.2 
5.3 
4.0 
3.0 
1.2 
- 
2.6 
4.4 
4.9 
4.1 
2.8 
2.2 
- 
2.8 
3.9 
4.9 
3.7 
2.7 
1.8 
- 
2.5 
4.5 
4.9 
3.8 
2.9 
1.0 
- 
2.4 
4.1 
4.9 
4.4 
3.1 
2.5 
- 
2.7±0.87 
4.2±0.56 
5.1±0.46 
        5.6±0.54 
2.9±0.85 
2.0±0.23 
- 
 
 
 
 
 
 
 
 
 
 
 
 
HPLC Chromatograms 
 
Group-VI- Rifampicin nanoparticles+ isoniazid 
 
 
Figure 65(a).  0.5hr 
 
 
Figure 65(b).  1
st
 hr 
 
  
Figure 65(c).  2
nd
 hr 
 
 
 
Figure 65(d).  4
th
 hr 
 Figure 65(e).  6
th
 hr 
 
 
 
 
Figure 65(f).  9
th
 hr 
 
 
 
 
Table 59 Group-VII –Rifampicin- ascorbic acid nanoparticles (n=6, mean±SD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time(hr) Concentration(µg/ml) 
 
Mean±S.D 
1 2 3 4 5 6 
0.5 
1 
2 
4 
6 
9 
12 
6.0 
7.1 
8.7 
9.9 
8.0 
4.1 
2.7 
6.2 
7.6 
8.4 
10.2 
8.1 
4.3 
1.9 
6.4 
7.4 
8.9 
9.8 
7.9 
3.9 
2.3 
5.8 
7.0 
8.6 
9.8 
7.7 
4.0 
2.5 
6.3 
7.5 
8.3 
9.8 
8.2 
4.2 
2.0 
6.5 
7.6 
9.1 
9.8 
8.1 
4.1 
2.4 
6.2±0.67 
7.3±0.43 
8.8±0.34 
  10.11±0.33 
 8.0±0.069 
 4.1±0. 15 
2.3±0.1 9 
HPLC Chromatograms 
 
Group-VII –Rifampicin- ascorbic acid nanoparticles 
 
 
Figure 66(a).  0.5 hr 
 
 
 
Figure 66(b).  1
st
 hr 
  
Figure 66(c).  2
nd
 hr 
 
 
 
 
Figure 66(d).  4
th
 hr 
 
 
  
 
Figure 66(e).  6th hr 
 
 
 
 
Figure 66(f).  9th hr 
 
  
 
Figure 66(g).  12
th
 hr 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 60 Group-VIII- Rifampicin-ascorbic acid nanoparticles + isoniazid 
(n=6, mean±SD) 
 
    
  Time(hr) Concentration(µg/ml) 
 
Mean±S.D 
1 2 3 4 5 6 
0.5 
1 
2 
4 
6 
9 
12 
5.2 
6.9 
9.0 
8.6 
6.9 
3.8 
1.6 
5.8 
7.4 
9.1 
8.0 
6.3 
2.3 
2.1 
6.2 
7.4 
9.2 
8.8 
6.6 
3.7 
2.1 
6.0 
6.6 
9.2 
8.4 
6.7 
3.5 
1.4 
5.1 
7.5 
9.2 
8.1 
6.2 
2.4 
2.0 
6.1 
7.6 
9.2 
8.9 
6.9 
3.9 
2.4 
6.0±0.46 
7.4±0.98 
9.1±0.56 
 10.4±0.34 
6.7±0.56 
3.8±0.45 
2.1±0.34 
 
 
 
 
 
 
 
 
 
 
HPLC Chromatograms 
 
Group-VIII- Rifampicin-ascorbic acid nanoparticles + isoniazid 
 
Figure 67(a).  0.5hr 
 
 
 
Figure 67(b).  1st hr 
 Figure 67(c).  2
nd
 hr 
 
 
 
Figure 67(d).  4
th
 hr 
 
 
 
 
 
  
Figure 67(e).  6
th
 hr 
 
 
 
Figure 67(f).  9
th
 hr 
 
 
 
  
 
Figure 67(g).  12th hr 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data of pharmacokinetic study 
Table 61 Group I - Rifampicin alone (n=6, mean±SD) 
 
 
S.No 
 
Parameters 
 
Trails 
      
Mean±S.D 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
1 Ke(1/h) 
 
0.398 0.335 
 
0.358 0.397 0.334 0.360 0.363±0.0184 
 
2 Ka 
 
0.419 0.425 
 
0.431 0.418 0.424 0.433 0.425±0.0034 
3 t 1/2 (h) 
 
1.70 
 
1.85 1.92 1.60 1.84 1.94 1.823±0.064 
4 Vd (l) 
 
0.91 
 
0.93 0.95 
 
0.90 0.92 0.97 0.93±0.011 
5 Tmax (h) 
 
1.20 
 
1.30 
 
1.50 
 
1.10 1.2 1.7 1.333±0.088 
6 Cmax(µg/ml) 
 
5.90 
 
5.82 6.0 
 
5.89 5.81 6.2 5.906±0.052 
7 AUC0-12(µg/mlh) 
 
34.31 36.21 31.36 34.30 36.20 31.38 33.96±1.411 
 
8 AUC0- (µg/mlh) 60.61 62.60 59.94 60.60 62.59 
 
59.96 61.05±0.798 
 
 
    
 
Table 62 Group II - Rifampicin+ isoniazid ((n=6, mean±SD) 
 
 
S.No 
 
Parameters 
 
Trails 
      
Mean±S.D 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
1 Ke(1/h) 
 
0.295 
  
0 .299 0.310 
 
0.294 
 
0.298 0.312 0.301±0.004 
 
2 Ka 
 
0.315 0.318 0.321 0.314 0.317 0.323 0.318±0.001 
 
3 t1/2(h) 
 
2.7 2.4 2.5 2.6 2.3 2.7 2.533±0.088 
 
4 Vd (l) 
 
0.83 0.87 0.89 0.82 0.86 0.91 0.863±0.017 
 
5 Tmax (h) 
 
1.61 1.63 1.68 1.60 1.62 1.70 1.64±0.020 
6 Cmax(µg/ml) 
 
4.10 4.16 4.0 4.09 4.15 4.2 4.086±0.046 
 
7 AUC0-12(µg/mlh) 
 
29.13 28.16 
 
26.15 29.12 28.15 26.17 27.81±0.877 
8 AUC0- (µg/mlh) 50.14 54.31 56.14 50.13 
 
54.30 56.16 53.53±1.775 
 
 
 
 
 
Table 63 Group III- Rifampicin+ ascorbic acid   (n=6, mean±SD) 
 
 
S.No 
 
Parameters 
 
Trails       
Mean±S.D 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
1 Ke(1/h) 
 
0.418 
 
0.421 
 
0.433  0.417 0.420 0.435   0.424±0.004 
    
2 Ka 
 
0.525 0.533 0.545 0.524 0.532 0.547 0.534±0.005 
 
3 t1/2(h) 
 
0.99 0.97 1.0 0.98 0.96 1.2 1.594±0.008 
4 Vd (l) 
 
0.99 1.0 1.2 0.98 0.9 1.4 1.603±0.068 
 
5 Tmax (h) 
 
1.0 
 
1.1 1.3 0.9 1.0 1.5 1.133±0.088 
6 Cmax(µg/ml) 
 
9.24 9.28 9.31 9.23 9.27 9.33 9.276±0.020 
7 AUC0-12(µg/mlh) 
 
64.68 68.16 74.6 64.67 68.15 74.8 69.146±2.906 
8 AUC0- (µg/mlh) 78.90 81.77 86.7 78.89 81.76 86.9 82.48±2.099 
 
 
 
 
 
   
Table 64 Group IV-Rifampicin-ascorbic acid+ Isoniazid (n=6, mean±SD) 
 
 
S.No 
 
Parameters 
 
                                           Trails 
      
Mean±S.D 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
1 Ke(1/h) 
 
0.615 
 
0.614 
 
0.616 
 
0.614 0.613 0.618   0.518±.006 
 
2 Ka 
 
0.514 0.511 0.531 0.513 0.510 0.533 0.615±0.000
5 
3 t1/2(h) 
 
0.95 0.97 
 
0.94 0.92 0.93 1.01 0.953±0.008 
4 Vd (l) 
 
1.0 1.3 1.5 0.9 1.2 1.7 1.266±0.145 
5 Tmax (h) 
 
1.2 
 
1.4 
 
1.6 
 
1.1 1.3 1.8 1.02±0.115 
 
6 Cmax(µg/ml) 
 
10.0 10.2 10.4 9.9 10.1 10.6 10.2±0.115 
7 AUC0-12(µg/mlh) 
 
70.81 72.03 71.42 70.80 72.02 71.44 71.42±0.352 
 
8 AUC0- (µg/mlh) 77.90 86.77 89.10 77.89 86.76 89.12 89.54±2.593 
 
 
 
 
 
 
 
   
   
Table 65 Group- V- Rifampicin nanoparticles (n=6, mean±SD) 
 
 
S.No 
 
Parameters 
 
Trails 
      
Mean±S.D 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
1 Ke(1/h) 
 
0.421 
 
0.435 
 
0.438 
 
0.420 0.434 0.440 0.431±0.008 
 
2 Ka 
 
0.456 
 
0.452 
 
0.445 
 
0.455 0.451 0.447 0.451±0.003 
 
3 t1/2(h) 
 
 1.2 
 
 1.4 
 
 1.7 
 
1.1 1.3 1.9 1.43±0.063 
 
4 Vd (l) 
 
 1.97 
 
 1.93 
 
2.04 
 
1.96 1.92 2.06 1.98±0.0031 
 
5 Tmax (h) 
 
 1.8 
 
 1.9 
 
  1.4 
 
1.7 1.8 1.6 1.7±0.07 
 
6 Cmax(µg/ml) 
 
6.19 
 
 6.45 
 
6.34 
 
6.18 6.44 6.36 6.32±0.017 
 
7 AUC0-12(µg/mlh) 
 
63.18 
 
65.06 
 
62.85 
 
63.17 65.05 62.87 63.69±1.42 
 
8 AUC0- (µg/mlh) 68.45 
 
69.38 
 
68.56 
 
68.44 69.37 68.58 68.79±0.95 
 
 
    
   
    Table 66 Group VI- Rifampicin nanoparticles +Isoniazid (n=6, mean±SD) 
 
 
S.No 
 
Parameters 
 
Trails       
Mean±S.D 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
1 Ke(1/h) 
 
0.319 
 
0.299 
    
0.310 
 
0.318 0.298 0.312 0.309±0.01 
 
2 Ka 
 
0.276 
 
0.318 
 
0.321 
 
0.275 0.317 0.323 0.305±0.63 
 
3 t1/2(h) 
 
 2.1 
 
 2.3 
 
 2.5 
 
2.0 2.2 2.7 2.3±0.04 
 
4 Vd (l) 
 
 0.99 
 
0.97 
 
0.99 
 
0.98 0.96 1.0 0.98±0.13 
 
5 tmax (h) 
 
 1.61 1.63 
 
1.68 
 
1.60 1.62 1.70 1.64±0.63 
 
6 Cmax(µg/ml) 
 
 5.45 
 
5.78 5.43 
 
5.44 5.77 5.45 5.55±0.54 
 
7 AUC0-12(µg/mlh) 
 
53.38 
 
55.13 
 
52.79 
 
53.37 55.12 52.81 53.76±1.481 
 
8 AUC0- (µg/mlh) 57.72 
 
58.76 58.56 
 
57.71 58.75 58.58 58.34±0.904 
 
 
 
 
 
    
    
Table 67 Group VII- Rifampicin -ascorbic acid nanoparticles   (n=6, mean±SD) 
 
 
S.No 
 
Parameters 
 
Trails       
Mean±S.D 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
1 Ke(1/h) 
 
0.493 
 
0.498 
 
0.493 
 
0.492 0.497 0.495 0.494±0.01 
 
2 Ka 
 
0.589 
 
0.587 
 
0.576 
 
0.588 0.584 0.580 0.584±0.05 
 
3 t1/2(h) 
 
 0.85 
 
0.87 
 
0.87 
 
0.84 0.86 0.89 0.863±0.13 
 
4 Vd (l) 
 
 0.78 
 
0.76 
 
0.80 
 
0.77 0.75 0.82 0.78±0.04 
 
5 tmax (h) 
 
 2.1 
 
  2.1 
 
  2.3 
 
2.0 1.9 2.6 2.16±0.13 
 
6 Cmax(µg/ml) 
 
10.78 
 
9.78 
 
9.79 
 
10.77 9.77 9.81 10.11±1.33 
 
7 AUC0-12(µg/mlh) 
 
71.04 
 
69.89 
 
70.13 
 
71.03 69.88 70.15 70.35±1.368 
 
8 AUC0- (µg/mlh) 79.89 80.12 76.77 79.88 80.11 76.79 79.92±2.031 
 
 
 
   
    
Table 68 Group -VIII-  Rifampicin - ascorbic acid nanoparticles +isoniazid 
(n=6, Mean±SD) 
 
 
S.No 
 
Parameters 
 
Trails 
      
Mean±S.D 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
1 Ke(1/h) 
 
0.612 
 
0.625 
 
0.607 
 
0.611 0.624 0.609 0.61±0.09 
 
2 Ka 
 
0.534 
 
0.530 
 
0.531 
 
0.533 0.528 0.534 0.531±0.12 
 
3 t1/2(h) 
 
 0.91 
 
0.98 
 
0.96 
 
0.90 0.97 0.98 0.95±0.013 
 
4 Vd (l) 
 
 1.0 
 
  1.3 
 
  1.5 
 
0.9 1.2 1.7 1.266±0.63 
 
5 Tmax (h) 
 
 1.28 
 
1.40 
 
1.60 
 
1.27 1.30 1.80   1.42±0.26 
 
6 Cmax(µg/ml) 
 
 10.7 
 
10.2 
 
10.4 
 
10.6 10.1 10.6 10.43±1.63 
 
7 AUC0-12(µg/mlh) 
 
70.81 
 
72.13 
 
72.42 
 
70.80 72.12 72.44 71.78±1.73 
 
8 AUC0- (µg/mlh)  77.90 82.78 
 
81.17 77.89 82.77 81.19 80.61±2.18 
 
 
Cumulative data of pharmacokinetics study 
Table 69 (mean±S.D, n=6) 
 
Parameters Rifampicin 
Rifampicin 
+ isoniazid 
Rifampicin -
ascorbic 
acid 
Rifampicin -
ascorbic acid 
+isoniazid 
Rifampicin 
nanoparticle 
Rifampicin 
nps+isoniazid 
Rifampicin-  
ascorbic     
acid nps 
Rifampicin -
ascorbic acid 
nps+isoniazid 
Ke(1/h) 0.363±0.0184 0.301±0.004 0.424±0.004 0.518±.006 0.431±0.008 0.309±0.01 0.494±0.01 0.61±0.09 
Ka 0.425±0.0034 0.318±0.001 0.534±0.005 0.615±0.0005 0.451±0.003 0.305±0.63 0.584±0.05 0.531±0.12 
T1/2(h) 1.823±0.064 2.533±0.088 1.594±0.008 0.953±0.008 1.43±0.063 2.3±0.04 0.863±0.13 0.95±0.013 
Vd (l) 0.93±0.011 0.863±0.017 1.603±0.068 1.266±0.145 1.98±0.0031 0.98±0.13 0.78±0.04 1.266±0.63 
Tmax (h) 1.333±0.088 1.64±0.020 1.133±0.088 1.02±0.115 1.7±0.07 1.64±0.63 2.16±0.13 1.42±0.26 
Cmax(µg/ml) 5.906±0.052 4.086±0.046 9.276±0.020 10.2±0.115 6.32±0.017 5.55±0.54 10.11±1.33 10.43±1.63 
AUC0-12(µg/mlh) 33.96±1.411 27.81±0.877 69.146±2.906 71.42±0.352 63.69±1.42 53.76±1.481 70.35±1.368 71.78±1.73 
AUC0-(µg/mlh) 61.05±0.798 53.53±1.775 82.48±2.099 89.54±2.593 68.79±0.95 58.34±0.904   9.92±2.031 80.61±2.18 
Table 70 Significance difference between groups (n=6, mean±SD) 
 
Comparison Ke Ka t 1/2 Vd Tmax Cmax AUC 0-12 AUC 0-  
 
Group I   VS Group II *** *** *** *** *** *** *** ** 
Group I   VS Group III ** ** ** ** ** ** ** *** 
Group I   VS Group IV *** * *** *** *** *** * *** 
Group I   VS Group V *** * *** *** *** *** * *** 
Group I   VS Group VI *** *** * *** *** *** *** * 
Group I   VS Group VII *** ** *** *** *** *** ** *** 
Group I  VS Group VIII *** *** *** *** *** *** * *** 
Group II  VS Group III ** *** ** ** ** ** *** ** 
Group II  VS Group IV *** ** *** * *** *** ** *** 
Group II  VS Group V *** *** *** *** * ** *** *** 
Group II  VS Group VI *** *** *** *** *** *** *** *** 
Group II  VS Group VII *** *** *** *** *** ** *** ** 
Group II  VS Group VIII * *** * ** * * *** * 
Group III  VS Group VI ** * ** ** ** ** * ** 
Group III  VS Group V ** ** ** *** ** ** ** ** 
Group III  VS Group VI *** ** *** *** ** ** ** *** 
Group III  VS Group VII *** *** ** *** *** ** *** ** 
Group III  VS Group VIII *** *** *** *** *** *** *** ** 
Group IV  VS Group V *** *** *** * *** *** *** *** 
Group IV  VS Group VI * *** * ** * * *** * 
Group IV  VS Group VII ** * ** ** ** ** * ** 
Group IV  VS Group VIII ** ** ** ** ** ** ** ** 
Group V  VS Group VI ** ** * *** ** ** ** * 
Group V  VS Group VII *** ** *** *** *** ** ** *** 
Group V  VS Group VIII *** *** *** *** *** *** *** ** 
***P<0.001, **P<0.01, *P<0.05 
 
Graphical representation of pharmacokinetics parameters 
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Figure 68.  C max 
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Figure 69.  AUC 0-12 
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Figure 70.  AUC 0-∞ 
 
 
0
1
2
3
R IF
R IF + IN H
R IF + A S C .A C ID + IN H
R IF + A S C .A C ID
R IF  N p s
R IF N p s + A S C .A C ID
R IF + A S C .A C ID  N p s
R IF + A S C .A C ID  N p s + IN H
H a lf  l i f e  t1 / 2
T im e (M in )
C
o
n
c
e
n
t
r
a
t
i
o
n
(

g
/
m
l
)
 
Figure 71. Half life t 1/2 
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Figure 72. Tmax 
 
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
R IF
R IF  +  IN H
R IF  +  A S C  A C ID
R IF  +  A S C  A C ID  +  IN H
R IF  N P S
R IF  N P S  +  IN H
R IF  +  A S C  A C ID  N P S
R IF  +  A S C  A C ID  N P S  +  IN H
V o lu m e  o f  d is t r ib u t io n  V d
T im e ( M in )
C
o
n
c
e
n
t
r
a
t
i
o
n
(

g
/
m
l
 
Figure 73. Volume of distribution Vd 
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Figure 74. Absorption rate constant Ka 
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Figure 75.  Elimination rate constant Kel 
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